

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 31, 2003, 14:07:03 ; Search time 74 Seconds
(without alignments)
496.989 Million cell updates/sec

Title: US-10-092-404-1

Perfect score: 1522

Sequence: 1 RLLRSHSLHYLFMGASEQDL.....RYTCQVHPGLDPLVIWE 276

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_101002.*
1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1522	100.0	276	20 AAW94295	Wild-type HFE poly
2	1522	100.0	348	18 AAW36499	Hereditary haemoch
3	1522	100.0	348	21 AAB19149	A human histocompa
4	1522	100.0	348	22 AAB36869	Human hereditary h
5	1517	99.7	438	23 AAB80035	Beta 2 microglobul
6	1513	99.4	276	20 AAW94296	HFE mutant (H63D-H
7	1513	99.4	348	22 AAB36871	Human hereditary h
8	1511	99.3	348	22 AAB36870	Human hereditary h
9	1502	98.7	276	20 AAW94297	HFE mutant (H111A/
10	1502	98.7	348	22 AAB36872	Human hereditary h

11	522	34.3	361	22 AAB36873	Rabbit leukocyte a
12	513	33.7	365	22 AAB36874	MHC class I protei
13	505	33.2	274	21 AAY68275	Human leukocyte an
14	505	33.2	274	21 AAY52929	HLA-A2/A28 family
15	505	33.2	274	22 AAB58690	HLA-A2/A28 protein
16	505	33.2	280	22 AAU10225	Human leukocyte an
17	505	33.2	415	22 AAU10224	Human leukocyte an
18	504	33.1	365	21 AAY68265	Human leukocyte an
19	504	33.1	365	21 AAY52919	HLA-A2/A28 family
20	504	33.1	365	22 AAB58680	HLA-A2/A28 protein
21	504	33.1	368	22 AAM24017	Human EST encoded
22	503	33.0	274	21 AAY68276	Human leukocyte an
23	503	33.0	274	21 AAY52930	HLA-A2/A28 family
24	503	33.0	274	22 AAB58691	HLA-A2/A28 protein
25	503	33.0	365	21 AAY68268	Human leukocyte an
26	503	33.0	365	21 AAY52922	HLA-A2/A28 family
27	503	33.0	365	22 AAB58683	HLA-A2/A28 protein
28	502	33.0	274	9 AAP80911	Consensus sequence
29	502	33.0	365	21 AAY68267	Human leukocyte an
30	502	33.0	365	21 AAY52921	HLA-A2/A28 family
31	502	33.0	365	22 AAB58682	HLA-A2/A28 protein
32	501	32.9	274	21 AAY68274	Human leukocyte an
33	501	32.9	274	21 AAY52928	HLA-A2/A28 family
34	501	32.9	274	22 AAB58689	HLA-A2/A28 protein
35	501	32.9	365	21 AAY68266	Human leukocyte an
36	501	32.9	365	21 AAY52920	HLA-A2/A28 family
37	501	32.9	365	22 AAB58681	HLA-A2/A28 protein
38	500	32.9	412	19 AAW68385	Chimeric HLA-A2.1/
39	499	32.8	274	21 AAY68273	Human leukocyte an
40	499	32.8	274	21 AAY52927	HLA-A2/A28 family
41	499	32.8	274	22 AAB58688	HLA-A2/A28 protein
42	497	32.7	365	21 AAY68270	Human leukocyte an
43	497	32.7	365	21 AAY68272	Human leukocyte an
44	497	32.7	365	21 AAY52924	HLA-A2/A28 family
45	497	32.7	365	21 AAY52926	HLA-A2/A28 family

ALIGNMENTS

RESULT 1
AAW94295
ID AAW94295 standard: peptide; 276 AA.
AC AAW94295;
XX
XX
DT 27-APR-1999 (first entry)
XX
DE Wild-type HFE polypeptide sequence.
XX
KW HFE; beta-2-microglobulin; beta2m; iron overload; hemochromatosis;
transfusion; protein replacement therapy; hereditary hemochromatosis;
transferrin receptor; iron deficiency; anemia.
XX
XX Unidentified.
OS
XX
FH Key Location/Qualifiers
FT Misc-difference 2 /note= "indicated in the sequence listing as Arg"
FT
XX
XX WO9856814-Al.
XX
PD 17-DEC-1998.
XX
PF 12-JUN-1998; 98WO-US12436.
XX
PR 13-JUN-1997; 97US-0876010.
XX
PA (CALY) CALIFORNIA INST OF TECHNOLOGY.
PA (PROG-) PROGENITOR INC.
XX
PI Bjorkman PJ, Feder JN, Schatzman RC;
XX

DR WI; 1999-080886/07.
 XX
 PT New treatment of an iron overload disease - comprises use of HFE
 PT polypeptides provided in a complex with full length, wild type human
 PT (2m), useful in protein replacement therapy
 XX
 XX
 XX Claim 1; Page 13; 36pp; English.
 XX
 XX The present sequence represents a wild-type HFE polypeptide. The HFE
 CC polypeptides (AAW94295-297) provided in a complex with full length,
 CC wild type human beta-2-microglobulin (beta2m) form compositions in the
 CC treatment of primary iron overload diseases (e.g. hemochromatosis), or
 CC other iron overload conditions resulting from secondary causes (e.g.
 CC repeated transfusions). Data regarding the structure and function
 CC correlations of HFE polypeptides is useful in designing drugs that
 CC modulate the HFE gene and HFE activity. The polypeptides are also useful
 CC in protein replacement therapy for individuals possessing a defective
 CC HFE gene (e.g. Hereditary hemochromatosis). (Antagonists of the
 CC polypeptides are also useful in treating primary and secondary iron
 CC overload diseases. The modulators of the transferrin receptor are useful
 CC in treating iron deficiency conditions such as anemia, and in modulating
 CC the amount of iron transported into a cell. The HFE polypeptides provide
 CC a molecular basis for the relationship between HFE and iron metabolism,
 CC which enables treatment of iron overload and deficiency diseases.
 XX
 SQ Sequence 276 AA;
 Query Match 100.0%; Score 1522; DB 20; Length 276;
 Best Local Similarity 100.0%; Pred. No. 3.5e-135;
 Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RLLRSLSHLVFMGASQDGLSLFEALGYDDQLFVFDHESRRVPRTPWVSSRISQ 60
 DB 1 RLLRSLSHLVFMGASQDGLSLFEALGYDDQLFVFDHESRRVPRTPWVSSRISQ 60
 QY 61 MWLQLSQSLKGWDHMTVDFTWNTMENHNSKESHTLQVILGCCEQEDNSTEGYWKYGDG 120
 DB 61 MWLQLSQSLKGWDHMTVDFTWNTMENHNSKESHTLQVILGCCEQEDNSTEGYWKYGDG 120
 QY 121 QDHLFCPDTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDCPAQLQOLLELGRGVL 180
 DB 121 QDHLFCPDTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDCPAQLQOLLELGRGVL 180
 QY 181 DQOVPLPVKVTHTVTSVTLRCALNYPQNTITMKWLKDKQPMDAKEFEKPKDVLNPGDG 240
 DB 181 DQOVPLPVKVTHTVTSVTLRCALNYPQNTITMKWLKDKQPMDAKEFEKPKDVLNPGDG 240
 QY 241 TYOGWITLAVPGGEORYTCQVEHPGLDQPLVIWE 276
 DB 241 TYOGWITLAVPGGEORYTCQVEHPGLDQPLVIWE 276
 RESULT 2
 AAW36499
 ID AAW36499 standard; Protein; 348 AA.
 XX
 AC AAW36499;
 XX
 DT 14-APR-1998 (first entry)
 XX
 XX Hereditary haemochromatosis gene product.
 DE
 XX Hereditary haemochromatosis; metal toxicity; diagnosis;
 KW gene therapy; prenatal screening; human.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH
 FT Misc-difference 63
 FT /note= "substituted by Asp in 24s2 mutant"
 FT Misc-difference 65
 FT /note= "substituted by Cys in 24d7 variant"
 FT Misc-difference 282

FT
 XX
 PN WO9738137-A1.
 XX
 PD 16-OCT-1997.
 XX
 PF 04-APR-1997; 97WO-US06254.
 XX
 XX 23-MAY-1996; 96US-0652265.
 PR 04-APR-1996; 96US-0830912.
 PR 16-APR-1996; 96US-0832673.
 XX
 PA (MERC-) MERCATOR GENETICS INC.
 XX
 XX Drayna DT, Feder JN, Gnikre A, Ruddy D, Thomas WJ;
 PI Tsuchihashi Z, Wolff RK;
 PI
 DR WPI; 1997-512743/47.
 DR N-PSDB; AAT96690-91.
 XX
 XX Hereditary haemochromatosis gene and variants - useful for diagnosis
 XX and treatment of hereditary haemochromatosis disease
 PT
 PT Disclosure; Fig 4; 115pp; English.
 XX
 CC This polypeptide is the expression product of a novel human gene
 CC (see AAT96690) whose mutated form is associated with hereditary
 CC haemochromatosis (HH). A single mutation (24d1) in the HH gene
 CC appears responsible for the majority of HH disease. This comprises
 CC a G to A substitution that is present in 86% of affected
 CC chromosomes and in 4% of unaffected chromosomes. It results in a
 CC Cys to Tyr substitution in the encoded protein at a critical
 CC disulphide bridge important for secondary structure. The following
 CC are claimed: the 10825 bp genomic DNA sequence (I), a 1437 bp cDNA
 CC sequence (Ia) (see AAT96691) and their 24d1, 24d2 and 24d7 variants;
 CC a cloning or expression vector; host cells; a peptide product
 CC chosen from the HH gene product, its variants (24d1, 24d2 and
 CC 24d7), or a peptide of at least 56 amino acid residues of these; an
 CC antibody produced using the peptide as an immunogen; a method to
 CC determine the presence or absence of the common HH gene mutation;
 CC an animal model for the HH disease; metal chelation agents; T-cell
 CC differentiation factors and therapeutic agents for the mitigation
 CC of injury due to oxidative process in vivo or mitigation of iron
 CC overload; a method for screening potential therapeutic agents for
 CC activity in connection with HH disease; an antisense oligonucleotide
 CC directed against a transcriptional product of a nucleic acid
 CC sequence as above; and oligonucleotides or pairs of oligonucleotides
 CC covering a range of nucleotides from (I), (Ia) or their variants,
 CC useful for detecting a polymorphism in the HH gene. The invention
 CC also relates to methods for screening for HH homozygotes, to HH
 CC diagnosis, prenatal screening and diagnosis, and therapies of HH
 CC disease, including gene therapy, protein- and antibody-based
 CC therapeutics, and small molecule therapeutics.
 XX
 SQ Sequence 348 AA;

Query Match 100.0%; Score 1522; DB 18; Length 348;
 Best Local Similarity 100.0%; Pred. No. 4.8e-135;
 Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSLSHLVFMGASQDGLSLFEALGYDDQLFVFDHESRRVPRTPWVSSRISQ 60
 DB 23 RLLRSLSHLVFMGASQDGLSLFEALGYDDQLFVFDHESRRVPRTPWVSSRISQ 82
 QY 61 MWLQLSQSLKGWDHMTVDFTWNTMENHNSKESHTLQVILGCCEQEDNSTEGYWKYGDG 120
 DB 83 MWLQLSQSLKGWDHMTVDFTWNTMENHNSKESHTLQVILGCCEQEDNSTEGYWKYGDG 142
 QY 121 QDHLFCPDTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDCPAQLQOLLELGRGVL 180
 DB 143 QDHLFCPDTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDCPAQLQOLLELGRGVL 202
 QY 181 DQOVPLPVKVTHTVTSVTLRCALNYPQNTITMKWLKDKQPMDAKEFEKPKDVLNPGDG 240

|||||
Db 203 DQVPLVKVTHHTVSSVTTLCRALNYYPONITMKWLKDKPMDAKEFEKDPKLVLPNGDG 262
Qy 241 TYQGWITLAVPPGEQRYTCQVEHPGLDPLIWI 276
Db 263 TYQGWITLAVPPGEQRYTCQVEHPGLDPLIWI 298
RESULT 3
AAB19149
ID AAB19149 standard; Protein; 348 AA.
XX AC
XX AAB19149;
XX
DT 19-FEB-2001 (first entry)
XX
DE A human histocompatibility iron loading (HFE) protein.
XX
KW Human; histocompatibility iron loading protein; HFE protein;
KW major histocompatibility complex; non-classical class I gene;
KW chromosome 6p; iron disorder; haemochromatosis.
XX
OS Homo sapiens.
XX
FH Key
FH Peptide 1..22
FT /note= "signal peptide"
FT Misc-difference 63
FT /note= "when nucleotide 187 is mutated to G, then
FT this residue is Asp"
FT Misc-difference 65
FT /note= "when nucleotide 193 is mutated to T, then
FT this residue is Cys"
FT Domain 80..108
FT /note= "alpha domain"
FT Misc-difference 93
FT /note= "when nucleotide 277 is mutated to C, then
FT this residue is Arg"
FT Misc-difference 105
FT /note= "when nucleotide 314 is mutated to C, then
FT this residue is Thr"
XX
PN WO200058515-A1.
XX
XX 05-OCT-2000.
XX
XX 24-MAR-2000; 2000WO-US07982.
XX
XX 26-MAR-1999; 99US-0277457.
XX
XX (BILL-) BILLUPS-ROTHENBERG INC.
XX
XX Rothenberg BE, Sawada-Hirai R, Barton JC;
XX
XX WPI; 2000-647244/62.
XX
XX N-PSDB; AAA96769.
XX
XX Diagnosing an iron disorder e.g. hemochromatosis or a genetic
XX susceptibility to develop it, by determining the presence of a mutation
XX in exon 2 or an intron of a histocompatibility iron loading nucleic
XX acid -
XX
XX Disclosure; Page 3; 55pp; English.
XX
XX The present sequence represents a human histocompatibility iron loading
XX (HFE) protein. The HFE gene is a major histocompatibility (MHC)
XX non-classical class I gene located on chromosome 6p. Mutations in the
XX gene lead to iron disorders. The specification describes a method for
XX diagnosing an iron disorder or a genetic susceptibility to develop the
XX disorder in a mammal. The method comprises determining the presence of
XX a mutation in exon 2 or an intron of a HFE gene or protein. The mutation
XX is not a C to G missense mutation at nucleotide 187 of the sequence
XX given in A96769 (Genbank Accession number U60319). The presence of the

CC mutation indicates the disorder or the genetic susceptibility to the
CC disorder. The method is used to diagnose an iron disorder
CC e.g. haemochromatosis, or a genetic susceptibility to develop it.
XX
SQ Sequence 348 AA;
Query Match 100.0%; Score 1522; DB 21; Length 348;
Best Local Similarity 100.0%; Pred. No. 4.8e-135;
Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RLLRSLSLHYLFMGASEQDGLSLFEALGYDDQLFVFDHESRRVPRTPWSSRISQ 60
Db 23 RLLRSLSLHYLFMGASEQDGLSLFEALGYDDQLFVFDHESRRVPRTPWSSRISQ 82
Qy 61 MWLQLSQSLKGDHMTVDFTWIMENHNHSHKESHTLQVILGCEMQEDNSTEGYWKYGYDG 120
Db 83 MWLQLSQSLKGDHMTVDFTWIMENHNHSHKESHTLQVILGCEMQEDNSTEGYWKYGYDG 142
Qy 121 ODHLEFCFDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCPAQLQELLEGRGVL 180
Db 143 ODHLEFCFDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCPAQLQELLEGRGVL 202
Qy 181 DQVPLVKVTHHTVSSVTTLCRALNYYPONITMKWLKDKPMDAKEFEKDPKLVLPNGDG 240
Db 203 DQVPLVKVTHHTVSSVTTLCRALNYYPONITMKWLKDKPMDAKEFEKDPKLVLPNGDG 262
Qy 241 TYQGWITLAVPPGEQRYTCQVEHPGLDPLIWI 276
Db 263 TYQGWITLAVPPGEQRYTCQVEHPGLDPLIWI 298
RESULT 4
AAB36869
ID AAB36869 standard; Protein; 348 AA.
XX
XX AC AAB36869;
XX
DT 21-FEB-2001 (first entry)
XX
DE Human hereditary hemochromatosis protein.
XX
KW HH; hereditary hemochromatosis; chelation agent;
KW T-cell differentiation factor; iron overload.
XX
XX Homo sapiens.
XX
XX (PN US6140305-A)
XX
XX 31-OCT-2000.
XX
XX 04-APR-1997; 97US-0834497.
XX
XX 04-APR-1996; 96US-0630912.
XX 16-APR-1996; 96US-0632673.
XX 23-MAY-1996; 96US-0652265.
XX
XX (BIRA) BIO-RAD LAB INC.
XX
XX Thomas-WJ--Drayna-DT, Gnirke A, Ruddy D, Tsuchida-Shinji, Wolffe AP;
XX Feder JN;
XX
XX WPI; 2001-006341/01.
XX
XX N-PSDB; AAC68425.
XX
XX New hereditary hemochromatosis gene products or polypeptides, useful
XX for treating hereditary hemochromatosis in a patient, and as a metal
XX chelation agent alleviating iron overload -
XX
XX Claim 1; Fig 4; 108pp; English.
XX
XX The present invention relates to hereditary hemochromatosis gene
XX products. These proteins may be used to treat a patient diagnosed as
XX having human hemochromatosis disease. It is also useful as a metal

CC chelation agent or as a T-cell differentiation factor, and for
CC alleviating iron overload. They may also be used in protein replacement
CC therapy for individuals having a defective human hemochromatosis gene.
XX
SQ Sequence 348 AA;

Query Match 100.0%; Score 1522; DB 22; Length 348;
Best Local Similarity 100.0%; Pred. No. 4.8e-135;
Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASQDGLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 60
DB 23 RLLRSHSLHYLFMGASQDGLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 82
QY 61 MWLQSLQSLKGDHMTVDFTWIMENHNHSHKESHTLQVILGCMEQDNSTEGYWKYGYDG 120
DB 83 MWLQSLQSLKGDHMTVDFTWIMENHNHSHKESHTLQVILGCMEQDNSTEGYWKYGYDG 142
QY 121 QDHLFCFCDTLDRAAEPRAWPTKLEWERHKIRARQNRAYLERDCPAQLQQLLELGRGVL 180
DB 143 QDHLFCFCDTLDRAAEPRAWPTKLEWERHKIRARQNRAYLERDCPAQLQQLLELGRGVL 202
QY 181 DQOVPLVKVTHHTVSSVTTLCRCALNYPQNTITMKWLKDKQPMDAKEFEFPKDVLPNGDG 240
DB 203 DQOVPLVKVTHHTVSSVTTLCRCALNYPQNTITMKWLKDKQPMDAKEFEFPKDVLPNGDG 262
QY 241 TYOGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIW 276
DB 263 TYOGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIW 298

RESULT 5
AAU80035
ID AAU80035 standard; Protein; 438 AA.
AC
XX
AC AAU80035;
XX
DT 15-JUL-2002 (first entry)
XX
DE Beta 2 microglobulin (beta2m)/HFE monochain.
XX
KW Human; beta 2 microglobulin; beta2m/HFE monochain; HFE; ischaemia;
KW iron absorption regulator; intracellular iron absorption; lung injury;
KW haemochromatosis; transfusion; thalassemia; haemolytic anaemia;
KW chronic infection; transferrin receptor; Tfr; brain tumour; cancer;
KW oxidative stress disorder; tissue damage; vascular disease;
KW inflammation; atherosclerosis; autoimmune disease;
KW inflammatory condition.
XX
OS Homo sapiens.
XX
PN WO200224929-A2.
XX
PD 28-MAR-2002.
XX
PF 24-SEP-2001; 2001WO-US29873.
XX
PR 22-SEP-2000; 2000US-234843P.
XX
PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
PA (MCIN/) MCINNIS P.
XX
PI Ehrlich R, Rotem-Yehudar R, Laham N;
XX
WPI: 2002-383192/41.
DR N-PSDB; ABK49917.
XX
PT Soluble beta 2 microglobulin/HFE monochain useful for treating
PT iron-overload conditions e.g. thalassemia and chronic infections,
PT comprises human beta 2 microglobulin linked to alpha domains of HFE by
PT a linker peptide -
XX
PS Example 2; Fig 2; 77pp; English.

XX
CC The invention relates to a soluble polypeptide (I) of beta 2
CC microglobulin (beta2m)/HFE monochain comprising human beta2m (or its
CC analogue or active fragment), linked to alpha1-alpha3 domains of human
CC HFE (a central regulator of iron absorption; undefined), or its analogue
CC or active fragment, by a flexible linker peptide, or a functional
CC derivative or salt of (I). (I) is useful for reducing intracellular iron
CC absorption in patients having hereditary haemochromatosis, transfusions,
CC thalassemias, haemolytic anaemia or chronic infections, and for
CC delivering a therapeutic to cells that over-express transferrin receptor
CC (Tfr) which are preferably lymphocytes or leukocytes, across the blood-
CC brain barrier. (I) is further useful for treating brain tumour. (I)
CC is also useful for treating oxidative stress disorders resulting in
CC tissue damage e.g. vascular diseases, inflammation, atherosclerosis,
CC lung injury, ischaemia, etc. A DNA molecule (II) encoding (I) is useful
CC as a platform for drug delivery of therapeutic use for cancer,
CC autoimmune diseases and inflammatory conditions. The monochain manifests
CC specific characteristics advantageous for drug delivery systems. It is a
CC soluble, stable and fully conformed protein. It binds specifically to
CC transferrin receptor (Tfr) and therefore targets cells that over-express
CC this receptor. It is continuously internalised by the target cells, thus
CC enabling efficient drug delivery. It dissociates from the receptor in the
CC cells, minimising side effects. It negatively regulates iron absorption,
CC reducing growth of undesired cells and preventing lymphocyte activation.
CC It is not diluted in the blood as is transferrin. It should not induce an
CC immune response since it is a self non-polymorphic protein and delivery of
CC drugs via monochain is expected to overcome drug-resistance since it is a
CC natural Tfr-binding protein. The present sequence represents the amino
CC acid sequence of beta2m/HFE monochain.
XX
SQ Sequence 438 AA;

Query Match 99.7%; Score 1517; DB 23; Length 438;
Best Local Similarity 100.0%; Pred. No. 1.9e-134;
Matches 275; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASQDGLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 60
DB 135 RLLRSHSLHYLFMGASQDGLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 194
QY 61 MWLQSLQSLKGDHMTVDFTWIMENHNHSHKESHTLQVILGCMEQDNSTEGYWKYGYDG 120
DB 195 MWLQSLQSLKGDHMTVDFTWIMENHNHSHKESHTLQVILGCMEQDNSTEGYWKYGYDG 254
QY 121 QDHLFCFCDTLDRAAEPRAWPTKLEWERHKIRARQNRAYLERDCPAQLQQLLELGRGVL 180
DB 255 QDHLFCFCDTLDRAAEPRAWPTKLEWERHKIRARQNRAYLERDCPAQLQQLLELGRGVL 314
QY 181 DQOVPLVKVTHHTVSSVTTLCRCALNYPQNTITMKWLKDKQPMDAKEFEFPKDVLPNGDG 240
DB 315 DQOVPLVKVTHHTVSSVTTLCRCALNYPQNTITMKWLKDKQPMDAKEFEFPKDVLPNGDG 374
QY 241 TYOGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIW 275
DB 375 TYOGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIW 409

RESULT 6
AAW94296
ID AAW94296 standard; peptide; 276 AA.
XX
AC AAW94296;
XX
DT 27-APR-1999 (first entry)
XX
DE HFE mutant (H63D-HFE) polypeptide sequence.
XX
KW HFE; beta-2-microglobulin; beta2m; iron overload; hemochromatosis;
KW transfusion; protein replacement therapy; hereditary hemochromatosis;
KW transferrin receptor; iron deficiency; anemia; mutant.
XX
XX Synthetic.
XX

FH Key Location/Qualifiers
FT Misc-difference 2
FT /note= "indicated in the sequence listing as Arg"
FT Misc-difference 41
FT /label= H63D
FT /note= "wild type His (of the mature protein sequence)
is replaced by Asp"
XX
PN W09856814-A1.
XX
XX
PD 17-DEC-1998.
XX
XX PF 12-JUN-1998; 98WO-US12436.
XX
XX PR 13-JUN-1997; 97US-0876010.
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
PA (PROG-) PROGENITOR INC.
XX
XX Bjorkman PJ, Feder JN, Schatzman RC;
XX
XX WPI; 1999-080886/07.
XX
XX New treatment of an iron overload disease - comprises use of HFE
PT polypeptides provided in a complex with full length, wild type human
PT (2m), useful in protein replacement therapy
XX
PS Claim 3; Page 14; 36pp; English.

XX The present sequence represents a H63D-HFE mutant polypeptide. The HFE
CC polypeptides (AAW94295-297) provided in a complex with full length,
CC wild type human beta-2-microglobulin (beta2m) form compositions in the
CC treatment of primary iron overload diseases (e.g. hemochromatosis), or
CC other iron overload conditions resulting from secondary causes (e.g.
CC repeated transfusions). Data regarding the structure and function
CC correlations of HFE polypeptides is useful in designing drugs that
CC modulate the HFE gene and HFE activity. The polypeptides are also useful
CC in protein replacement therapy for individuals possessing a defective
CC HFE gene (e.g. Hereditary hemochromatosis). (Antagonists of the
CC polypeptides are also useful in treating primary and secondary iron
CC overload diseases. The modulators of the transferrin receptor are useful
CC in treating iron deficiency conditions such as anemia, and in modulating
CC the amount of iron transported into a cell. The HFE polypeptides provide
CC a molecular basis for the relationship between HFE and iron metabolism,
CC which enables treatment of iron overload and deficiency diseases.

XX Sequence 276 AA;

Query Match 99.4%; Score 1513; DB 20; Length 276;
Best Local Similarity 99.6%; Pred. No. 2.5e-134;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RLLRSHSLHYLFPMGASEQDGLSLFEALGYVDDQLFVFDIESRRVPRTPWVSSRISQ 60
Db 1 RLLRSHSLHYLFPMGASEQDGLSLFEALGYVDDQLFVFDIESRRVPRTPWVSSRISQ 60
Qy 61 MWLQLSQSLKGDHMTVDVFTIMENHNHKSHTLQVILGCEQEDNSTEGYWKYGYDG 120
Db 61 MWLQLSQSLKGDHMTVDVFTIMENHNHKSHTLQVILGCEQEDNSTEGYWKYGYDG 120
Qy 121 QDHLFECPDPTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRGVL 180
Db 121 QDHLFECPDPTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRGVL 180
Qy 181 DQQVPLVKVTHHVTSSVTTLLRCRALNYYPQNTMKWLKQKOPMDAKEFEPRKDVLPNGDG 240
Db 181 DQQVPLVKVTHHVTSSVTTLLRCRALNYYPQNTMKWLKQKOPMDAKEFEPRKDVLPNGDG 240
Qy 241 TYQGWITLAVPPGEGEQRVTCQVEHPGLDQPLIVWE 276
Db 241 TYQGWITLAVPPGEGEQRVTCQVEHPGLDQPLIVWE 276

RESULT 7

AAB36871
ID AAB36871 standard; Protein; 348 AA.
XX
AC AAB36871;
XX
DT 21-FEB-2001 (first entry)
XX
DE Human hereditary hemochromatosis 24d2 mutation protein.
XX
XX HH; hereditary hemochromatosis; chelation agent;
KW T-cell differentiation factor; iron overload.
XX
OS Homo sapiens.
XX
PN US6140305-A.
XX
PD 31-OCT-2000.
XX
PF 04-APR-1997; 97US-0834497.
XX
PR 04-APR-1996; 96US-0630912.
PR 16-APR-1996; 96US-0632673.
PR 23-MAY-1996; 96US-0652265.
XX
PA (BIRA) BIO-RAD LAB INC.
XX
PI Thomas WJ, Drayna DT, Gnirke A, Ruddy D, Tsuchihashi Z, Wolff RK;
PI Feder JN;
XX
XX WPI; 2001-006341/01.
DR N-PSDB; AAC68427.
XX
XX New hereditary hemochromatosis gene products or polypeptides, useful
PT for treating hereditary hemochromatosis in a patient, and as a metal
PT chelation agent alleviating iron overload -
XX
PS Claim 3; Fig 4; 108pp; English.
XX
CC The present invention relates to hereditary hemochromatosis gene
CC products. These proteins may be used to treat a patient diagnosed as
CC having human hemochromatosis disease. It is also useful as a metal
CC chelation agent or as a T-cell differentiation factor, and for
CC alleviating iron overload. They may also be used in protein replacement
CC therapy for individuals having a defective human hemochromatosis gene.
XX
SQ Sequence 348 AA;

Query Match 99.4%; Score 1513; DB 22; Length 348;
Best Local Similarity 99.6%; Pred. No. 3.4e-134;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 RLLRSHSLHYLFPMGASEQDGLSLFEALGYVDDQLFVFDIESRRVPRTPWVSSRISQ 60
Db 23 RLLRSHSLHYLFPMGASEQDGLSLFEALGYVDDQLFVFDIESRRVPRTPWVSSRISQ 82
Qy 61 MWLQLSQSLKGDHMTVDVFTIMENHNHKSHTLQVILGCEQEDNSTEGYWKYGYDG 120
Db 83 MWLQLSQSLKGDHMTVDVFTIMENHNHKSHTLQVILGCEQEDNSTEGYWKYGYDG 142
Qy 121 QDHLFECPDPTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRGVL 180
Db 143 QDHLFECPDPTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRGVL 202
Qy 181 DQQVPLVKVTHHVTSSVTTLLRCRALNYYPQNTMKWLKQKOPMDAKEFEPRKDVLPNGDG 240
Db 203 DQQVPLVKVTHHVTSSVTTLLRCRALNYYPQNTMKWLKQKOPMDAKEFEPRKDVLPNGDG 262
Qy 241 TYQGWITLAVPPGEGEQRVTCQVEHPGLDQPLIVWE 276
Db 263 TYQGWITLAVPPGEGEQRVTCQVEHPGLDQPLIVWE 298

```
RESULT 8
AAB36870
ID AAB36870 standard; Protein; 348 AA.
XX AC AAB36870;
XX DT 21-FEB-2001 (first entry)
XX DE Human hereditary hemochromatosis 24d1 mutation protein.
XX KW HH; hereditary hemochromatosis; chelation agent;
XX KW T-cell differentiation factor; iron overload.
XX OS Homo sapiens.
XX PN US6140305-A.
XX PD 31-OCT-2000.
XX PF 04-APR-1997; 97US-0834497.
XX PR 04-APR-1996; 96US-0630912.
XX PR 16-APR-1996; 96US-0632673.
XX PR 23-MAY-1996; 96US-0652265.
XX PA (BIRA ) BIO-RAD LAB INC.
XX PI Thomas WJ, Drayna DT, Gairke A, Ruddy D, Tsuchihashi Z, Wolff RK;
XX PI Feder JN;
XX DR N-PSDB; AAC68426.
XX DR New hereditary hemochromatosis gene products or polypeptides, useful
XX PT for treating hereditary hemochromatosis in a patient, and as a metal
XX PT chelation agent alleviating iron overload -
XX PS Claim 2; Fig 3; 108pp; English.
XX CC The present invention relates to hereditary hemochromatosis gene
XX CC products. These proteins may be used to treat a patient diagnosed as
XX CC having human hemochromatosis disease. It is also useful as a metal
XX CC chelation agent or as a T-cell differentiation factor, and for
XX CC alleviating iron overload. They may also be used in protein replacement
XX CC therapy for individuals having a defective human hemochromatosis gene.
XX SQ Sequence 348 AA;

Query Match 99.3%; Score 1511; DB 22; Length 348;
Best Local Similarity 99.6%; Pred. No. 5.2e-134;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASQDGLSLFEALGYVDDQLFYFDHESRVRPPTWVSSRISQ 60
DB 23 RLLRSHSLHYLFMGASQDGLSLFEALGYVDDQLFYFDHESRVRPPTWVSSRISQ 82
QY 61 MWLQSLQSLGWDHMTVDFTWMENHNHSHKESHTLQVILGCENQEDNSTEGYWKYGYDG 120
DB 83 MWLQSLQSLGWDHMTVDFTWMENHNHSHKESHTLQVILGCENQEDNSTEGYWKYGYDG 142
QY 121 QDHLFECPTDLWRAAEPRAMPPTKLEWRHKIRARONRAYLERDPCPAQLQLLELGRGVL 180
DB 143 QDHLFECPTDLWRAAEPRAMPPTKLEWRHKIRARONRAYLERDPCPAQLQLLELGRGVL 202
QY 181 DQOVPPLVKVTHHTVSSVTLRCALANYPQNTIMKWLKQKPMQDAKEFEFKDVLPGNDG 240
DB 203 DQOVPPLVKVTHHTVSSVTLRCALANYPQNTIMKWLKQKPMQDAKEFEFKDVLPGNDG 262
QY 241 TYQGWTILAVPPGGEQRYTCQVEHPGLDQPLVIWE 276
DB -263 TYQGWTILAVPPGGEQRYTCQVEHPGLDQPLVIWE 298
```

```
RESULT 9
AAW94297
ID AAW94297 standard; peptide; 276 AA.
XX AC AAW94297;
XX DT 27-APR-1999 (first entry)
XX DE HFE mutant (H111A/H145A-HFE) polypeptide sequence.
XX KW HFE; beta-2-microglobulin; beta2m; iron overload; hemochromatosis;
XX KW transfusion; protein replacement therapy; hereditary hemochromatosis;
XX KW transferrin receptor; iron deficiency; anemia; mutant.
XX OS Synthetic.
XX PN WO9856814-A1.
XX FT Misc-difference 2 /note= "indicated in the sequence listing as Arg"
XX FT Misc-difference 89 /label= H111A /note= "wild type His (of the mature protein sequence)
XX FT Misc-difference 123 /label= H145A /note= "wild type His (of the mature protein sequence)
XX FT Misc-difference 123 /label= H145A /note= "wild type His (of the mature protein sequence)
XX PN WO9856814-A1.
XX FT 17-DEC-1998.
XX FT 12-JUN-1998; 98WO-US12436.
XX PR 13-JUN-1997; 97US-0876010.
XX PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX PA (PROG-) PROGENITOR INC.
XX PI Bjorkman PJ, Feder JN, Schatzman RC;
XX WPI; 1999-080886/07.
XX DR New treatment of an iron overload disease - comprises use of HFE
XX PT polypeptides provided in a complex with full length, wild type human
XX PT (2m), useful in protein replacement therapy
XX PS Claim 5; Page 15; 36pp; English.
XX CC The present sequence represents a H111A/H145A-HFE mutant polypeptide.
XX CC The HFE polypeptides (AAW94295-297) provided in a complex with full
XX CC length, wild type human beta-2-microglobulin (beta2m) form compositions
XX CC in the treatment of primary iron overload diseases (e.g.
XX CC hemochromatosis), or other iron overload conditions resulting from
XX CC secondary causes (e.g. repeated transfusions). Data regarding the
XX CC structure and function correlations of HFE polypeptides is useful in
XX CC designing drugs that modulate the HFE gene and HFE activity. The
XX CC polypeptides are also useful in protein replacement therapy for
XX CC individuals possessing a defective HFE gene (e.g. Hereditary
XX CC hemochromatosis). (Antagonists of the polypeptides are also useful in
XX CC treating primary and secondary iron overload diseases. The modulators of
XX CC the transferrin receptor are useful in treating iron deficiency
XX CC conditions such as anemia, and in modulating the amount of iron
XX CC transported into a cell. The HFE polypeptides provide a molecular basis
XX CC for the relationship between HFE and iron metabolism, which enables
XX CC treatment of iron overload and deficiency diseases.
XX SQ Sequence 276 AA;

Query Match 98.7%; Score 1502; DB 20; Length 276;
Best Local Similarity 99.3%; Pred. No. 2.7e-133;
Matches 274; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1 RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPEPTPWSSRISSQ 60
DB 1 RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPEPTPWSSRISSQ 60
QY 61 MWLQLSQSLSKLGWDHMTVDFTWMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 120
DB 61 MWLQLSQSLSKLGWDHMTVDFTWMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 120
QY 121 ODHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDQCPAQLOQLLELGRGVL 180
DB 121 ODHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDQCPAQLOQLLELGRGVL 180
QY 181 DOQVPLVKVTHHVTSSVTTLCRALNYYPNQITMKWLKDKQPMDAKEPEPKDVL PNGDG 240
DB 181 DOQVPLVKVTHHVTSSVTTLCRALNYYPNQITMKWLKDKQPMDAKEPEPKDVL PNGDG 240
QY 241 TYOGWITLAVPGEQRVTCQVEHFGDLOPLIWIWE 276
DB 241 TYOGWITLAVPGEQRVTCQVEHFGDLOPLIWIWE 276

RESULT 10
AAB36872
ID AAB36872 standard; Protein; 348 AA.
XX
AC AAB36872;
XX
DT 21-FEB-2001 (first entry)
XX
DE Human hereditary hemochromatosis 24d1/2 mutation protein.
XX
KW HH; hereditary hemochromatosis; chelation agent;
KW T-cell differentiation factor; iron overload.
XX
OS Homo sapiens.
XX
PN US6140305-A.
XX
PD 31-OCT-2000.
XX
PF 04-APR-1997; 97US-0834497.
XX
PR 04-APR-1996; 96US-0630912.
PR 16-APR-1996; 96US-0632673.
PR 23-MAY-1996; 96US-0652265.
XX
PA (BIRA) BIO-RAD LAB INC.
XX
PI Thomas WJ, Drayna DT, Gnirke A, Ruddy D, Tsuchihashi Z, Wolff RK;
PI Feder JN;
XX
DR WPI; 2001-006341/01.
DR N-PSDB; AAC68428.
XX
PT New hereditary hemochromatosis gene products or polypeptides, useful
PT for treating hereditary hemochromatosis in a patient, and as a metal
PT chelation agent alleviating iron overload -
XX
PS Claim 4; Fig 4; 108pp; English.
XX
CC The present invention relates to hereditary hemochromatosis gene
CC products. These proteins may be used to treat a patient diagnosed as
CC having human hemochromatosis disease. It is also useful as a metal
CC chelation agent or as a T-cell differentiation factor, and for
CC alleviating iron overload. They may also be used in protein replacement
CC therapy for individuals having a defective human hemochromatosis gene.
XX
SQ Sequence 348 AA;

Query Match 98.7%; Score 1502; DB 22; Length 348;
Best Local Similarity 99.3%; Pred. No. 3.7e-133;
Matches 274; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPEPTPWSSRISSQ 60
DB 23 RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPEPTPWSSRISSQ 82
QY 61 MWLQLSQSLSKLGWDHMTVDFTWMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 120
DB 83 MWLQLSQSLSKLGWDHMTVDFTWMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 142
QY 121 ODHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDQCPAQLOQLLELGRGVL 180
DB 143 ODHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDQCPAQLOQLLELGRGVL 202
QY 181 DOQVPLVKVTHHVTSSVTTLCRALNYYPNQITMKWLKDKQPMDAKEPEPKDVL PNGDG 240
DB 203 DOQVPLVKVTHHVTSSVTTLCRALNYYPNQITMKWLKDKQPMDAKEPEPKDVL PNGDG 262
QY 241 TYOGWITLAVPGEQRVTCQVEHFGDLOPLIWIWE 276
DB 263 TYOGWITLAVPGEQRVTCQVEHFGDLOPLIWIWE 298

RESULT 11
AAB36873
ID AAB36873 standard; Protein; 361 AA.
XX
AC AAB36873;
XX
DT 21-FEB-2001 (first entry)
XX
DE Rabbit leukocyte antigen.
XX
KW HH; hereditary hemochromatosis; chelation agent;
KW T-cell differentiation factor; iron overload.
XX
OS Oryctolagus cuniculus.
XX
PN US6140305-A.
XX
PD 31-OCT-2000.
XX
PF 04-APR-1997; 97US-0834497.
XX
PR 04-APR-1996; 96US-0630912.
PR 16-APR-1996; 96US-0632673.
PR 23-MAY-1996; 96US-0652265.
XX
PA (BIRA) BIO-RAD LAB INC.
XX
PI Thomas WJ, Drayna DT, Gnirke A, Ruddy D, Tsuchihashi Z, Wolff RK;
PI Feder JN;
XX
DR WPI; 2001-006341/01.
XX
PT New hereditary hemochromatosis gene products or polypeptides, useful
PT for treating hereditary hemochromatosis in a patient, and as a metal
PT chelation agent alleviating iron overload -
XX
PS Disclosure; Fig 7; 108pp; English.
XX
CC The present invention relates to hereditary hemochromatosis gene
CC products. These proteins may be used to treat a patient diagnosed as
CC having human hemochromatosis disease. It is also useful as a metal
CC chelation agent or as a T-cell differentiation factor, and for
CC alleviating iron overload. They may also be used in protein replacement
CC therapy for individuals having a defective human hemochromatosis gene.
XX
SQ Sequence 361 AA;

Query Match 34.3%; Score 522; DB 22; Length 361;
Best Local Similarity 40.1%; Pred. No. 9.1e-41;
Matches 111; Conservative 44; Mismatches 114; Indels 8; Gaps 7;
QY 5 SHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPEPTPWSSRISSQ 62

Db	26	SHSMRYFTSVSRGCEPRPIAVGVYDDTQTVRFVSDDAASQRMEDPRAPWBOE-QPEYW 84
Qy	63	LQLSQSLKGDHMTFVDFWTIMENHNHKSKE-SHTLQVILGCMEQED-NSTEGYWKYGYDG 120
Db	85	DGETRKVKASHQTHRVLDGLTGRVYNGSEAGSHTLQMMFGCDVGSWRFLRGVYHQYAYDG 144
Qy	121	QDHLEFCPDILDHRAAEPRAMPRTKLEWERHKIIRARQNRAYLERCDRCPAQLOLLELGRGVL 180
Db	145	KDYIALKEDLSRWTAAADMAAQTTKKWEAAHV-AEQLRAYLEGTCTVEWLRRLYLENGKETL 203
Qy	181	DOQVPLPVKVTHH-VTSSVTTLRCRALNYYPQNTMKWLKDKQPMDAKEFEPEKDVLPNGD 239
Db	204	QRTDAPKTHTHHVAVSDEHATLKCWLSFYPAETLTWDRDGED-QTQDTVELVETRPAGD 262
Qy	240	GYQGWITLAVPGEQRYTCQVEHPGLDQPLIVIVE 276
Db	263	GTFOKWAUVVPSCQEQRYTCHVQHEGLPKPLIRWE 299
RESULT 13		
AAV68275		
ID	AAV68275	standard; Peptide; 274 AA.
XX	AAV68275;	
AC	AAV68275;	
XX		
DT	13-APR-2000	(first entry)
XX		
DE		Human leukocyte antigen A2/A28 family related protein SEQ ID NO:107.
XX		
KW		MHC class I; major histocompatibility complex; microglobulin; antigen
KW		immune response; immunisation; AIDS; multiple sclerosis; toxic shock;
KW		cancer; lupus erythematosus; snake bite; cytostatic; antiviral;
KW		immunomodulatory; dermatological; immunosuppressive; antiinflammatory
KW		neuroprotective.
XX		
OS		Homo sapiens.
XX		
PN		US6011146-A.
XX		
PD		04-JAN-2000.
XX		
PF		07-JUN-1995; 95US-0481985.
XX		
PR		15-NOV-1991; 91US-0792473.
PR		05-DEC-1991; 91US-0801818.
XX		
PA		(INSP) INST PASTEUR.
PA		(INRM) INST NAT SANTE & RECH MEDICALE.
XX		
PI		Kourilsky P, Mottez E, Abastado J;
XX		
DR		WPI; 2000-125951/11.
XX		
PT		New recombinant DNA encoding covalently linked form of major
PT		histocompatibility complex Class I determinant, used for immune system
PT		stimulation, e.g. for treating cancer
XX		
XX		
PS		Disclosure; Column 127-128; 88pp; English.
XX		
CC		The present invention describes a recombinant DNA molecule (I)
CC		containing a sequence (Ia) that encodes an altered MHC (major
CC		histocompatibility complex) Class I determinant (II) comprises a
CC		polypeptide with alpha1, alpha2, alpha3 and beta2-microglobulin
CC		domains, in which alpha3 and beta2 are covalently linked, thorough C-
CC		and N-termini respectively, via a nucleotide spacer sequence encoding
CC		polypeptide. (II) includes an antigen-binding site and when (II) and
CC		the antigen are associated they are recognized by a mammalian T cell
CC		receptor (TCR). (I) are used to produce (II) which are used to study
CC		functional interactions between the various MHC domains. They can also
CC		be used to modulate (in vivo or in vitro) the immune system by induci-
CC		ng an effector response (cytotoxicity, antibody synthesis, phagocytosis)
CC		of immune system cells, typically for treating, or immunising against
CC		cancer, acquired immune deficiency syndrome, lupus erythematosus,

CC multiple sclerosis, toxic shock and snake bite, but also for selective
CC destruction of autoreactive cells, diagnostically to assay T cell
CC receptors and to raise specific antibodies (useful for diagnosis,
CC therapy, studying MHC-associated cellular processes and for affinity
CC purification). AA57558 and AA568186 to AA568316 are sequences used in
CC the exemplification of the present invention.

XX Sequence 274 AA;

Query Match 33.2%; Score 505; DB 21; Length 274;
Best Local Similarity 39.9%; Pred. No. 2.5e-39;
Matches 110; Conservative 43; Mismatches 115; Indels 8; Gaps 7;

QY 5 SHSLHYLFMGASEQDLGLSLFEALGYDDQLFVFDHE--SRRVEPRTPWVSSRISQMW 62
DB 2 SHSMRYFTSVSRGEGPREIAVGYDDTQFVRFSDAASRRMEPRAPWIEQE-GPEYW 60
QY 63 LQLSOSLKGWDHMTFTVDFWTIMENHNSKE-SHTLQVILGCEMOED-NSTGEGYKGYVDG 120
DB 61 DGETRKKVAHSQTHRVLDLSTLRGYNQSEAGSHTLQRMVGDVSGDWRFLRGYHQYAYDG 120
QY 121 QDHLFEFCPDTLDWRAAEPRAMPKLEWERHKIRARONRAYLERDCCPAOLQQLLELGRGVL 180
DB 121 KDYIALKEDLSRWTAAADMAAQTTHKWEAAHV-AEQWRAYLEGTCVEWLRRLYLENGKETL 179
QY 181 DQVPPPLVKVTHH-VTSSVTLRLCRALNYYPQNTMKWKDKQPMDAKEFEFKDVLNPGD 239
DB 180 QRTDAPKTHMTHHVAUSDHEATLRCWALSFPYPAEITLTWQRDGED-QTQDTLVELTRPAGD 238
QY 240 GTYGGWITLAVPGGEQRYTCQVEHPGLDQPLIVW 275
DB 239 GTFOKAAVVPVSGEQRYTCHVQHEGLPKPLTPW 274

RESULT 14
AA52929

ID AA52929 standard; Peptide: 274 AA.

XX AC AA52929;

XX DT 14-FEB-2000 (first entry)

XX DE HLA-A2/A38 family peptide A2.2F SEQ ID NO:107.

XX KW Major histocompatibility complex; MHC class I; MHC class II; antigen;
KW immune response; diagnosis; antibody; immunisation; autoimmune disease;
KW acquired immune deficiency syndrome; AIDS; cytostatic; dermatological;
KW anti-inflammatory; neuroprotective; immunosuppressive; antithyroid;
KW vaccine; lupus erythematosus; multiple sclerosis; thyroiditis;
KW toxic shock; tumour; snakebite.

XX OS Mammalia.

XX PN US976551-A.

XX PD 02-NOV-1999.

XX PF 07-JUN-1995; 95US-0484905.

XX PR 05-DEC-1991; 91US-0801818.

XX PR 13-NOV-1991; 91US-0792473.

XX PA (INSP) INST PASTEUR.

XX PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX PI Kourilsky P, Mottet E, Abastado J;

XX DR WPI; 2000-037081/03.

XX PT Composition containing an antigen and altered major histocompatibility
XX Class II determinant, used to immunize against autoimmune diseases,
XX e.g. acquired immune deficiency syndrome

PS Disclosure; Column 149-152; 96pp; English.

XX The present invention describes a composition capable of eliciting
CC anti-major histocompatibility (MHC) antibodies. The composition
CC comprises an antigen associated with an altered MHC Class II determinant
CC (I) comprising alpha1, alpha2, beta1 and beta2 polypeptide domains
CC encoded by a mammalian MHC Class II locus covalently linked to form a
CC polypeptide (I) containing beta2, alpha2, alpha1 and beta1 domains in
CC sequence. The resulting Antigen-MHC complex is recognizable by the T cell
CC receptor. The compositions are used for immunisation against, or
CC treatment of, a wide range of autoimmune diseases, e.g. acquired immune
CC deficiency syndrome (AIDS), lupus erythematosus, multiple sclerosis,
CC thyroiditis, toxic shock, tumour and snakebite, depending on the nature
CC of antigen. (I) is also used to analyse functional interactions between
CC the various domains and for targeting lymphocyte receptors. Antibodies
CC against (I) are produced by usual methods of immunisation or cell fusion,
CC and may be humanised by standard methods. These antibodies are useful for
CC diagnosis (detection or purification of MHC gene products), therapy
CC (neutralising MHC on cell surfaces) and in the study of MHC and cellular
CC processes. AA33240 to AA33242 and AA52840 to AA52970 represent
CC sequences used in the exemplification of the present invention.

XX Sequence 274 AA;

Query Match 33.2%; Score 505; DB 21; Length 274;
Best Local Similarity 39.9%; Pred. No. 2.5e-39;
Matches 110; Conservative 43; Mismatches 115; Indels 8; Gaps 7;

QY 5 SHSLHYLFMGASEQDLGLSLFEALGYDDQLFVFDHE--SRRVEPRTPWVSSRISQMW 62
DB 2 SHSMRYFTSVSRGEGPREIAVGYDDTQFVRFSDAASRRMEPRAPWIEQE-GPEYW 60
QY 63 LQLSOSLKGWDHMTFTVDFWTIMENHNSKE-SHTLQVILGCEMOED-NSTGEGYKGYVDG 120
DB 61 DGETRKKVAHSQTHRVLDLSTLRGYNQSEAGSHTLQRMVGDVSGDWRFLRGYHQYAYDG 120
QY 121 QDHLFEFCPDTLDWRAAEPRAMPKLEWERHKIRARONRAYLERDCCPAOLQQLLELGRGVL 180
DB 121 KDYIALKEDLSRWTAAADMAAQTTHKWEAAHV-AEQWRAYLEGTCVEWLRRLYLENGKETL 179
QY 181 DQVPPPLVKVTHH-VTSSVTLRLCRALNYYPQNTMKWKDKQPMDAKEFEFKDVLNPGD 239
DB 180 QRTDAPKTHMTHHVAUSDHEATLRCWALSFPYPAEITLTWQRDGED-QTQDTLVELTRPAGD 238
QY 240 GTYGGWITLAVPGGEQRYTCQVEHPGLDQPLIVW 275
DB 239 GTFOKAAVVPVSGEQRYTCHVQHEGLPKPLTPW 274

RESULT 15

AA58690

ID AAB58690 standard; protein; 274 AA.

XX AC AAB58690;

XX DT 13-MAR-2001 (first entry)

XX DE HLA-A2/A28 protein #11.

XX KW Major histocompatibility complex; MHC class I; immune; snake bite;
KW T cell mediated autoimmune disease; AIDS; lupus erythematosus;
KW toxic shock.

XX OS Unidentified.

XX PN US6153408-A.

XX PD 28-NOV-2000.

XX PF 09-JAN-1995; 95US-0370476.

XX PR 15-NOV-1991; 91US-0792473.

XX PR 07-SEP-1993; 93US-0117575.

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 31, 2003, 14:07:04 ; Search time 28. Seconds
(without alignments)
290.026 Million cell updates/sec

Title: US-10-092-404-1

Perfect score: 1522
Sequence: 1 RLRRSHSLHYLFWGASEQDL.....RYTCQVHFGLDQPLIVIME 276

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2.6/ptodata/1/iaa/5A_COMB.pep.*
2: /cgn2.6/ptodata/1/iaa/5B_COMB.pep.*
3: /cgn2.6/ptodata/1/iaa/6A_COMB.pep.*
4: /cgn2.6/ptodata/1/iaa/6B_COMB.pep.*
5: /cgn2.6/ptodata/1/iaa/PCTUS_COMB.pep.*
6: /cgn2.6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1522	100.0	276	4 US-09-094-964-1	Sequence 1, Appl
2	1522	100.0	348	3 US-08-652-265-2	Sequence 2, Appl
3	1522	100.0	348	4 US-08-834-497A-2	Sequence 2, Appl
4	1522	100.0	348	4 US-09-503-444A-2	Sequence 2, Appl
5	1522	100.0	348	4 US-09-277-457-2	Sequence 2, Appl
6	1513	99.4	276	4 US-09-094-964-2	Sequence 2, Appl
7	1513	99.4	348	3 US-08-652-265-6	Sequence 6, Appl
8	1513	99.4	348	4 US-08-834-497A-6	Sequence 6, Appl
9	1513	99.4	348	4 US-09-503-444A-6	Sequence 6, Appl
10	1511	99.3	348	3 US-08-652-265-4	Sequence 4, Appl
11	1511	99.3	348	4 US-08-834-497A-4	Sequence 4, Appl
12	1511	99.3	348	4 US-09-503-444A-4	Sequence 4, Appl
13	1502	98.7	276	4 US-09-094-964-3	Sequence 3, Appl
14	1502	98.7	348	3 US-08-652-265-8	Sequence 8, Appl
15	1502	98.7	348	4 US-08-834-497A-8	Sequence 8, Appl
16	1502	98.7	348	4 US-09-503-444A-8	Sequence 8, Appl
17	522	34.3	361	3 US-08-652-265-22	Sequence 22, Appl
18	522	34.3	361	4 US-08-834-497A-22	Sequence 22, Appl
19	522	34.3	361	4 US-09-503-444A-22	Sequence 22, Appl
20	513	33.7	365	3 US-08-652-265-23	Sequence 23, Appl
21	513	33.7	365	4 US-08-834-497A-23	Sequence 23, Appl
22	513	33.7	365	4 US-09-503-444A-23	Sequence 23, Appl
23	505	33.2	274	3 US-08-484-905-107	Sequence 107, App
24	505	33.2	274	3 US-08-481-985B-107	Sequence 107, App
25	505	33.2	274	4 US-08-370-476-107	Sequence 107, App
26	505	33.2	341	3 US-08-890-719-38	Sequence 38, Appl
27	504	33.1	365	2 US-08-484-905-97	Sequence 97, Appl

28	504	33.1	365	3	US-08-481-985B-97	Sequence 97, Appl
29	504	33.1	365	4	US-08-370-476-97	Sequence 97, Appl
30	503	33.0	274	2	US-08-484-905-108	Sequence 108, App
31	503	33.0	274	3	US-08-481-985B-108	Sequence 108, App
32	503	33.0	274	4	US-08-370-476-108	Sequence 108, App
33	503	33.0	365	2	US-08-484-905-100	Sequence 100, App
34	503	33.0	365	3	US-08-481-985B-100	Sequence 100, App
35	503	33.0	365	4	US-08-370-476-100	Sequence 100, App
36	502	33.0	274	1	US-08-222-851-1	Sequence 1, Appl
37	502	33.0	365	2	US-08-484-905-99	Sequence 99, Appl
38	502	33.0	365	3	US-08-481-985B-99	Sequence 99, Appl
39	502	33.0	365	4	US-08-370-476-99	Sequence 99, Appl
40	501	32.9	274	2	US-08-484-905-106	Sequence 106, App
41	501	32.9	274	3	US-08-481-985B-106	Sequence 106, App
42	501	32.9	274	4	US-08-370-476-106	Sequence 106, App
43	501	32.9	365	2	US-08-484-905-98	Sequence 98, Appl
44	501	32.9	365	3	US-08-481-985B-98	Sequence 98, Appl
45	501	32.9	365	4	US-08-370-476-98	Sequence 98, Appl

ALIGNMENTS

RESULT 1
US-09-094-964-1
; Sequence 1, Application US/09094964
; Patent No. 6391852
; GENERAL INFORMATION:
; APPLICANT: Feder, John N.
; APPLICANT: Bjorkman, Pamela J.
; APPLICANT: Schatzman, Randall C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF IRON OVERLOAD DISEASES
; TITLE OF INVENTION: AND IRON DEFICIENCY DISEASES
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds, LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,964
; FILING DATE: June 12, 1998
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/876,010
; FILING DATE: June 13, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Poissant, Brian M
; REGISTRATION NUMBER: 28,462
; REFERENCE/DOC# NUMBER: 8907-0074-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; TYPE: amino acid
; LENGTH: 276 amino acids
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-094-964-1

Query Match 100.0%; Score 1522; DB 4; Length 276;
Best Local Similarity 100.0%; Pred. No. 1.4e-142;

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-834-497A-2

Query Match 100.0%; Score 1522; DB 4; Length 348;
Best Local Similarity 100.0%; Pred. No. 1.9e-142;
Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASEQDLGLSLFALGYVDDQLFVFDHESRRRVEPRTPMWSSRISSQ 60
DB 23 RLLRSHSLHYLFMGASEQDLGLSLFALGYVDDQLFVFDHESRRRVEPRTPMWSSRISSQ 82

QY 61 MWLQSLQSLKGWDHMTVDFTWIMENHNHKSHTLQVILGCEMQEDNSTEGYWKYGYDG 120
DB 83 MWLQSLQSLKGWDHMTVDFTWIMENHNHKSHTLQVILGCEMQEDNSTEGYWKYGYDG 142

QY 121 QHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVL 180
DB 143 QHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVL 202

QY 181 DQOVPLVKVTHVTSVTTLCRALNYYPONTMKNLKDOPMDAKEPEPKDVLPGDNG 240
DB 203 DQOVPLVKVTHVTSVTTLCRALNYYPONTMKNLKDOPMDAKEPEPKDVLPGDNG 262

QY 241 TYQGWITLAVPGEEOQRYTCQVEHPGLDQPLIVIE 276
DB 263 TYQGWITLAVPGEEOQRYTCQVEHPGLDQPLIVIE 298

RESULT 4

US-09-503-444A-2
Sequence 2, Application US/09503444A
Patent No. 6228594
GENERAL INFORMATION:
APPLICANT: Thomas, Winston J.
APPLICANT: Drayna, Dennis T.
APPLICANT: Feder, John N.
APPLICANT: Gnirke, Andreas
APPLICANT: Ruddy, David
APPLICANT: Tsuchihashi, Zenta
APPLICANT: Wolff, Roger K.
TITLE OF INVENTION: Hereditary Hemochromatosis Gene
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: pennie & Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: WordPerfect Version 8
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/503,444A
FILING DATE: 14-Feb-2000
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/652,265
FILING DATE: 23-May-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/632,673
FILING DATE: 16-Apr-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/630,912
FILING DATE: 04-Apr-1996
ATTORNEY/AGENT INFORMATION:
NAME: Poissant, Brian M.
REGISTRATION NUMBER: 28,462
REFERENCE/DOCKET NUMBER: 8907-0088-999

TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-9741
TELEX: 66141
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 348 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-503-444A-2

Query Match 100.0%; Score 1522; DB 4; Length 348;
Best Local Similarity 100.0%; Pred. No. 1.9e-142;
Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASEQDLGLSLFALGYVDDQLFVFDHESRRRVEPRTPMWSSRISSQ 60
DB 23 RLLRSHSLHYLFMGASEQDLGLSLFALGYVDDQLFVFDHESRRRVEPRTPMWSSRISSQ 82

QY 61 MWLQSLQSLKGWDHMTVDFTWIMENHNHKSHTLQVILGCEMQEDNSTEGYWKYGYDG 120
DB 83 MWLQSLQSLKGWDHMTVDFTWIMENHNHKSHTLQVILGCEMQEDNSTEGYWKYGYDG 142

QY 121 QHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVL 180
DB 143 QHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVL 202

QY 181 DQOVPLVKVTHVTSVTTLCRALNYYPONTMKNLKDOPMDAKEPEPKDVLPGDNG 240
DB 203 DQOVPLVKVTHVTSVTTLCRALNYYPONTMKNLKDOPMDAKEPEPKDVLPGDNG 262

QY 241 TYQGWITLAVPGEEOQRYTCQVEHPGLDQPLIVIE 276
DB 263 TYQGWITLAVPGEEOQRYTCQVEHPGLDQPLIVIE 298

RESULT 5

US-09-277-457-2
Sequence 2, Application US/09277457
Patent No. 6355425
GENERAL INFORMATION:
APPLICANT: Rothenberg, Barry E.
APPLICANT: Sawada-Hirai, Ritsuko
APPLICANT: Barton, James C.
TITLE OF INVENTION: MUTATIONS ASSOCIATED WITH IRON DISORDERS
FILE REFERENCE: 10653/002001
CURRENT APPLICATION NUMBER: US/09/277,457
CURRENT FILING DATE: 1999-03-26
NUMBER OF SEQ ID NOS: 30
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 348
TYPE: PRT
ORGANISM: Homo Sapiens
US-09-277-457-2

Query Match 100.0%; Score 1522; DB 4; Length 348;
Best Local Similarity 100.0%; Pred. No. 1.9e-142;
Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSHSLHYLFMGASEQDLGLSLFALGYVDDQLFVFDHESRRRVEPRTPMWSSRISSQ 60
DB 23 RLLRSHSLHYLFMGASEQDLGLSLFALGYVDDQLFVFDHESRRRVEPRTPMWSSRISSQ 82

QY 61 MWLQSLQSLKGWDHMTVDFTWIMENHNHKSHTLQVILGCEMQEDNSTEGYWKYGYDG 120
DB 83 MWLQSLQSLKGWDHMTVDFTWIMENHNHKSHTLQVILGCEMQEDNSTEGYWKYGYDG 142

QY 121 QHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVL 180
DB 143 QHLEFCPDTLDWRAAEPRAPWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVL 202

Query Match 99.4%; Score 1513; DB 4; Length 276;
Best Local Similarity 99.6%; Pred. NO. 1.1e-141;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

	Matches	2/3; Conservative	Mismatches	Indels	Gaps
Qy	1	RLLRSHLHFLFMGASEQDGLSLFALGYVDDQFLVFYDHESRRRVEPRTPWVSSRISSQ	0	1	0

RESULT 7
US-08-652-265-6
: Sequence 6, Application US/08652265
: Patent No. 6025130
: GENERAL INFORMATION:
: APPLICANT: Thomas, Winston J.
: APPLICANT: Drayna, Dennis T.
: APPLICANT: Feder, John N.
: APPLICANT: Gnirke, Andreas
: APPLICANT: Ruddy, David
: APPLICANT: Tsuchihashi, Zenta
: APPLICANT: Wolff, Roger K.
: TITLE OF INVENTION: Hereditary Hemochromatosis Gene
: NUMBER OF SEQUENCES: 44
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Townsend and Townsend and Crew LLP
: STREET: Two Embarcadero Center, Eighth Floor
: CITY: San Francisco
: STATE: California
: COUNTRY: USA
: ZIP: 94111-3834
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/652,265
: FILING DATE: 23-MAY-1996
: CLASSIFICATION: 514
: ATTORNEY/AGENT INFORMATION:
: NAME: Smith, William M.
: REGISTRATION NUMBER: 30,223
: REFERENCE/DOCKET NUMBER: 17957-000500
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 576-0200
: TELEFAX: (415) 576-0300
: INFORMATION FOR SEQ ID NO: 6:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 348 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
US-08-652-265-6

Query Match 99.4%; Score 1513; DB 3; Length 348;
Best Local Similarity 99.6%; Pred. No. 1.5e-141;
Matches 275; Conservative 0; Mismatches 1; Indels

QY	1	RLRSHSLHYLFMGASBQDGLGLSLFALG	VYDQDLFFVYDHSRRVPEPRTPWVSSRISSQ	60
Db	23	RLRSHSLHYLFMGASBQDGLGLSLFALG	VYDQDLFFVYDHSRRVPEPRTPWVSSRISSQ	82
QY	61	MWLQSLSLKGWDMHFTVDFWTTMEHNHSHKESHT	LQVILGCEMQEDNSTEGYWKYGYDG	120
Db	83	MWLQSLSLKGWDMHFTVDFWTTMEHNHSHKESHT	LQVILGCEMQEDNSTEGYWKYGYDG	142
QY	121	QDHLFCFDTLDWRAAEPRAMPKTLKLEWRIKIRARONRAY	LERDCEPAQLQQLLELGRGVL	180
Db	143	QDHLFCFDTLDWRAAEPRAMPKTLKLEWRIKIRARONRAY	LERDCEPAQLQQLLELGRGVL	202
QY	181	DOQVPLPVKVTHTVSSVTTLRCAUNYYPONTIMKWLKDQ	PMDAKEFEKDPVLPNGDG	240
Db	203	DOQVPLPVKVTHTVSSVTTLRCAUNYYPONTIMKWLKDQ	PMDAKEFEKDPVLPNGDG	262

QY 241 TYQGWITLAVPPGEQORYTCQVEHPGLDQPLIWIWE 276
|||||
Db 263 TYQGWITLAVPPGEQORYTCQVEHPGLDQPLIWIWE 298

RESULT 8

US-08-834-497A-6
; Sequence 6, Application US/08834497A
; Patent No. 6140305
; GENERAL INFORMATION:
; APPLICANT: Thomas, Winston J.
; APPLICANT: Drayna, Dennis T.
; APPLICANT: Feder, John N.
; APPLICANT: Goirke, Andreas
; APPLICANT: Ruddy, David
; APPLICANT: Tsuchihashi, Zenta
; APPLICANT: Wolff, Roger K.
; TITLE OF INVENTION: HEREDITARY HEMOCHROMATOSIS GENE PRODUCTS
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/834,497A
; FILING DATE: 04-APR-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/652,265
; FILING DATE: 23-MAY-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/632,673
; FILING DATE: 16-APR-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,912
; FILING DATE: 04-APR-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Poissant, Brian M.
; REGISTRATION NUMBER: 28,462
; REFERENCE/DOCKET NUMBER: 8907-0056-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 348 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-834-497A-6

Query Match 99.4%; Score 1513; DB 4; Length 348;
Best Local Similarity 99.6%; Pred. No. 1.5e-141;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RLLRSHSLHYLPMGASEQDGLSLFALGYVDDQLFVFDHESRRVPRTPWVSSRISSQ 60
|||||
Db 23 RLLRSHSLHYLPMGASEQDGLSLFALGYVDDQLFVFDHESRRVPRTPWVSSRISSQ 82
QY 61 MWLQLSQLKGWDHMTVDFTWIMENHNHNSKESHTLQVLGCEMQEDNSTEGYWKYGYDG 120

Db 83 MWLQLSQLKGWDHMTVDFTWIMENHNHNSKESHTLQVLGCEMQEDNSTEGYWKYGYDG 142
QY 121 QHLEFCPDTLWRAAEPRAWPTKLEWERHKIRARONRAYLERDPCPAQLQQLLELGRGVL 180
|||||
Db 143 QHLEFCPDTLWRAAEPRAWPTKLEWERHKIRARONRAYLERDPCPAQLQQLLELGRGVL 202
QY 181 DQOVPLVKVTHVTSSVTTLCRALNYYPNITMKWLKDKQPMDAKEPEKDVLPNGDG 240
|||||
Db 203 DQOVPLVKVTHVTSSVTTLCRALNYYPNITMKWLKDKQPMDAKEPEKDVLPNGDG 262
QY 241 TYQGWITLAVPPGEQORYTCQVEHPGLDQPLIWIWE 276
|||||
Db 263 TYQGWITLAVPPGEQORYTCQVEHPGLDQPLIWIWE 298

RESULT 9

US-09-503-444A-6
; Sequence 6, Application US/09503444A
; Patent No. 6228594
; GENERAL INFORMATION:
; APPLICANT: Thomas, Winston J.
; APPLICANT: Drayna, Dennis T.
; APPLICANT: Feder, John N.
; APPLICANT: Goirke, Andreas
; APPLICANT: Ruddy, David
; APPLICANT: Tsuchihashi, Zenta
; APPLICANT: Wolff, Roger K.
; TITLE OF INVENTION: Hereditary Hemochromatosis Gene
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect Version 8
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/503,444A
; FILING DATE: 14-Feb-2000
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/652,265
; FILING DATE: 23-May-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/632,673
; FILING DATE: 16-Apr-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/630,912
; FILING DATE: 04-Apr-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Poissant, Brian M.
; REGISTRATION NUMBER: 28,462
; REFERENCE/DOCKET NUMBER: 8907-0088-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-790-9090
; TELEFAX: 212-869-9741
; TELEX: 66141
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 348 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-503-444A-6
Query Match 99.4%; Score 1513; DB 4; Length 348;
Best Local Similarity 99.6%; Pred. No. 1.5e-141;

```
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RLLRSHSLHYLFMGASEQDGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 60
Db 23 RLLRSHSLHYLFMGASEQDGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 82
QY 61 MWLQSLKSGWDMFTVDFWTIMENHNHSHKESHTLQVILGCEQEDNSTEGYWKYGYDG 120
Db 83 MWLQSLKSGWDMFTVDFWTIMENHNHSHKESHTLQVILGCEQEDNSTEGYWKYGYDG 142
QY 121 QDHLFPCPDTLDWRAAEPRAMPPTKLEWHRHKIRARQNRAYLERDCPAQLOQLLELGRGVL 180
Db 143 QDHLFPCPDTLDWRAAEPRAMPPTKLEWHRHKIRARQNRAYLERDCPAQLOQLLELGRGVL 202
QY 181 DQVPPPLVKVTHHTVSSVTTLCRCALNYPQNTMKWLKDKQPMDAKEFEFKDVLPGNDG 240
Db 203 DQVPPPLVKVTHHTVSSVTTLCRCALNYPQNTMKWLKDKQPMDAKEFEFKDVLPGNDG 262
QY 241 TYQGWITLAVPPGGEQRYTCQVEHPGLDQPLIVWE 276
Db 263 TYQGWITLAVPPGGEQRYTCQVEHPGLDQPLIVWE 298

RESULT 10
US-08-652-265-4
; Sequence 4, Application US/08652265
; Patent No. 6025130
; GENERAL INFORMATION:
; APPLICANT: Thomas, Winston J.
; APPLICANT: Drayna, Dennis T.
; APPLICANT: Feder, John N.
; APPLICANT: Gnirke, Andreas
; APPLICANT: Ruddy, David
; APPLICANT: Tsuchihashi, Zenta
; APPLICANT: Wolff, Roger K.
; TITLE OF INVENTION: Hereditary Hemochromatosis Gene
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/652,265
; FILING DATE: 23-MAY-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 17957-000500
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 348 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-652-265-4
Query Match 99.3%; Score 1511; DB 3; Length 348;
Best Local Similarity 99.6%; Pred. No. 2.3e-141;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 RLLRSHSLHYLFMGASEQDGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 60
```

```
Db 23 RLLRSHSLHYLFMGASEQDGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 82
QY 61 MWLQSLKSGWDMFTVDFWTIMENHNHSHKESHTLQVILGCEQEDNSTEGYWKYGYDG 120
Db 83 MWLQSLKSGWDMFTVDFWTIMENHNHSHKESHTLQVILGCEQEDNSTEGYWKYGYDG 142
QY 121 QDHLFPCPDTLDWRAAEPRAMPPTKLEWHRHKIRARQNRAYLERDCPAQLOQLLELGRGVL 180
Db 143 QDHLFPCPDTLDWRAAEPRAMPPTKLEWHRHKIRARQNRAYLERDCPAQLOQLLELGRGVL 202
QY 181 DQVPPPLVKVTHHTVSSVTTLCRCALNYPQNTMKWLKDKQPMDAKEFEFKDVLPGNDG 240
Db 203 DQVPPPLVKVTHHTVSSVTTLCRCALNYPQNTMKWLKDKQPMDAKEFEFKDVLPGNDG 262
QY 241 TYQGWITLAVPPGGEQRYTCQVEHPGLDQPLIVWE 276
Db 263 TYQGWITLAVPPGGEQRYTCQVEHPGLDQPLIVWE 298

RESULT 11
US-08-834-497A-4
; Sequence 4, Application US/08834497A
; Patent No. 6140305
; GENERAL INFORMATION:
; APPLICANT: Thomas, Winston J.
; APPLICANT: Drayna, Dennis T.
; APPLICANT: Feder, John N.
; APPLICANT: Gnirke, Andreas
; APPLICANT: Ruddy, David
; APPLICANT: Tsuchihashi, Zenta
; APPLICANT: Wolff, Roger K.
; TITLE OF INVENTION: HEREDITARY HEMOCHROMATOSIS GENE PRODUCTS
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/834,497A
; FILING DATE: 04-APR-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/652,265
; FILING DATE: 23-MAY-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/630,912
; FILING DATE: 04-APR-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Poissant, Brian M.
; REGISTRATION NUMBER: 28,462
; REFERENCE/DOCKET NUMBER: 8907-0056-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 348 amino acids
```

```

; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-834-497A-4

Query Match          99.3%: Score 1511; DB 4; Length 348;
Best Local Similarity 99.6%: Pred. No. 2.3e-141;
Matches 275; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 RLLRSHSLHLVLFMGASQDGLGLSLFEALGYVDDQLFVFDHESRRVPRTPWVSSRISSQ 60
   |||||
Db 23 RLLRSHSLHLVLFMGASQDGLGLSLFEALGYVDDQLFVFDHESRRVPRTPWVSSRISSQ 82
   |||||

QY 61 MWLQLSQSLKGWDMFTVDFWTTIMENHNHKSHTLQVILGCMEQEDNSTEGYWKYGYDG 120
   |||||
Db 83 MWLQLSQSLKGWDMFTVDFWTTIMENHNHKSHTLQVILGCMEQEDNSTEGYWKYGYDG 142
   |||||

QY 121 QDHLFECDDTLDMRAAPRAWPTKLEWRHKIRARONRAYLERDQPAQLQLLELGRGVL 180
   |||||
Db 143 QDHLFECDDTLDMRAAPRAWPTKLEWRHKIRARONRAYLERDQPAQLQLLELGRGVL 202
   |||||

QY 181 DQQVPLPVKVTHVHTSSVTLRCRALNYPONITMKWLKDKQPMDAKEFEFKDVLPNGDG 240
   |||||
Db 203 DQQVPLPVKVTHVHTSSVTLRCRALNYPONITMKWLKDKQPMDAKEFEFKDVLPNGDG 262
   |||||

QY 241 TYGQWITLAVPPGEGEQRYYTCQVEHPGLDQDPLVIWE 276
   |||||
Db 263 TYGQWITLAVPPGEGEQRYYTCQVEHPGLDQDPLVIWE 298
   |||||

RESULT 12
US-09-503-444A-4
; Sequence 4, Application US/0950344A
; Patent No. 6228594
; GENERAL INFORMATION:
; APPLICANT: Thomas, Winston J.
; APPLICANT: Drayna, Dennis T.
; APPLICANT: Feder, John N.
; APPLICANT: Gnirke, Andreas
; APPLICANT: Ruddy, David
; APPLICANT: Tsuchihashi, Zenta
; APPLICANT: Wolff, Roger K.
; TITLE OF INVENTION: Hereditary Hemochromatosis Gene
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect Version 8
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/503,444A
; FILING DATE: 14-Feb-2000
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/652,265
; FILING DATE: 23-May-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/632,673
; FILING DATE: 16-Apr-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/630,912
; FILING DATE: 04-Apr-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Poissant, Brian M.
; REGISTRATION NUMBER: 28,462
; REFERENCE/DOCKET NUMBER: 8907-0088-999

```

TELEPHONE: 650-493-4935
TELEFAX: 650-493-5556
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 276 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-094-964-3

Query Match 98.7%; Score 1502; DB 4; Length 276;
Best Local Similarity 99.3%; Pred. No. 1.3e-140;
Matches 274; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RLLRSHSHYLFMGASEODLGLSLFEALGYVDDQLFVYDHSRVRERPTPMWSSRISQ 60
Db 1 RLLRSHSHYLFMGASEODLGLSLFEALGYVDDQLFVYDHSRVRERPTPMWSSRISQ 60
Qy 61 MWLQLSQSLKGDHMTVDFTIMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 120
Db 61 MWLQLSQSLKGDHMTVDFTIMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 120
Qy 121 QDHLEFCPDTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRVYL 180
Db 121 QDHLEFCPDTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRVYL 180
Qy 181 DOQVPLVKVTHHTVSSVTTLCRCALNYPONITMKWLKDKOPMDAKEFEKPDVLPNGDG 240
Db 181 DOQVPLVKVTHHTVSSVTTLCRCALNYPONITMKWLKDKOPMDAKEFEKPDVLPNGDG 240
Qy 241 TYQGWTITLAVPPGGEORYTCQVEHPGLDQPLIWIWE 276
Db 241 TYQGWTITLAVPPGGEORYTCQVEHPGLDQPLIWIWE 276

RESULT 14
US-08-652-265-8
Sequence 8, Application US/08652265
Patent No. 6025130
GENERAL INFORMATION:
APPLICANT: Thomas, Winston J.
APPLICANT: Drayna, Dennis T.
APPLICANT: Feder, John N.
APPLICANT: Gnirke, Andreas
APPLICANT: Ruddy, David
APPLICANT: Tsuchihashi, Zenta
APPLICANT: Wolff, Roger K.
TITLE OF INVENTION: Hereditary Hemochromatosis Gene
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652,265
FILING DATE: 23-MAY-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30, 223
REFERENCE/DOCKET NUMBER: 17957-000500
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 348 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-652-265-8

Query Match 98.7%; Score 1502; DB 3; Length 348;
Best Local Similarity 99.3%; Pred. No. 1.8e-140;
Matches 274; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RLLRSHSHYLFMGASEODLGLSLFEALGYVDDQLFVYDHSRVRERPTPMWSSRISQ 60
Db 23 RLLRSHSHYLFMGASEODLGLSLFEALGYVDDQLFVYDHSRVRERPTPMWSSRISQ 82
Qy 61 MWLQLSQSLKGDHMTVDFTIMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 120
Db 83 MWLQLSQSLKGDHMTVDFTIMENHNHKSHTLQVILGCEMOEDNSTEGYWKYGYDG 142
Qy 121 QDHLEFCPDTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRVYL 180
Db 143 QDHLEFCPDTLDWRAAEPRAMPPTKLEWERHKIRARQNRAYLERDCPAQLQELLEGRVYL 202
Qy 181 DOQVPLVKVTHHTVSSVTTLCRCALNYPONITMKWLKDKOPMDAKEFEKPDVLPNGDG 240
Db 203 DOQVPLVKVTHHTVSSVTTLCRCALNYPONITMKWLKDKOPMDAKEFEKPDVLPNGDG 262
Qy 241 TYQGWTITLAVPPGGEORYTCQVEHPGLDQPLIWIWE 276
Db 263 TYQGWTITLAVPPGGEORYTCQVEHPGLDQPLIWIWE 298

RESULT 15
US-08-834-497A-8
Sequence 8, Application US/08834497A
Patent No. 6140305
GENERAL INFORMATION:
APPLICANT: Thomas, Winston J.
APPLICANT: Drayna, Dennis T.
APPLICANT: Feder, John N.
APPLICANT: Gnirke, Andreas
APPLICANT: Ruddy, David
APPLICANT: Tsuchihashi, Zenta
APPLICANT: Wolff, Roger K.
TITLE OF INVENTION: HEREDITARY HEMOCHROMATOSIS GENE PRODUCTS
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2811
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: FastSeq for Windows Version 2.0b
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/834,497A
FILING DATE: 04-APR-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/652,265
FILING DATE: 23-MAY-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/632,673
FILING DATE: 16-APR-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/630,912
FILING DATE: 04-APR-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Poissant, Brian M.
REGISTRATION NUMBER: 28,462
REFERENCE/DOCKET NUMBER: 8907-0056-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-493-4935
TELEFAX: 650-493-5556
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 348 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-834-497A-8

Query Match 98.7%; Score 1502; DB 4; Length 348;
Best Local Similarity 99.3%; Pred. No. 1.8e-140;
Matches 274; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	1	RLRSHSLHYLFMGASEQDGLSLFEALGYVDDQLFVFDHESRRVPRTPWVSSRISSQ	60
Db	23	RLRSHSLHYLFMGASEQDGLSLFEALGYVDDQLFVFDHESRRVPRTPWVSSRISSQ	82
QY	61	MWLQSLQSLKGWDHMTVDFTIMEHNHNSKESHTLQVILGCEMOEDNSTEGYKYGVDG	120
Db	83	MWLQSLQSLKGWDHMTVDFTIMEHNHNSKESHTLQVILGCEMOEDNSTEGYKYGVDG	142
QY	121	QDHLEFCPTDLWRAAEPRAWPTKLEWERHKIRARONRAYLERDCPAQLQQLLELGRGVL	180
Db	143	QDHLEFCPTDLWRAAEPRAWPTKLEWERHKIRARONRAYLERDCPAQLQQLLELGRGVL	202
QY	181	DQVPPPLVKYTHVTSVTTLRCRALNYYPONITMKWKDKQPMDAKEFEPEKDVLPNGDG	240
Db	203	DQVPPPLVKYTHVTSVTTLRCRALNYYPONITMKWKDKQPMDAKEFEPEKDVLPNGDG	262
QY	241	TYOGWITLAVPPGGEQRYTCQVEHPGLDQPLIVIWE	276
Db	263	TYOGWITLAVPPGGEQRYTYQVEHPGLDQPLIVIWE	298

Search completed: March 31, 2003, 14:10:25
Job time : 30 secs

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 31, 2003, 14:09:13 ; Search time 35 Seconds
(without alignments)
463.078 Million cell updates/sec

Title: US-10-092-404-1

Perfect score: 1522

Sequence: 1 RLLRSHSLHYLFMGASEQDL.....RYTCQVHFGLDQPLIVWE 276

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 237916 seqs, 58723674 residues

Total number of hits satisfying chosen parameters: 237916

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published_Applications_AA.*

```
1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
2: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
8: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
9: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
10: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
12: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pep.*
13: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
14: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*
```

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	514	33.8	92	9	US-10-016-634A-120
2	505	33.2	280	9	US-10-073-300-6
3	505	33.2	415	9	US-10-073-300-5
4	476	31.3	542	9	US-10-015-535-32
5	476	31.3	542	9	US-10-015-535-34
6	475	31.2	542	9	US-10-015-535-36
7	473	31.1	540	9	US-10-015-535-22
8	473	31.1	541	9	US-10-015-535-28
9	473	31.1	542	9	US-10-015-535-24
10	473	31.1	542	9	US-10-015-535-26
11	447	29.4	332	10	US-09-870-521-3
12	444	29.2	540	9	US-10-015-535-30
13	443	29.1	334	10	US-09-870-521-4
14	358.5	23.6	170	10	US-09-925-301-1307
15	335	22.0	271	10	US-09-925-301-1431
16	275	18.1	145	10	US-09-810-560-8
17	242	15.9	184	9	US-09-858-580-21
18	242	15.9	184	9	US-09-847-172-21
19	226	14.8	91	10	US-09-864-761-38005

```
20 223 14.7 91 10 US-09-864-761-35461 Sequence 35461, A
21 210.5 13.8 104 10 US-09-925-302-835 Sequence 835, App
22 207 13.6 117 10 US-09-810-560-9 Sequence 9, Appli
23 196.5 12.9 93 10 US-09-864-761-39479 Sequence 39479, A
24 196.5 12.9 110 10 US-09-864-761-35339 Sequence 35339, A
25 196.5 12.9 114 10 US-09-864-761-37988 Sequence 37988, A
26 174.5 11.5 261 9 US-09-925-664-30 Sequence 30, Appl
27 174 11.4 411 9 US-10-015-536-17 Sequence 17, Appl
28 173 11.4 110 9 US-09-796-692-799 Sequence 799, App
29 173 11.4 110 9 US-09-796-692-2139 Sequence 2139, App
30 171.5 11.3 285 10 US-09-756-983-24 Sequence 24, Appl
31 167 11.0 772 10 US-09-815-837-74 Sequence 74, Appl
32 166.5 10.9 448 12 US-10-081-281-111 Sequence 111, App
33 166 10.9 246 9 US-09-992-598-225 Sequence 225, App
34 166 10.9 246 9 US-09-989-293A-225 Sequence 225, App
35 166 10.9 246 9 US-09-989-735-225 Sequence 225, App
36 166 10.9 246 9 US-09-990-444-225 Sequence 225, App
37 166 10.9 246 9 US-09-989-730-225 Sequence 225, App
38 166 10.9 246 9 US-09-990-436-225 Sequence 225, App
39 166 10.9 246 9 US-09-991-181-225 Sequence 225, App
40 166 10.9 246 9 US-09-993-687-225 Sequence 225, App
41 166 10.9 246 9 US-09-989-734-225 Sequence 225, App
42 166 10.9 246 9 US-10-028-072-436 Sequence 436, App
43 166 10.9 246 9 US-09-997-653-225 Sequence 225, App
44 166 10.9 246 9 US-10-174-590-600 Sequence 600, App
45 166 10.9 246 9 US-10-176-758-600 Sequence 600, App
```

ALIGNMENTS

RESULT 1

US-10-016-634A-120
Sequence 120, Application US/10016634A
Publication No. US20020192666A1

GENERAL INFORMATION:
APPLICANT: Sun, Yongming
APPLICANT: Recipon, Hervé

APPLICANT: Ghosh, Malavika

APPLICANT: Liu, Chinghua

TITLE OF INVENTION: Compositions and Methods Relating to Colon Specific Genes and

FILE REFERENCE: DEX-0255

CURRENT APPLICATION NUMBER: US/10/016,634A

CURRENT FILING DATE: 2001-10-31

PRIOR APPLICATION NUMBER: US 60/244,258

PRIOR FILING DATE: 2000-10-31

NUMBER OF SEQ ID NOS: 176

SOFTWARE: PatentIn version 3.1

SEQ ID NO 120

LENGTH: 92

TYPE: PRT

ORGANISM: Homo sapiens

US-10-016-634A-120

Query Match 33.8%; Score 514; DB 9; Length 92;

Best Local Similarity 100.0%; Pred. No. 4.5e-40;

Matches 92; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 ESHTLQVILCCMQEDNSTEGYWKYGDGQDHLFCFDDTLDWRAAEPRAWPTKLEWRHK 151
|||||

Db 1 ESHTLQVILCCMQEDNSTEGYWKYGDGQDHLFCFDDTLDWRAAEPRAWPTKLEWRHK 60
|||||

QY 152 IRARQNAYLERDCPAQLQQLLELGRGVLDQ 183
|||||

Db 61 IRARQNAYLERDCPAQLQQLLELGRGVLDQ 92
|||||

RESULT 2

US-10-073-300-6

Sequence 6, Application US/10073300

Publication No. US2003000353A1

GENERAL INFORMATION:

APPLICANT: Reiter, Yoram


```

> US-10-015-335-22
> Sequence 22, Application US/10015535
> Publication No. US20030036506A1
> GENERAL INFORMATION:
> APPLICANT: Kranz, David M.
> APPLICANT: Brophy, Susan
> TITLE OF INVENTION: Mutated Class I Major Histocompatibility proteins a
> TITLE OF INVENTION: Complexes
> FILE REFERENCE: 100-00
> CURRENT APPLICATION NUMBER: US/10/015,535
> CURRENT FILING DATE: 2001-12-10
> PRIOR APPLICATION NUMBER: 60/254,495
> PRIOR FILING DATE: 2000-12-08
> NUMBER OF SEQ ID NOS: 37
> SOFTWARE: PatentIn Ver. 2.0
> SEQ ID NO 22
> LENGTH: 540
> TYPE: PRT
> ORGANISM: Artificial Sequence
> FEATURE:

```

[illegible]

361 TFQAWASVVVPLGKREYIITCHVHQGLFEPLLRWE 410
 DO
 RESULT 8
 US-10-015-535-28
 ; Sequence 28, Application US/10015535
 ; Publication No. US20030036506A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kranz, David M.
 ; APPLICANT: Brophy, Susan
 ; TITLE OF INVENTION: Mutated Class I Major Histocompatibility proteins a
 ; TITLE OF INVENTION: Complexes
 ; FILE REFERENCE: 100-00

APPLICANT: Goto, Ronald
; TITLE OF INVENTION: METHOD FOR BREEDING AND GENOTYPING CHICKENS AND PROBES THEREFOR
; FILE REFERENCE: 1954-310
; CURRENT APPLICATION NUMBER: US/09/870,521
; CURRENT FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208471
; PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Gallus sp.
US-09-870-521-3

Query Match 29.4%; Score 447; DB 10; Length 332;
Best Local Similarity 35.3%; Pred. No. 3.2e-33;
Matches 96; Conservative 49; Mismatches 125; Indels 2; Gaps 2;
Qy 5 SHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQMWLQ 64
Db 2 SHSLRYFLTGMDPGPGMPRFVIVGVDDKIFGTYSKSRTAQPIVEMLPQE-DQEHWD 60
Qy 65 LSQSLKGDHMTVDVFTWIMENHNHSHKESHTLQVILGCEMQEDNSTEGYWKYGYDGDHL 124
Db 61 OTQKAQGGERDFDNLNRLPERYNKSGSHTMQMMFGCDILEDSIRGYDQVAFDGRFL 120
Qy 125 EFCPTDLWRAAPRAWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVLDQ 184
Db 121 AFDMDTMTFTAADPVAETTKRWETEGTYAERKKHELGTVCVQNLRRYLEHSGAALKRRV 180
Qy 185 PPLVKVTHVTSVTTLCRCALNYYPNITMKWLKDKQPMDAKEPEKDVLPNGDGTQY 244
Db 181 QPEVRWCKEADGILTLSCAHGFFPRPTISWMDGWVRD-QETRWGGIVPNSDGTIHA 239
Qy 245 WITLAVPGEQRYTCQVEHPGLDQPLIWI 276
Db 240 SAAIDVLPEDGDKYWCVRVEHASLPQGLFSWE 271

RESULT 12
US-10-015-535-30
; Sequence 30, Application US/10015535
; Publication No. US20030036506A1
; GENERAL INFORMATION:
; APPLICANT: Krausz, David M.
; APPLICANT: Brophy, Susan
; TITLE OF INVENTION: Mutated Class I Major Histocompatibility proteins and
; FILE REFERENCE: 100-00
; CURRENT APPLICATION NUMBER: US/10/015,535
; CURRENT FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/254,495
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 30
; LENGTH: 540
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-015-535-30

Query Match 29.2%; Score 444; DB 9; Length 540;
Best Local Similarity 35.9%; Pred. No. 1.1e-32;
Matches 99; Conservative 52; Mismatches 117; Indels 8; Gaps 7;
Qy 6 HSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDH--ESRVRPRTWSSRISSQWL 63
Db 144 HSMRYFETAVSRRLGPEYISVGYNDFVDFVDSDAENPRYEPRAPMWEQ-GPEYWE 202

Qy 64 QLSQSLKGDHMTVDVFTWIMENHNHSHKESHTLQVILGCEMQEDNSTEGYWKYGYDGO 121
Db 203 RITQIAKGQEQWFRVNLRLILGYYNQSGAGTTLQWMYCDSGRLLRGVEQFAYDGC 262
Qy 122 DHLEFCPTDLWRAAPRAWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVLD 181
Db 263 DYIALNEDLKTWTFADMSMITRRKWEQAG-AAEYRYAYLEGECEVWHLRYLKNGNATLL 321
Qy 182 QQVPLVKVTHVTS-SVTTLCRCALNYYPNITMKWLKDKQPMDAKEPEKDVLPNGDG 240
Db 322 RTDSPRAHVTYHPRSKGCVTLRCWALGFYPADITTLWQNGEEL-TQDMELVETRAPD 380
Qy 241 TYQGWITLAVPGEQRYTCQVEHPGLDQPLIWI 276
Db 381 TFQKVASVVVPLGKEQNTYCRVYHEGLPHPLRLWE 416
RESULT 13
US-09-870-521-4
; Sequence 4, Application US/09870521
; Patent No. US20020051989A1
; GENERAL INFORMATION:
; APPLICANT: Miller, Marcia
; APPLICANT: Goto, Ronald
; TITLE OF INVENTION: METHOD FOR BREEDING AND GENOTYPING CHICKENS AND PROBES THEREFOR
; FILE REFERENCE: 1954-310
; CURRENT APPLICATION NUMBER: US/09/870,521
; CURRENT FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208471
; PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 334
; TYPE: PRT
; ORGANISM: Gallus sp.
US-09-870-521-4

Query Match 29.1%; Score 443; DB 10; Length 334;
Best Local Similarity 34.2%; Pred. No. 7.5e-33;
Matches 93; Conservative 53; Mismatches 122; Indels 4; Gaps 4;
Qy 6 HSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQMWLQ 65
Db 3 HTLRVIQTAMTDPGPGWFWTVGVGDELFPVHYNSTARRYVPRTEWIAAKAQEQ-YDTG 61
Qy 66 SOSLKGWDHMTVDVFTWIMENHNHSHKESHTLQVILGCEMQEDNSTEGYWKYGYDGDHL 124
Db 62 TQKIGGGRQRIDRELNGIPQRYNKOTGSGHTVQWMYGCDILEGGPIRGYQIMAYDGRDFT 121
Qy 125 EFCPTDLWRAAPRAWPTKLEWERHKIRARONRAYLERDCAQLOQLLELGRGVLDQ 184
Db 122 AFDKGTMTFTAADPVAEPTKRWEESEPERW-KNYLETCTVWELRRYVEYKAELEGRR 180
Qy 185 PPLVKVTHVTSVTTLCRCALNYYPNITMKWLKDKQPMDAKEPEKDVLPNGDGTQY 244
Db 181 RPEVRWCKEADGILTLSCAHGFFPRPTIVVSWLKD-GAVRQODAHSGGIVPNGDGTYHT 239
Qy 245 WITLAVPGEQRYTCQVEHPGLDQPLIWI 276
Db 240 WVTIDAQPGDGDYQCRVEHASLPQGLYSWE 271
RESULT 14
US-09-925-301-1307
; Sequence 1307, Application US/09925301
; Patent No. US20020052308A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA106
; CURRENT APPLICATION NUMBER: US/09/925,301
; CURRENT FILING DATE: 2001-08-10

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 31, 2003, 14:07:03 : Search time 11 Seconds
(without alignments)
1040.679 Million cell updates/sec

Title: US-10-092-404-1

Perfect score: 1522

Sequence: 1 RLLRSHSLHYLFMGASEQDL.....RYTCQVEHPGLDPLVIWE 276

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	1522	100.0	348	1 HFE_HUMAN	Q30201 homo sapien
2	1165	76.5	360	1 HFE_RAT	O35799 rattus norv
3	1149	75.5	359	1 HFE_MOUSE	P70387 mus musculus
4	522	34.3	361	1 H1A1_RABIT	P01894 oryctolagus
5	522	34.3	361	1 H1A1_RABIT	P06140 oryctolagus
6	516	33.9	365	1 H1A1_PANTR	P16209 pan troglod
7	515	33.8	364	1 H1A1_BOVIN	P13753 bos taurus
8	513	33.7	365	1 H1A1_HUMAN	P13746 homo sapien
9	511	33.6	370	1 H1A3_HUMAN	P04439 homo sapien
10	509	33.4	365	1 H1A0_HUMAN	Q09160 homo sapien
11	507	33.3	365	1 H1A31_HUMAN	P16189 homo sapien
12	505	33.2	365	1 H1A02_HUMAN	P01892 homo sapien
13	505	33.2	365	1 H1A30_HUMAN	P16188 homo sapien
14	505	33.2	365	1 H1A74_HUMAN	P30459 homo sapien
15	503	33.0	365	1 H1A03_PANTR	P13748 pan troglod
16	502	33.0	365	1 H1A33_HUMAN	P16190 homo sapien
17	502	33.0	365	1 H1A36_HUMAN	P30455 homo sapien
18	502	33.0	365	1 H1A68_HUMAN	P01891 homo sapien
19	500.5	32.9	362	1 H1A19_CANFA	P18466 canis famil
20	500	32.9	365	1 H1A01_HUMAN	P30443 homo sapien
21	499	32.8	373	1 H1A69_HUMAN	P10316 homo sapien
22	499	32.8	365	1 H1A04_PANTR	P13749 pan troglod
23	499	32.8	365	1 H1A24_HUMAN	P05534 homo sapien
24	497	32.7	360	1 H1A1A_BOVIN	P13752 bos taurus
25	496	32.6	296	1 H1A2G_RAT	Q63678 rattus norv
26	496	32.6	362	1 H1A45_HUMAN	P30467 homo sapien
27	495	32.5	365	1 H1A23_HUMAN	P30447 homo sapien
28	493	32.4	338	1 H1B20_HUMAN	P30467 homo sapien
29	492	32.3	363	1 H1B04_GORGO	P30382 gorilla gor
30	491	32.3	295	1 H1A2G_HUMAN	P25311 homo sapien
31	491	32.3	322	1 H1A10_MOUSE	P01898 mus musculus
32	491	32.3	362	1 H1B29_HUMAN	P18463 homo sapien
33	491	32.3	371	1 H1A12_RAT	P16391 rattus norv

ALIGNMENTS

RESULT 1

ID	HFE_HUMAN	STANDARD;	PRT;	348 AA.
AC	Q30201: 075929; 075930; 075931;			
DT	01-NOV-1997 (Rel. 35, Created)			
DT	01-NOV-1997 (Rel. 35, Last sequence update)			
DT	15-JUN-2002 (Rel. 41, Last annotation update)			
DE	Hereditary hemochromatosis protein precursor (HLA-H).			
GN	HFE OR HLAH.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A. (ISOFORM 1), AND VARIANTS HH ASP-63 AND TYR-282.			
RX	MEDLINE=96331279; PubMed=8696333;			
RA	Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A.,			
RA	Basava A., Dormishian F., Domingo R., Ellis M.C. Jr., Fullan A.,			
RA	Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P.,			
RA	Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C.,			
RA	Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E.,			
RA	Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J.,			
RA	Drayna D.T., Risch N.J., Bacon B.R., Wolff R.K.;			
RT	"A novel MHC class I-like gene is mutated in patients with hereditary			
RT	hemochromatosis";			
RN	Nat. Genet. 13:399-409(1996).			
RN	[2]			
RP	SEQUENCE FROM N.A. (ISOFORM 1).			
RA	Albig W., Burnester N., Bode C., Doenecke D., Drabent B.;			
RA	Submitted (MAR-1997) to the EMBL/GenBank/DBJ databases.			
RN	[3]			
RP	SEQUENCE FROM N.A. (ISOFORM 1).			
RX	MEDLINE=97294057; PubMed=9149941;			
RA	Ruddy D.A., Kronmal G.S., Lee V.K., Mintier G.A., Quintana L.,			
RA	Domingo R. Jr., Meyer N.C., Irinkki A., McClelland E.E., Fullan A.,			
RA	Mapa F.A., Moore T., Thomas W., Loeb D.B., Harmon C., Tsuchihashi Z.,			
RA	Wolff R.K., Schatzman R.C., Feder J.N.;			
RT	"A 1.1-Mb transcript map of the hereditary hemochromatosis locus";			
RT	Genome Res. 7:441-456(1997).			
RN	[4]			
RP	SEQUENCE FROM N.A. (ISOFORM 1).			
RA	Gasparini P.;			
RA	Submitted (SEP-1997) to the EMBL/GenBank/DBJ databases.			
RN	[5]			
RP	SEQUENCE FROM N.A. (ISOFORMS 2; 3 AND 4).			
RX	MEDLINE=99180629; PubMed=10079302;			
RA	Rhodes D.A., Trowsdale J.;			
RT	"Alternate splice variants of the hemochromatosis gene Hfe.";			
RT	Immunogenetics 49:357-359(1999).			
RN	[6]			
RP	SEQUENCE FROM N.A. (ISOFORM 2).			
RA	Oliva R., Sanchez M.;			
RT	"Identification of different alternative splicing forms of the HFE			
RT	gene.";			
RT	Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.			
RN	[7]			

P30453 homo sapien
P30457 homo sapien
P17693 homo sapien
P03989 homo sapien
P10318 homo sapien
P30385 gorilla gor
P30387 gorilla gor
P13750 pan troglod
P19373 homo sapien
Q08136 homo sapien
P16211 pongo pygma
P10314 homo sapien

RP FUNCTION.
RX MEDLINE=98132614; PubMed=9465039;
RA Feder J.N., Penny D.M., Iirinki A., Lee V.K., Lebron J.A., Watson N.,
RA Tsuchihashi Z., Sigal E., Bjorkman P.J., Schatzman R.C.;
RT "The hemochromatosis gene product complexes with the transferrin
RT receptor and lowers its affinity for ligand binding.";
RL Proc. Natl. Acad. Sci. U.S.A. 95:1472-1477(1998).
[8]
RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX MEDLINE=98206473; PubMed=9546397;
RA Lebron J.A., Bennett M.J., Vaughn D.E., Chirino A.J., Snow P.M.,
RA Mintler G.A., Feder J.N., Bjorkman P.J.;
RT "Crystal structure of the hemochromatosis protein HFE and
RT characterization of its interaction with transferrin receptor.";
RL Cell 93:111-123(1998).
[9]
RP VARIANTS HH ASP-63 AND TYR-282.
RX MEDLINE=97260408; PubMed=9108528;
RA Carella M., D'Ambrosio L., Totaro A., Grifa A., Valentino M.A.,
RA Piperno A., Girelli D., Roetto A., Franco B., Gasparini P.,
RA Camaschella C.;
RT "Mutation analysis of the HLA-H gene in Italian hemochromatosis
RT patients.";
RL Am. J. Hum. Genet. 60:828-832(1997).
[10]
RP VARIANT HH/PCT TYR-282.
RX MEDLINE=97176837; PubMed=9024376;
RA Roberts A.G., Whitley S.D., Morgan R.R., Worwood M., Elder G.H.;
RT "Increased frequency of the hemochromatosis Cys282Tyr mutation in
RT sporadic porphyria cutanea tarda.";
RL Lancet 349:321-323(1997).
[11]
RP VARIANT HH/PCT ASP-63.
RX MEDLINE=98085904; PubMed=9425935;
RA Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A.,
RA Corbetta N., Malosio I., Maffioli M., Fracanzani A.L.,
RA Cappellini M.D., Fiorelli G., Fargion S.;
RT "High prevalence of the Hfe63Asp HFE mutation in Italian patients with
RT porphyria cutanea tarda.";
RL Hepatology 27:181-184(1998).
[12]
RP VARIANTS HH/PCT ASP-63 AND TYR-282.
RX MEDLINE=98281650; PubMed=9620340;
RA Bonkovsky H.L., Poh-Fitzpatrick M., Plimstone N., Obando J.,
RA Di Bisceglie A., Tattire C., Tortorelli K., LeClair P., Mercurio M.G.,
RA Lambrecht R.W.;
RT "Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North
RT America.";
RL Hepatology 27:1661-1669(1998).
[13]
RP VARIANTS HH ASP-63; CYS-65 AND TYR-282;
RX MEDLINE=99211934; PubMed=10194428;
RA Mura C., Raques O., Ferrec C.;
RT "HFE mutations analysis in 711 hemochromatosis probands: evidence for
RT S65C implication in mild form of hemochromatosis.";
RL Blood 93:2502-2505(1999).
[14]
RP VARIANTS HH CYS-65; ARG-93 AND THR-105.
RX MEDLINE=20042794; PubMed=10575540;
RA Barton J.C., Sawada-Hirai R., Rothenberg B.E., Acton R.T.;
RT "Two novel missense mutations of the HFE gene (I105T and G93R) and
RT identification of the S65C mutation in Alabama hemochromatosis
RT probands.";
RL Blood Cells Mol. Dis. 25:147-155(1999).
[15]
RP VARIANTS VP D-63 AND H-127, VARIANT HH M-330, AND VARIANTS M-53 AND
RP M-59.
RX MEDLINE=99330560; PubMed=10401000;
RA de Villiers J.N.P., Hillermann R., Loubser L., Kotze M.J.;
RT "Spectrum of mutations in the HFE gene implicated in haemochromatosis
RT and porphyria.";
RL Hum. Mol. Genet. 8:1517-1522(1999).
[16]

RP VARIANTS HH ASP-63 AND TYR-282.
RX MEDLINE=99140260; PubMed=10094552;
RA Merryweather-Clarke A.T., Simonsen H., Shearman J.D., Pointon J.J.,
RA Norgaard-Pedersen B., Robson K.J.H.;
RT "A retrospective anonymous pilot study in screening newborns for HFE
RT mutations in Scandinavian populations.";
RL Hum. Mutat. 13:154-159(1999).
[17]
RP VARIANT HH CYS-65.
RX Egan E., Payne S.J.;
RT "A novel missense mutation S65C in the HFE gene with a possible role
RT in hereditary haemochromatosis.";
RL Hum. Mutat. 13:507-508(1999).
[18]
RP VARIANT LYS-277.
RX MEDLINE=20081073; PubMed=10612845;
RA Bradbury R., Egan E., Payne S.J.;
RT "Two novel polymorphisms (E277K and V212V) in the haemochromatosis
RT gene HFE.";
RL Hum. Mutat. 15:120-120(2000).
CC -!- FUNCTION: BINDS TO TRANSFERRIN RECEPTOR (TFR) AND REDUCES ITS
CC AFFINITY FOR IRON-LOADED TRANSFERRIN.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- ALTERNATIVE PRODUCTS: 4 isoforms; 1 (shown here), 2/delete2,
CC 3/delete14E4 and 4/delete214E4; are produced by alternative splicing.
CC -!- TISSUE SPECIFICITY: IN ALL TISSUES TESTED EXCEPT BRAIN.
CC -!- DISEASE: DEFECTS IN HFE ARE A CAUSE OF HEREDITARY HEMOCHROMATOSIS
CC (HH). HH IS AN AUTOSOMAL RECESSIVE INBORN DISORDER OF IRON
CC METABOLISM, FREQUENT AMONG CAUCASIANS. HH IS CHARACTERIZED BY
CC ABNORMAL INTESTINAL IRON ABSORPTION AND PROGRESSIVE INCREASE OF
CC TOTAL BODY IRON, WHICH RESULTS IN MIDLIFE IN CLINICAL
CC COMPLICATIONS INCLUDING CIRRHOSIS, CARDIOPATHY, DIABETES,
CC ENDOCRINE DYSFUNCTIONS, ARTHROPATHY, AND SUSCEPTIBILITY TO LIVER
CC CANCER. SINCE THE DISEASE COMPLICATIONS CAN BE EFFECTIVELY
CC PREVENTED BY REGULAR PHLEBOTOMIES, EARLY DIAGNOSIS IS MOST
CC IMPORTANT TO PROVIDE A NORMAL LIFE EXPECTANCY TO THE AFFECTED
CC SUBJECTS.
CC -!- DISEASE: DEFECTS IN HFE ARE A CAUSE OF PORPHYRIA CUTANEA
CC TARDIA (PCT), A DISORDER CHARACTERIZED BY LIGHT-SENSITIVE
CC DERMATITIS AND PRESENCE OF LARGE AMOUNTS OF UROPORPHYRIN IN
CC URINE. IRON OVERLOAD IS OFTEN PRESENT IN ASSOCIATION WITH VARYING
CC DEGREES OF LIVER DAMAGE. PCT IS THE MOST COMMON FORM OF PORPHYRIA
CC WORLDWIDE. IT OCCURS IN TWO FORMS: THE SPORADIC TYPE (PCT TYPE I)
CC AND THE FAMILIAL TYPE (PCT TYPE II), WHICH IS INHERITED IN AN
CC AUTOSOMAL DOMINANT MANNER.
CC -!- DISEASE: DEFECTS IN HFE ARE A CAUSE OF VARIEGATE PORPHYRIA (VP),
CC THE MOST COMMON FORM OF PORPHYRIA IN SOUTH AFRICA. THIS AUTOSOMAL
CC DOMINANT DISEASE IS CHARACTERIZED BY SKIN HYPERPIGMENTATION AND
CC HYPERTRICHOSIS, ABDOMINAL PAIN, TACHYCARDIA, HYPERTENSION AND
CC NEUROMUSCULAR DISTURBANCES. HIGH FECAL LEVELS OF PROTOPORPHYRIN
CC AND COPROPORPHYRIN, INCREASED URINE UROPORPHYRINS AND IRON
CC OVERLOAD ARE TYPICAL MARKERS OF THE DISEASE.
CC -!- SIMILARITY: TO MHC CLASS I ANTIGENS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U60319; AAC51823.1; -;
DR EMBL; 292910; CAB07442.1; -;
DR EMBL; U91328; AB82083.1; -;
DR EMBL; Y09801; CAA70934.1; -;
DR EMBL; Y09800; CAA70934.1; JOINED.
DR EMBL; Y09803; CAA70934.1; JOINED.
DR EMBL; Y09799; CAA70934.1; JOINED.
DR EMBL; AF079407; AAC62646.1; -;
DR EMBL; AF079408; AAC62647.1; -;
DR EMBL; AF079409; AAC62648.1; -;
DR EMBL; AJ249336; CAC67793.1; -;

```
Query Match 100.0%; Score 1522; DB 1; Length 348;
Best Local Similarity 100.0%; Pred. No. 6.9e-123;
Matches 276; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RLLRSHLYLPMGASEODLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 60
    |||||
Db 23 RLLRSHLYLPMGASEODLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 82
    |||||

QY 61 MWLQISQSLKGDHMTVDFTWIMENHNHSHKESHTLOVILGCEMDNSTEGYWKYGYDG 120
    |||||
Db 83 MWLQISQSLKGDHMTVDFTWIMENHNHSHKESHTLOVILGCEMDNSTEGYWKYGYDG 142
    |||||

QY 121 QHLEFPCPTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDPCPAOLOQLLELGRGVL 180
    |||||
Db 143 QHLEFPCPTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDPCPAOLOQLLELGRGVL 202
    |||||

QY 181 DQVPLVKVTHHTVSSVTLRCRALNYPQNITMKWLKDKOPMDAKEFEKPDVLPNGDG 240
    |||||
Db 203 DQVPLVKVTHHTVSSVTLRCRALNYPQNITMKWLKDKOPMDAKEFEKPDVLPNGDG 262
    |||||

QY 241 TYOGWITLAVPGEORVTCQVEHPGLDQPLIVWE 276
    |||||
Db 263 TYOGWITLAVPGEORVTCQVEHPGLDQPLIVWE 298
    |||||

RESULT 2
HFE_RAT
ID HFE_RAT STANDARD; PRT; 360 AA.
AC O35799; O35175;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Hereditary hemochromatosis protein homolog precursor (RTI-CAFE).
GN HFE.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
[1]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RA Banasch M.W., Schaefer H., Schmidt W.E.;
RL Submitted (SEP-1997) to the EMBL/GenBank/DBJ databases.
[2]
RP SEQUENCE OF 42-303 FROM N.A.
RC TISSUE=Small intestine;
RA Sawada-Hirai R., Rothenberg B.E.;
RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
-|- FUNCTION: BINDS TO TRANSFERRIN RECEPTOR (TFR) AND REDUCES ITS
CC AFFINITY FOR IRON-LOADED TRANSFERRIN (BY SIMILARITY).
CC -|- SUBCELLULAR LOCATION: Type I membrane protein.
CC -|- SIMILARITY: TO MHC CLASS I ANTIGENS.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; AJ001517; CAA04799.1; -
DR EMBL; AF008587; AAB86597.1; -
DR HSSP; Q30201; 1A6Z
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR001039; MHC_I.
DR Pfam; PF00047; Ig; 1.
DR Pfam; PF00129; MHC_I; 1.
DR ProDom; PD000050; MHC_I; 1.
DR SMART; SM00407; Igc1; 1.
DR PROSITE; PS00290; IG_MHC; 1.
```

```
KW MHC I; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1 25
FT CHAIN 26 360
FT HEREDITARY HEMOCHROMATOSIS PROTEIN
FT HOMOLOG.
FT DOMAIN 26 127
    EXTRACELLULAR ALPHA-1.
FT DOMAIN 128 218
    EXTRACELLULAR ALPHA-2.
FT DOMAIN 219 310
    EXTRACELLULAR ALPHA-3.
FT DOMAIN 311 319
    CONNECTING PEPTIDE.
FT TRANSMEM 320 340
    POTENTIAL.
FT DOMAIN 341 360
    CYTOPLASMIC TAIL.
FT DISULFID 137 200
    BY SIMILARITY.
FT DISULFID 238 295
    BY SIMILARITY.
FT CARBOHYD 115 115
    N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 143 143
    N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 167 167
    N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 247 247
    N-LINKED (GLCNAC. .) (POTENTIAL).
FT CONFLICT 198 198
    R -> K (IN REF. 2).
SQ SEQUENCE 360 AA; 40988 MW; CC819834EE3240B3 CRC64;

Query Match 76.5%; Score 1165; DB 1; Length 360;
Best Local Similarity 73.9%; Pred. No. 2.3e-92;
Matches 207; Conservative 29; Mismatches 36; Indels 8; Gaps 1;

QY 5 SHSLHYLPMGASEODLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQMWLQ 64
    |||||
Db 32 SHSLHYLPMGASKPDLGLPFFALGYVDDQLFVSYNHSRRAPRAPWILGOTSSQLWLQ 91
    |||||

QY 65 LSQSLKGDHMTVDFTWIMENHNHSHKESHTLOVILGCEMDNSTEGYWKY 116
    |||||
Db 92 LSQSLKGDHMTVDFTWIMENHNHSHKESHTLOVILGCEMDNSTEGYWKY 151
    |||||

QY 117 GYDGDHLEFCPTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDPCPAOLOQLLELG 176
    |||||
Db 152 GYDGDHLEFCPTLDWRAAEPRAPWTKLEWERHKIRARONRAYLERDPCPAOLOQLLELG 211
    |||||

QY 177 RGVLDQVPLVKVTHHTVSSVTLRCRALNYPQNITMKWLKDKOPMDAKEFEKPDVLP 236
    |||||
Db 212 RGVLDQVPLVKVTHHTVSSVTLRCRALNYPQNITMKWLKDKOPMDAKEFEKPDVLP 271
    |||||

QY 237 NGDGTGYGHTLAVPGEORVTCQVEHPGLDQPLIVWE 276
    |||||
Db 272 NGDGTGYGHTLAVPGEORVTCQVEHPGLDQPLIVWE 311
    |||||

RESULT 3
HFE_MOUSE
ID HFE_MOUSE STANDARD; PRT; 359 AA.
AC P70387;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Hereditary hemochromatosis protein homolog precursor.
GN HFE OR MR2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=129/SVJ;
RX MEDLINE=98060831; PubMed=9396865;
RA Riegert P., Gilfillan S., Nanda I., Schmid M., Bahram S.;
RT "The mouse HFE gene."
RL Immunogenetics 47:174-177(1998).
[2]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/c; TISSUE=Lung;
RA Hashimoto K.;
RL Submitted (SEP-1996) to the EMBL/GenBank/DBJ databases.
[3]
RP SEQUENCE OF 37-211 FROM N.A.
RC STRAIN=BALB/c; TISSUE=Liver;
RX MEDLINE=97148566; PubMed=9020055;
```

RA Hashimoto K., Hirai M., Kurosawa Y.;
 RT "Identification of a mouse homolog for the human hereditary
 RL haemochromatosis candidate gene.";
 RN Biochem. Biophys. Res. Commun. 230:35-39(1997).
 RP [4].
 RC SEQUENCE OF 79-359 FROM N.A.
 RD STRAIN=129;
 RA Albig W., Drabent B., Doenecke D.;
 RL Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.
 CC -1- FUNCTION: BINDS TO TRANSFERRIN RECEPTOR (TFR) AND REDUCES ITS
 CC AFFINITY FOR IRON-LOADED TRANSFERRIN (BY SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -1- SIMILARITY: TO MHC CLASS I ANTIGENS.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF007558; AAC03447.1; -.
 DR EMBL; U66849; AAB07525.1; -.
 DR EMBL; Y12650; CAA73197.1; -.
 DR EMBL; U80604; AAB51504.1; -.
 DR HSSP; Q30201; 1A62.
 DR MGD; MGI:109191; Hfe.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003597; Ig_cl.
 DR InterPro; IPR001039; MHC_I.
 DR Pfam; PF00047; Ig; 1.
 DR Pfam; PF00129; MHC_I; 1.
 DR ProDom; PD000050; MHC_I; 1.
 DR SMART; SM00407; Igcl; 1.
 DR PROSITE; PS00290; Ig_MHC; 1.
 DR MHC I; Transmembrane; Glycoprotein; Signal.
 FT SIGNAL 1 24
 FT CHAIN 25 359
 FT -----
 FT HEREDITARY HEMOCHROMATOSIS PROTEIN
 FT HOMOLOG.
 FT DOMAIN 25 126
 FT EXTRACELLULAR ALPHA-1.
 FT DOMAIN 127 217
 FT EXTRACELLULAR ALPHA-2.
 FT DOMAIN 218 309
 FT EXTRACELLULAR ALPHA-3.
 FT DOMAIN 310 318
 FT CONNECTING PEPTIDE.
 FT TRANSMEM 319 339
 FT POTENTIAL.
 FT DOMAIN 340 359
 FT CYTOPLASMIC TAIL.
 FT DISULFID 136 199
 FT BY SIMILARITY.
 FT DISULFID 237 294
 FT BY SIMILARITY.
 FT CARBOHYD 114 114
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 142 142
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 166 166
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 246 246
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 359 AA; 40548 MW; 4BDB6C27F9FF20B4 CRC64;
 Query Match 75.5%; Score 1149; DB 1; Length 359;
 Best Local Similarity 72.6%; Pred. No. 5.3e-91;
 Matches 204; Conservative 30; Mismatches 39; Indels 8; Gaps 1;
 QY 4 RSHSLYLFMGASERDGLSLFALGVVDDQLFVFDHESRRVPRTPWVSSRISOMWL 63
 DB 30 RSHSLYLFMGASERDGLSLFALGVVDDQLFVFDHESRRVPRTPWVSSRISOMWL 89
 QY 64 QLSOSLKGWDMFTVDFPTWIMENHNHSSK-----ESHTLQVLGCMEQDNSTGYWK 115
 DB 90 HLSOSLKGWDMFTVDFPTWIMENHNHSSK-----ESHTLQVLGCMEQDNSTGYWK 149
 QY 116 YGVDGDHLEFCFDPDLWDRAAEPRAPMTKLEWHRKIRAKONRAYLRDCPAQLQELLE 175
 DB 150 YGVDGDHLEFCFDPDLWDRAAEPRAPMTKLEWHRKIRAKONRAYLRDCPAQLQELLE 209
 QY 176 GRGVLGQVPTLVKVRTHWASTGTSLRCQALDFFPQNTNRWLKDNQPLDAKDVNPEKVL 235
 DB 210 GRGVLGQVPTLVKVRTHWASTGTSLRCQALDFFPQNTNRWLKDNQPLDAKDVNPEKVL 269

QY 236 PNGDGTQGWITLAVPPEGEORVTCQVEHPGLDQPLIVWE 276
 DB 270 PNGDGTQGWITLAVPPEGEORVTCQVEHPGLDQPLIVWE 310
 RESULT 4
 HAIA_RABIT STANDARD; PRT; 361 AA.
 AC P01894;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 01-JAN-1990 (Rel. 13, Last annotation update)
 DE RLA class I histocompatibility antigen, alpha chain 11/11 precursor.
 OS Oryctolagus cuniculus (Rabbit).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
 OC NCBI_TaxID=9986;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=84290724; PubMed=6432910;
 RA Tykocinski M.L., Marche P.N., Max E.E., Kindt T.J.;
 RT "Rabbit class I MHC genes: cDNA clones define full-length transcripts
 of an expressed gene and a putative pseudogene.";
 RL J. Immunol. 133:2261-2269(1984).
 CC -1- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO
 CC THE IMMUNE SYSTEM.
 CC -1- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
 CC MICROGLOBULIN).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; K02441; AAA98729.1; -.
 DR PIR; A02193; HLRB.
 DR HSSP; Q30201; 1A62.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003597; Ig_cl.
 DR InterPro; IPR001039; MHC_I.
 DR Pfam; PF00047; Ig; 1.
 DR Pfam; PF00129; MHC_I; 1.
 DR ProDom; PD000050; MHC_I; 1.
 DR SMART; SM00407; Igcl; 1.
 DR PROSITE; PS00290; Ig_MHC; 1.
 DR MHC I; Transmembrane; Glycoprotein; Signal.
 FT SIGNAL 1 24
 FT CHAIN 25 361
 FT -----
 FT RLA CLASS I HISTOCOMPATIBILITY ANTIGEN,
 FT ALPHA CHAIN 11/11.
 FT DOMAIN 25 114
 FT EXTRACELLULAR ALPHA-1.
 FT DOMAIN 115 206
 FT EXTRACELLULAR ALPHA-2.
 FT DOMAIN 207 298
 FT EXTRACELLULAR ALPHA-3.
 FT DOMAIN 299 308
 FT CONNECTING PEPTIDE.
 FT TRANSMEM 309 329
 FT POTENTIAL.
 FT DOMAIN 330 361
 FT CYTOPLASMIC.
 FT SIGNIFICANT WITH IMMUNOGLOBULIN C-REGION
 FT DOMAINS AND BETA-2-MICROGLOBULIN.
 FT CARBOHYD 110 110
 FT N-LINKED (GLCNAC. . .) (BY SIMILARITY).
 FT DISULFID 125 188
 FT BY SIMILARITY.
 FT DISULFID 227 283
 FT BY SIMILARITY.
 SQ SEQUENCE 361 AA; 40447 MW; 580B673323C1AE35 CRC64;
 Query Match 34.3%; Score 522; DB 1; Length 361;
 Best Local Similarity 40.1%; Pred. No. 2e-37;
 Matches 111; Conservative 44; Mismatches 114; Indels 8; Gaps 7;
 QY 5 SHSLHYLFMGASERDGLSLFALGVVDDQLFVFDHESRRVPRTPWVSSRISOMWL 62
 DB 26 SHSLHYLFMGASERDGLSLFALGVVDDQLFVFDHESRRVPRTPWVSSRISOMWL 84


```
FT DOMAIN 25 114 A-2 ALPHA CHAIN.
FT DOMAIN 115 206 EXTRACELLULAR ALPHA-1.
FT DOMAIN 207 298 EXTRACELLULAR ALPHA-2.
FT DOMAIN 299 308 EXTRACELLULAR ALPHA-3.
FT TRANSMEM 309 332 CONNECTING PEPTIDE.
FT DOMAIN 333 365 CYTOPLASMIC TAIL.
FT DISULFID 125 188 BY SIMILARITY.
FT DISULFID 227 283 BY SIMILARITY.
FT CARBOHYD 110 110 N-LINKED (GLCNAC...) (BY SIMILARITY).
SQ SEQUENCE 365 AA; 40848 MW; FC452786BD038D3E CRC64;

Query Match 33.9%; Score 516; DB 1; Length 365;
Best Local Similarity 39.7%; Pred. No. 6.6e-37;
Matches 110; Conservative 45; Mismatches 114; Indels 8; Gaps 7;

QY 5 SLSHLFLPFGASEQDLGLSLFEALGYDDQLFVFDHE--SRVPEPTPWSSSRSSOMW 62
DB 26 SHSMRYFTSVSRPGRGEPFIAVGYDDTQFVRDSDAASQMEPRAPWIEQE-GPEYW 84
QY 63 LQLSQSLKGWDHMTVDFTWIMENHNSKE-SHTLQVLGCMEQEDNS-TEGYWKYGDG 120
DB 85 DEETSAKASQSDTRVDLGTIRGYNQSDGSHTIQIYWGCVGSDGRFLRGYRQDAIDG 144
QY 121 QDHLEFCPTDLTDWRAAEPRAMPWKLEWRHKIRARQNRAYLERDCPAQLOQLLELGRVL 180
DB 145 KDYIALNEDLSRWSAADMAAQITKRKWEAAH-AARORRAYLEGTCVWLRYLENGKETL 203
QY 181 DOQVPLVVKVTHH-VTSSVTTLRCLALNYPQNTIMKWLKQKQMDAKEFEFKDVLPGND 239
DB 204 QRTDPKTHMTHHPISDHEATLRCLWALGFYPAEITLTWQREGED-QTQDTLVELTRPAGD 262
QY 240 GTYQGWITLAVPPGGEQRYTCOVEHPGLDPLVIWE 276
DB 263 GTFQKAAVVPVSGEEQRYTCHVQHEGLPKPLTRWE 299

RESULT 7
HA1B_BOVIN STANDARD; PRT; 364 AA.
ID HA1B_BOVIN
AC P13753;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-JAN-1990 (Rel. 13, Last sequence update)
DT 01-JAN-1990 (Rel. 13, Last annotation update)
DE BOLA class I histocompatibility antigen, alpha chain BL3-7 precursor.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88258075; PubMed=3133413;
RA Ennis P.D., Jackson A.P., Parham P.;
RT "Molecular cloning of bovine class I MHC cDNA.";
RL J. Immunol. 141:642-651(1988).
CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO
CC THE IMMUNE SYSTEM.
CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC MICROGLOBULIN).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement. Usage by and for commercial
CC or send an email to license@sib-sib.ch).
CC -----
CC EMBL; M21043; AAA30641.1; -.
CC PIR; B27638; B27638.
CC HSSP; P16391; 1ED3.
DR InterPro; IPR003006; Ig_MHC.
```

```
DR InterPro; IPR003597; Ig_cl.
DR InterPro; IPR001039; MHC_I.
DR Pfam; PF00047; ig; 1.
DR Pfam; PF00129; MHC_I; 1.
DR PRODOM; PD000050; MHC_I; 1.
DR SMART; SM00407; IGCL; 1.
DR PROSITE; PS00290; IG_MHC; 1.
KW MHC I; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1 27
FT CHAIN 28 364 BOLA CLASS I HISTOCOMPATIBILITY ANTIGEN,
FT DOMAIN 28 117 ALPHA CHAIN BL3-7.
FT DOMAIN 118 209 EXTRACELLULAR ALPHA-1.
FT DOMAIN 210 301 EXTRACELLULAR ALPHA-2.
FT DOMAIN 302 310 EXTRACELLULAR ALPHA-3.
FT TRANSMEM 311 331 CONNECTING PEPTIDE.
FT DOMAIN 332 364
FT SIMILAR 210 301
FT CARBOHYD 106 106
FT CARBOHYD 113 113
FT DISULFID 128 191
FT DISULFID 230 286
SQ SEQUENCE 364 AA; 41513 MW; 622036CF7DCF7873 CRC64;

Query Match 33.8%; Score 515; DB 1; Length 364;
Best Local Similarity 38.9%; Pred. No. 8e-37;
Matches 109; Conservative 50; Mismatches 113; Indels 8; Gaps 7;

QY 2 LLRSHSLFLPFGASEQDLGLSLFEALGYDDQLFVFDHE--SRVPEPTPWSSSRSS 59
DB 26 LAGSLRYFTSVSRPGRGEPFIAVGYDDTQFVRDSDAPNPREPRVPMWEQE-GP 84
QY 60 QMWLQSLQSGWDHMTVDFTWIMENHNSKE-SHTLQVLGCMEQEDNS-TEGYWKY 117
DB 85 EYWDNRNTRYKDTAQIFRVYDNLTLRGYNYQSETGSHNTOAMYGCVGDPGRLLRGFWQFG 144
QY 118 YDGDHLEFCPTDLTDWRAAEPRAMPWKLEWRHKIRARQNRAYLERDCPAQLOQLLELGR 177
DB 145 YDGRDYIALNEELRSWTAADTAQAQITKRKWEAAH-AETWRNYLSEGCVEWLRYLENGK 203
QY 178 GVLDQVPLVVKVTHH-VTSSVTTLRCLALNYPQNTIMKWLKQKQMDAKEFEFKDVL 236
DB 204 DTLRADPPKARVTHHSISDRVTLRCLWALGFYPEISLTWQREGED-QTQDMELVETRP 262
QY 237 NGDGYQGWITLAVPPGGEQRYTCOVEHPGLDPLVIWE 276
DB 263 SGDGTQKAAALVVPVSGEEQRYTCVQHEGLQEPPLTRWE 302

RESULT 8
LA11_HUMAN STANDARD; PRT; 365 AA.
ID LA11_HUMAN
AC P13746;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-JAN-1990 (Rel. 13, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE HLA class I histocompatibility antigen, A-11 alpha chain precursor.
DE HLA-A OR HLA-B.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (A*1101/A*1102).
RX MEDLINE=89030641; PubMed=2460344;
RA Mayer W.E., Jonker M., Klein D., Ivanyi P., van Sevrer G.,
RA Klein J.;
RT "Nucleotide sequences of chimpanzee MHC class I alleles: evidence for
RT trans-species mode of evolution.";
RL EMBO J. 7:2765-2774(1988).
RN [2]
RP SEQUENCE FROM N.A. (A*1101/A*1102).
```



```

26 SHSMRYEYTSVSRGRGEPRFIAGVYVDDTQFVRFDSDAAQRMEPRAPWIEQE-GPEYW 84
63 LQLSQSLKGDWHNFTVDFWTIMENHNHSKE-SHTLQVILGCCMOEDNS-TEGIWKYGYDG 120
85 DQETRNVAQSQTDRVDLGTGLRGYNNQSDGSHTIQIYMGCDVPGDGRFLRGYRQDAYDG 144
121 QDHLFECPTDLNRAAEPRAWPTKLEWERHKIRARONRAYLERDPCPAQLQOLLELGRVYL 180
145 KDYIALNEDLRSWTAADMAAQITKRKWEAAH-AAEQQRAYLEGRVCWEWLYRLENGKETL 203
181 DQVPPVLKVYTHH-VTSSVVTLLCRALNYYPQNTMKWLKDKQPMADAKEPEPKDVLPGND 239
204 QRTDPPKTHHTHPISDHEATLRCWALGFYPAEITLTWQRDGED-QTQDTLVELVETRPAGD 262
240 GTYQGWTITLAVPPGEEQRYTCVHEHGLDQPLIVIE 276
263 GTFQKAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWE 299

RESULT 9
ID 1A03_HUMAN
ID 1A03_HUMAN STANDARD; PRT; 370 AA.
AC P04439;
DT 13-AUG-1987 (Rel. 05, Created)
DT 13-AUG-1987 (Rel. 05, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE HLA class I histocompatibility antigen, A-3 alpha chain precursor.
GN HLA-A OR HLA-A.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxId:9606;
RN [1]
RP SEQUENCE FROM N.A. (A*0301).
RX MEDLINE=84207948; PubMed=6609814;
RT Strachan T., Sodoyeur R., Damotte M., Jordan B.R.;
RT "Complete nucleotide sequence of a functional class I HLA gene,
RT HLA-A*3: implications for the evolution of HLA genes.";
RT EMBO J. 3:887-894(1984).
RN [2]
RP SEQUENCE FROM N.A. (A*0302).
RX MEDLINE=85290871; PubMed=2993417;
RT Cowan E.P., Jordan B.E., Coligan J.E.;
RT "Molecular cloning and DNA sequence analysis of genes encoding
RT cytotoxic T lymphocyte-defined HLA-A3 subtypes: the E1 subtype.";
RT J. Immunol. 135:2835-2841(1985).
CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO
CC THE IMMUNE SYSTEM.
CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC POLYMERGLOBULIN).
CC -!- POLYMORPHISM: THE FOLLOWING ALLELES OF A-3 ARE KNOWN: A*0301 (A-
CC 3.1) AND A*0302. THE SEQUENCE SHOWN IS THAT OF A*0301.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announcement/
or send an email to license@isb-sib.ch).
-----
CC EMBL; X00492; CAA25162.1; ALT_TERM.
CC PIR; A02192; HLHUA3.
CC HSSP; Q19673; LHSD.
CC MIM; 142800; -.
CC InterPro; IPR003006; Ig_MHC..
CC InterPro; IPR003597; Ig_cI.
CC InterPro; IPR001039; MHC_I.
CC Pfam; PF00047; ig_1.
CC Pfam; PF00129; MHC_I; 1.
CC ProDom; PD000050; MHC_I; 1.
CC SMART; SM00407; IGc1; 1.
CC PROSITE; PS00290; IG_MHC; 1.

```


OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A. (A*3101).
 RX MEDLINE=90038496; PubMed=2478623;
 RA Kato K., Trapani J.A., Allopenna J., Dupont B., Yang S.Y.;
 RT "Molecular analysis of the serologically defined HLA-Aw19 antigens. A
 RT genetically distinct family of HLA-A antigens comprising A29, A31,
 RT A32, and Aw33, but probably not A30";
 RL J. Immunol. 143:3371-3378(1989).
 RN [2]
 RP SEQUENCE FROM N.A. (A*3101).
 RX MEDLINE=92269955; PubMed=1317015;
 RA Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
 RA Williams R.C., Luz R., Petzli-Erler M.L., Parham P.;
 RT "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
 RT Nature 357:326-329(1992).
 RN [3]
 RP SEQUENCE FROM N.A. (A*31012).
 RX MEDLINE=96387675; PubMed=8795145;
 RA Arnett K.L., Adams E.J., Parham P.;
 RT "On the sequence of A*3101.";
 RL Tissue Antigens 47:428-430(1996).
 RN [4]
 RP SEQUENCE OF 9-365 FROM N.A. (A*3101).
 RX MEDLINE=92269955; PubMed=1595035;
 RA Watkins D.I., McAdam S.N., Liu X., Stang C.R., Milford E.L.,
 RA Levine C.G., Garber T.L., Dogan A.L., Lord C.I., Ghim S.H.,
 RA Troup G.M., Hughes A.B., Letvin N.L.;
 RT "New recombinant HLA-B alleles in a tribe of South American
 RT Amerindians indicate rapid evolution of MHC class I loci";
 RL Nature 357:329-333(1992).
 RN [5]
 RP SEQUENCE FROM N.A. (A*3104).
 RA Bettinotti M.P., Dhillion G., Hackett J., Simonis T.B., Marincola F.M.;
 RT "A New HLA-A*31 allele";
 RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
 RN [6]
 RP SEQUENCE OF 26-206 FROM N.A. (A*3104).
 RA Mitsuishi Y.;
 RT "New HLA-A31 allele identified in African American population.";
 RL Submitted (NOV-1998) to the EMBL/GenBank/DBJ databases.
 CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO
 CC THE IMMUNE SYSTEM.
 CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
 CC MICROGLOBULIN).
 CC -!- POLYMORPHISM: THE FOLLOWING ALLELES OF A*31 ARE KNOWN: A*3101 AND
 CC A*3104. THE SEQUENCE SHOWN IS THAT OF A*3101.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL: M30578; AAA59613.1; -;
 CC EMBL: M84375; AAA59599.1; -;
 CC EMBL: L78918; AAB05976.1; -;
 CC EMBL: AF148863; AAD39981.1; -;
 CC EMBL: AF105028; AAC79721.1; -;
 CC EMBL: AF105027; AAC79721.1; JOINED.
 CC HSSP: O19673; 1HSB.
 CC MIM: 142800; -;
 CC InterPro: IPR003006; Ig_MHC.
 CC InterPro: IPR003597; Ig_c1.
 CC InterPro: IPR001039; MHC_I.
 CC Pfam: PF00047; Ig; 1.
 CC Pfam: PF00129; MHC_I; 1.
 CC ProDom: PD000050; MHC_I; 1.

DR SMART: SM00407; IGc1; 1.
 DR PROSITE; PS00290; IG_MHC; 1.
 KW MHC I; Transmembrane; Glycoprotein; Signal; Polymorphism.
 FT SIGNAL 1 24
 FT CHAIN 25 365 HLA CLASS I HISTOCOMPATIBILITY ANTIGEN,
 FT A-31 ALPHA CHAIN.
 FT DOMAIN 25 114 EXTRACELLULAR ALPHA-1.
 FT DOMAIN 115 206 EXTRACELLULAR ALPHA-2.
 FT DOMAIN 207 298 EXTRACELLULAR ALPHA-3.
 FT DOMAIN 299 308 CONNECTING PEPTIDE.
 FT TRANSMEM 309 332
 FT DOMAIN 333 365 CYTOPLASMIC TAIL.
 FT CARBOHYD 110 110 N-LINKED (GLCNAC. . .) (BY SIMILARITY).
 FT DISULFID 125 188 BY SIMILARITY.
 FT VARIANT 121 121 M -> I (IN A*3104).
 FT VARIANT 138 138 /FTID=VAR_010373.
 FT Q -> R (IN A*3104).
 FT /FTID=VAR_010374.
 SQ SEQUENCE 365 AA; 41004 MW; 4E760C821A3C553B CRC64;
 Query Match 33.3%; Score 507; DB 1; Length 365;
 Best Local Similarity 39.0%; Pred. No. 3.9e-36;
 Matches 108; Conservative 51; Mismatches 110; Indels 8; Gaps 7;
 QY 5 SLSLHLYFMGASEQDLGLSLFEALGYVDDQLFVFDH--SRRVEPRTPWSSRISQMW 62
 DB 26 SHSMRYFTTSVSRGRGEPRFIAVGYYDDQFVRFDSDAASORMEPAPWIEQE-RPEYW 84
 QY 63 LQLSOSLKGWDHMTVDFTWMENHNHKSKE-SHTLQVLGCEMOEDNS-TEGYWKYGYDG 120
 DB 85 DQETRNVAHSQIDRVDLGLTGLRGYNGSEAGSHTIQMWGCDVSGDGRFLRGYQDAYDG 144
 QY 121 QDHLEFCPDTLDWRAEPRAMPYKLEWERHKIRARQNAYLERDCCPAQLQQLLELGRVL 180
 DB 145 KDYALNEDLRSTAAADMAAQITQRKWEAARV-AEQLRAYLEGTCVFWLRYLENGKETL 203
 QY 181 DQQVPLLVKVTHH-VTSSVTTLRCALNYYQNTWKWKDKOPMDAKEPEPKDVLPGND 239
 DB 204 QRTDPPKTHMTHAVSDHEATLRWALSFPAPAEITLTWRDGED-QTQDTETLVETRPAGD 262
 QY 240 GTYQGWTTLAVPPGEEQRYTCOVHFGLDQPLIVINE 276
 DB 263 GTEQKASVVVPSGQEQRYTCHVQHEGLPKPLTLRWE 299
 RESULT 12
 ID 1A02_HUMAN STANDARD; PRT; 365 AA.
 AC P01892; P06338; P30514; P30444; P30445; P30446; Q29680; Q29899;
 AC Q95352; Q29837; Q95380;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 13-AUG-1987 (Rel. 05, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE HLA class I histocompatibility antigen, A-2 alpha chain precursor.
 GN HLA-A OR HLA-A.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A. (A*0201).
 RX MEDLINE=85132727; PubMed=2982951;
 RA Koller B.H., Orr H.T.;
 RT "Cloning and complete sequence of an HLA-A2 gene: analysis of two
 RT HLA-A alleles at the nucleotide level.";
 RL J. Immunol. 134:2727-2733(1985).
 RN [2]
 RP SEQUENCE FROM N.A. (A*0201).
 RX MEDLINE=89122144; PubMed=2914713;
 RA Cianetti L., Testa U., Scotto L., la Valle R., Simeone A.,
 RA Boccia G., Giannella G., Peschle C., Boncinelli E.;
 RT "Three new class I HLA alleles: structure of mRNAs and alternative

RT mechanisms of processing.";
 RL Immunogenetics 29:80-91(1989).
 RN [3]
 RP SEQUENCE FROM N.A. (A*0201).
 RX MEDLINE=90207291; PubMed=2320591;
 RA Ennis P.D., Zemmour J., Salter R.D., Parham P.;
 RT "Rapid cloning of HLA-A,B CDNA by using the polymerase chain
 RT reaction: frequency and nature of errors produced in amplification.";
 RL Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990).
 RN [4]
 RP SEQUENCE FROM N.A. (A*0201/A*0211/A*0212).
 RX MEDLINE=92269955; PubMed=1317015;
 RA Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J.,
 RT Williams R.C., Luz R., Pezdi-Erler M.L., Parham P.;
 RT "Unusual HLA-B alleles in two tribes of Brazilian Indians.";
 RL Nature 357:326-329(1992).
 RN [5]
 RP SEQUENCE OF 39-365 FROM N.A. (A*0201).
 RX MEDLINE=85230571; PubMed=3874058;
 RA Krangel M.S.;
 RT "Unusual RNA splicing generates a secreted form of HLA-A2 in a
 RT mutagenized B lymphoblastoid cell line.";
 RL EMBO J. 4:1205-1210(1985).
 RN [6]
 RP SEQUENCE OF 25-295 (A*0201).
 RX MEDLINE=80056745; PubMed=92029;
 RA Orr H.T., Lopez de Castro J.A., Parham P., Ploegh H.L.,
 RT Strominger J.L.;
 RT "Comparison of amino acid sequences of two human histocompatibility
 RT antigens, HLA-A2 and HLA-B7: location of putative alloantigenic
 RT sites.";
 RL Proc. Natl. Acad. Sci. U.S.A. 76:4395-4399(1979).
 RN [7]
 RP REVISIONS (A*0201).
 RX MEDLINE=82247941; PubMed=6179086;
 RA Lopez de Castro J.A., Strominger J.L., Strong D.M., Orr H.T.;
 RT "Structure of crossreactive human histocompatibility antigens HLA-A28
 RT and HLA-A2: possible implications for the generation of HLA
 RT polymorphism.";
 RL Proc. Natl. Acad. Sci. U.S.A. 79:3813-3817(1982).
 RN [8]
 RP SEQUENCE OF 26-298 FROM N.A. (A*0202/A*0203).
 RX MEDLINE=87308734; PubMed=3497874;
 RA Mattson D.H., Handy D.E., Bradley D.A., Coligan J.E., Cowan E.P.,
 RT Biddison W.E.;
 RT "DNA sequences of the genes that encode the CTL-defined HLA-A2
 RT variants M7 and DK1.";
 RL Immunogenetics 26:190-192(1987).
 RN [9]
 RP SEQUENCE FROM N.A. (A*0203/A*0205).
 RX MEDLINE=87252273; PubMed=3496393;
 RA Holmes N., Ennis P., Wan A.M., Denney D.W., Parham P.;
 RT "Multiple genetic mechanisms have contributed to the generation of
 RT the HLA-A2/A28 family of class I MHC molecules.";
 RL J. Immunol. 139:936-941(1987).
 RN [10]
 RP SEQUENCE FROM N.A. (A*0203/A*0205).
 RX Domena J.D.;
 RL Submitted (NOV-1993) to the EMBL/GenBank/DBJ databases.
 RN [11]
 RP SEQUENCE OF 9-365 FROM N.A. (A*0204).
 RX MEDLINE=92039809; PubMed=1937577;
 RA Castano A.R., Lopez de Castro J.A.;
 RT "Structure of the HLA-A*0204 antigen, found in South American
 RT Indians. Spatial clustering of HLA-A2 subtype polymorphism.";
 RL Immunogenetics 34:281-285(1991).
 RN [12]
 RP SEQUENCE OF 9-365 FROM N.A. (A*0204).
 RX MEDLINE=92269956; PubMed=1589035;
 RA Watkins D.I., McAdam S.N., Liu X., Stang C.R., Milford E.L.,
 RA Lévine C.G., Garber T.L., Dogon A.L., Lord C.I., Ghim S.H.,
 RA Troup G.M., Hughes A.L., Letwin N.L.;
 RT "New recombinant HLA-B alleles in a tribe of South American

RT Amerindians indicate rapid evolution of MHC class I loci.";
 RL Nature 357:329-333(1992).
 RN [13]
 RP SEQUENCE FROM N.A. (A*0206).
 RX MEDLINE=89235215; PubMed=2715640;
 RA Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.;
 RT "Diversity and diversification of HLA-A,B,C alleles.";
 RL J. Immunol. 142:3937-3950(1989).
 RN [14]
 RP PARTIAL SEQUENCE (A*0206).
 RX MEDLINE=86305811; PubMed=3489037;
 RA Ezquerria A., Domenech N., van der Poel J., Strominger J.L., Vega M.A.,
 RT Lopez de Castro J.A.;
 RT "Molecular analysis of an HLA-A2 functional variant CLA defined by
 RT cytolytic T lymphocytes.";
 RL J. Immunol. 137:1642-1649(1986).
 RN [15]
 RP PARTIAL SEQUENCE (A*0207).
 RX MEDLINE=88113844; PubMed=2448239;
 RA Domenech N., Ezquerria A., Castano R., Lopez de Castro J.A.;
 RT "Structural analysis of HLA-A2.4 functional variant KNE. Implications
 RT for the mapping of HLA-A2-specific T-cell epitopes.";
 RL Immunogenetics 27:196-202(1988).
 RN [16]
 RP PARTIAL SEQUENCE (A*0208).
 RX MEDLINE=88314183; PubMed=2457548;
 RA Domenech N., Castano R., Goumy E., Lopez de Castro J.A.;
 RT "Molecular analysis of HLA-A2.4 functional variant KLO: close
 RT structural and evolutionary relatedness to the HLA-A2.2 subtype.";
 RL Immunogenetics 28:143-152(1988).
 RN [17]
 RP PARTIAL SEQUENCE (A*0209).
 RX MEDLINE=88186100; PubMed=3258580;
 RA Castano R., Ezquerria A., Domenech N., Lopez de Castro J.A.;
 RT "An HLA-A2 population variant with structural polymorphism in the
 RT alpha 3 region.";
 RL Immunogenetics 27:345-355(1988).
 RN [18]
 RP SEQUENCE FROM N.A. (A*0210).
 RX MEDLINE=89122133; PubMed=2783680;
 RA Epstein H., Kennedy L., Holmes N.;
 RT "An Oriental HLA-A2 subtype is closely related to a subset of
 RT Caucasoid HLA-A2 alleles.";
 RL Immunogenetics 29:112-116(1989).
 RN [19]
 RP SEQUENCE OF 9-365 FROM N.A. (A*0211).
 RX MEDLINE=92218010; PubMed=1559719;
 RA Castano A.R., Lopez de Castro J.A.;
 RT "Structure of the HLA-A*0211 (A2.5) subtype: further evidence for
 RT selection-driven diversification of HLA-A2 antigens.";
 RL Immunogenetics 35:344-346(1992).
 RN [20]
 RP SEQUENCE FROM N.A. (A*0213).
 RX MEDLINE=94222455; PubMed=8168863;
 RA Barber D.F., Fernandez J.M., Lopez de Castro J.A.;
 RT "Primary structure of a new HLA-A2 subtype: HLA-A*0213.";
 RL Immunogenetics 39:378-378(1994).
 RN [21]
 RP SEQUENCE FROM N.A. (A*0216).
 RX MEDLINE=95278976; PubMed=7759139;
 RA Barouch D., Krausa P., Bodmer J., Browning M.J., McMichael A.J.;
 RT "Identification of a novel HLA-A2 subtype, HLA-A*0216.";
 RL Immunogenetics 41:388-388(1995).
 RN [22]
 RP SEQUENCE FROM N.A. (A*0217).
 RC TISSUE=Blood;
 RX MEDLINE=95381236; PubMed=7652742;
 RA Selvakumar A., Granja C.B., Salazar M., Alosco S.M., Yunis E.J.,
 RA Dupont B.;
 RT "A novel subtype of A2 (A*0217) isolated from the South American
 RT Indian B-cell line AMALA.";
 RL Tissue Antigens 45:343-347(1995).
 RN [23]

```

RP SEQUENCE FROM N.A. (A*0218).
RC TISSUE=Blood;
RA Kashiwase K., Tokunaga K., Ishikawa Y., Ohashi H., Hashimoto M.,
RT Akaza T., Tadokoro K., Juji T.;
RA "A new A2 sequence HLA-A2K from Japanese.";
RL Submitted (FEB-1996) to the EMBL/GenBank/DBJ databases.
RN [24]
RP SEQUENCE FROM N.A. (A*0220).
RC TISSUE=Blood;
RX MEDLINE=97161038; PubMed=9008310;
RA Fleschhauer K., Zino E., Mazzi B., Severini G.M., Benazzi E.,
RT Bordignon C.;
RA "HLA-A*02 subtype distribution in Caucasians from northern Italy:
RT identification of A*0220.";
RL Tissue Antigens 48:673-679(1996).
RN [25]
RP SEQUENCE FROM N.A. (A*0221).
RC TISSUE=Blood;
RA Szmania S., Baxter-Lowe L.A.;
RT "Nucleotide sequence of a novel HLA-A2 gene.";
RL Submitted (APR-1996) to the EMBL/GenBank/DBJ databases.
RN [26]
RP X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF A*0201.
RX MEDLINE=88014204; PubMed=3309677;
RA Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S.,
RT Strominger J.L., Wiley D.C.;
RA "Structure of the human class I histocompatibility antigen, HLA-A2.";
RL Nature 329:506-512(1987).
RN [27]

Query Match 33.2%; Score 505; DB 1; Length 365;
Best Local Similarity 39.4%; Pred. No. 5.8e-36;
Matches 109; Conservative 45; Mismatches 115; Indels 8; Gaps 7;

QY 5 SHSLHYLFWCASQDGLSLFEALGYVDOLFVYDHE--SRVRPTPWSSRISQMW 62
DB 26 SHSMRYFFTSVSPGRGPRFIAVGVDDTQFVRFDSDAASQRMPEPRWIEQE-GPEYW 84
QY 63 LQLSQSLKGDHMTVDFTIMENHNSKE-SHTLQVILGCMEQED-NSTEGYKWKYGDG 120
DB 85 DGETRKVKASHQTHRVLDLGLRGYVQSEAGSHTVQRMVGCDSWRFLRGYHQYAYDG 144
QY 121 QDHLEFCPTDLWRAEAPRAWPTKLEWERHKIRARONRAYLERDCPAQLOQLLELGRVYL 180
DB 145 KDVIALKDLRSWTAADMAAQTTHKWEAAHV-AEQLRAYLEGTVCVLELRRYLENGKETL 203
QY 181 DQOVPLVYVTHH-VTSSVTTLRCRALNYPQNIWKWKLDKQPMADKPEFQDVLNPGD 239
DB 204 QRTDAPKTHMTHAVSDHEATLRCWLSFYPAEITLTWQDGED-QTQDTELVELTRPAGD 262
QY 240 GTYQGWITLAVPGEQRYTCQVEHPGLDQPLIVIVE 276
DB 263 GTFQKAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE 299

RESULT 13
ID 1A30 HUMAN STANDARD; PRT; 365 AA.
AC P16188; P30452; Q9UIP7;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE HLA class I histocompatibility antigen, A-30(AW-19) alpha chain
DE precursor.
GN HLA-A OR HLA*
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (A*3001).
RX MEDLINE=90038496; PubMed=2478623;
RA Kato K., Trapani J.A., Allopenna J., Dupont B., Yang S.Y.;

```

```

RT "Molecular analysis of the serologically defined HLA-Aw19 antigens. A
RT genetically distinct family of HLA-A antigens comprising A29, A31,
RT A32, and A*33, but probably not A30.";
RL J. Immunol. 143:3371-3378(1989).
RN [2]
RP SEQUENCE FROM N.A. (A*3002).
RX MEDLINE=93056508; PubMed=1431115;
RA Madrigal J.A., Belich M.P., Hildebrand W.H., Benjamin R.J.,
RA Little A.-M., Zemmour J., Ennis P.D., Ward F.E., Petzl-Erler M.L.,
RA Martell R.W., du Toit E.D., Parham P.;
RT "Distinctive HLA-A,B antigens of black populations formed by
RT interallelic conversion.";
RL J. Immunol. 149:3411-3415(1992).
RN [3]
RP SEQUENCE OF 25-279 FROM N.A. (A*3003).
RX MEDLINE=93209813; PubMed=8458735;
RA Choo S.Y., Starling G.C., Anasetti C., Hansen J.A.;
RT "Selection of an unrelated donor for marrow transplantation
RT facilitated by the molecular characterization of a novel HLA-A
RT allele.";
RL Hum. Immunol. 36:20-26(1993).
RN [4]
RP SEQUENCE FROM N.A. (A*3001).
RX MEDLINE=95176329; PubMed=7871528;
RA Olerup O., Daniels T.J., Baxter-Lowe L.;
RT "Correct sequence of the A*3001 allele obtained by PCR-SSP typing and
RT automated nucleotide sequencing.";
RL Tissue Antigens 44:265-267(1994).
RN [5]
RP SEQUENCE FROM N.A. (A*3004).
RA Krausa P., Carcassi C., Orru S., Bodmer J.G., Browning M.J.,
RA Contu L.;
RL Submitted (FEB-1995) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A. (A*300X).
RA Cox S.T., McWhinnie A.J., Madrigal A.J., Little A.M.;
RT "New A*30 HLA allele found in an Afro-Caribbean bone marrow donor.";
RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.
RN [7]
RP SEQUENCE OF 26-206 FROM N.A. (A*3004).
RA Lienert K., Gao X., McCluskey J.;
RL Submitted (JAN-1995) to the EMBL/GenBank/DBJ databases.
RN [8]
RP SEQUENCE OF 28-205 FROM N.A. (A*3004).
RX MEDLINE=96124443; PubMed=8560452;
RA Blasczyk R., Wehling J., Paessler M., Hahn U., Huhn D., Salama A.;
RT "A novel HLA-A30 allele (A*3004) identified by single-strand
RT conformation polymorphism analysis and confirmed by solid-phase
RT sequencing.";
RL Tissue Antigens 46:322-326(1995).
CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO
CC THE IMMUNE SYSTEM.
CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC MICROGLOBULIN).
CC -!- POLYMORPHISM: THE FOLLOWING ALLELES OF A*30 ARE KNOWN: A*3001
CC (A*30.3), A*3002, A*3003 AND A*3004. THE SEQUENCE SHOWN IS THAT OF
CC A*3001.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; M30576; AAA59612.1; -
CC EMBL; X61702; CAA43871.1; -
CC EMBL; M93657; AAA58650.1; -
CC EMBL; U07234; AAA70162.1; -
CC EMBL; Z34921; CAA84401.1; -
CC EMBL; U19734; AAB53658.1; -
CC EMBL; U18988; AAB53658.1; JOINED.

```


GenCore version 5.1.4.p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 31, 2003, 14:07:04 ; Search time 19 Seconds
(without alignments)
1396.479 Million cell updates/sec

Title: US-10-092-404-1

Perfect score: 1522

Sequence: 1 RLLRSHSLHYLFMGASEQDL.....RYTQVHEHPGLDQPLVIWE 276

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_73:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1149	75.5	359	2	hereditary hemochr
2	541.5	35.6	341	2	class I histocompa
3	522	34.3	361	1	MHC class I histoc
4	522	34.3	361	2	MHC class I RIA pr
5	519	34.1	332	2	MHC class I histoc
6	516	33.9	365	2	MHC class I protei
7	515	33.8	361	2	MHC class I histoc
8	514	33.8	365	2	All.2 - human
9	513	33.7	365	2	MHC class I histoc
10	513	33.7	365	2	HLA-A*02.3 precurso
11	511	33.6	370	1	MHC class I histoc
12	509	33.4	365	2	MHC class I histoc
13	508	33.4	365	2	MHC class I histoc
14	508	33.4	365	2	gene HLA-A-0205 pr
15	508	33.4	365	2	MHC class I histoc
16	507	33.3	365	2	MHC class I histoc
17	507	33.3	365	2	gene HLA-A-6802 pr
18	505	33.2	365	1	MHC class I histoc
19	505	33.2	365	2	MHC class I histoc
20	505	33.2	365	2	MHC class I histoc
21	505	33.2	365	2	MHC class I histoc
22	504	33.1	365	2	MHC class I histoc
23	504	33.1	365	2	HLA-A*0210 - human
24	503	33.0	355	2	MHC class I histoc
25	503	33.0	364	2	class I histocompa
26	502	33.0	365	2	MHC class I histoc
27	502	33.0	365	2	MHC class I histoc
28	502	33.0	365	2	gene HLA-A-0203 pr
29	502	33.0	365	2	MHC HLA-A2.4a Chai

30	501.5	33.0	341	2	JC5663	major histocompati
31	501	32.9	357	2	I36965	MHC class I protei
32	500.5	32.9	362	2	A45845	MHC class I histoc
33	500	32.9	365	2	I61856	MHC class I histoc
34	500	32.9	365	2	I54493	MHC class I histoc
35	499	32.8	273	1	HLHU69	MHC class I histoc
36	499	32.8	365	2	S77963	MHC class I histoc
37	499	32.8	365	2	S01171	class I histocompa
38	499	32.8	365	2	I54416	HLA-AW24 protein -
39	498	32.7	365	2	I37483	HLA-AW34.2 antigen
40	497	32.7	273	1	HLHUAW	MHC class I histoc
41	497	32.7	360	2	A27638	MHC class I histoc
42	497	32.7	365	2	I72171	HLA-AW33.1, HLA-AW
43	496.5	32.6	339	2	I56071	MHC class I histoc
44	496	32.6	279	2	JX0353	zinc-alpha 2-glyco
45	496	32.6	362	2	I68724	MHC class I histoc

ALIGNMENTS

RESULT 1

JC5382 hereditary hemochromatosis protein precursor - mouse

C:Species: Mus musculus (house mouse)

C:Date: 02-Jun-1997 #sequence_revision 18-Jul-1997 #text_change 05-Nov-1999

C:Accession: JC5382

R:Hashimoto, K.; Hirai, M.; Kurosawa, Y.

Biochem. Biophys. Res. Commun. 230, 35-39, 1997

A:Title: Identification of a mouse homolog for the human hereditary haemochromatosis

A:Reference number: JC5382; MUID:97148566; PMID:9020055

A:Accession: JC5382

A:Status: nucleic acid sequence not shown

A:Molecule type: DNA

A:Residues: 1-359 <HA>

A:Cross-references: GB:U66849; MID:g1519484; PIDN:AA07525.1; PID:g1519485

C:Comment: This protein plays a role in iron metabolism.

C:Genetics:

A:Gene: mr2

C:Superfamily: class I histocompatibility antigen; Immunoglobulin homology

F:1-29/Domain: signal sequence #status predicted <SIG>

F:30-359/Product: hereditary haemochromatosis protein #status predicted <MAT>

F:30-117/Domain: alpha 1 #status predicted <ALF1>

F:118-217/Domain: alpha 2 #status predicted <ALF2>

F:218-309/Domain: alpha 3 #status predicted <ALF3>

F:314-340/Domain: transmembrane #status predicted <TRM>

F:341-359/Domain: intracellular #status predicted <INT>

Query Match 75.5%; Score 1149; DB 2; Length 359;

Best Local Similarity 72.6%; Pred. No. 8.1e-88;

Matches 204; Conservative 30; Mismatches 39; Indels 8; Gaps 1;

QY 4 RSHSLHYLFMGASEODLGLSLFEALGYDDQLFVFDHESRRVERPTWSSRISSQMWL 63

DB 30 RSHSLRYLFMGASEPDGLGLFELRGYVDDQLFVSVNHSRRRAEPRAPILEQTSSQLWL 89

QY 64 QLSQSLKGDHWFYVDFWTIMENHNHSHK-----ESHTLOVILCCMOEDNSTEGYWK 115

DB 90 HLSQSLKGDYMFVDFWTIMGNYNHSHKVTKLGVSVSESHILOVILGCEVHDNSTSGFWR 149

QY 116 YCYDGDHLEFCPDTLDWRAAPRAWPTKLEWERHKIRARQRAYLERDCPAQLOQLLEL 175

DB 150 YCYDGDHLEFCPKTLNWSAEPGAWATKVEWDEHKIRAKQNDYLEKDCPQLKRLLEL 209

QY 176 GRGLVDQDQVPLVKTTHVTSVTLRLCRALNYIPONITMKWLKDKQPMDAKEFEFKDYL 235

DB 210 GRGLVQQVPTLVKYTRHWASTGTSLRQALDFFPONITMRWLKDNQPLDANDVNPVKVL 269

QY 236 PNGDGTGYQWITLAVPPGGEQRYTCQVHPGLDQPLVIWE 276

DB 270 PNGDGTGYQWITLAVAPGDETRFTQVHEHPGLDQPLTASWE 310

I83063
All.2 - human
C:Species: Homo sapiens (man)
C:Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 21-Jan-2000
C:Accession: I83063
R:Lin, L.; Tokunaga, K.; Ishikawa, Y.; Bannai, M.; Kashiwase, K.; Kuwata, S.; Akaza, T.;
Tissue Antigens 43, 78-82, 1994
A:Title: Sequence analysis of serological HLA-A11 split antigens, All.1 and All.2.
A:Reference number: I60129; MUID:94287401; PMID:8016845
A:Accession: I83063
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-365 <RES>
A:Cross-references: GB:D16842; NID:g540517; PIDN:BAA04118.1; PID:g487911
C:Genetics:
A:Gene: GDB:HLA-A
A:Map position: 6p21.3-6p21.3
C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
F:220-285/Domain: immunoglobulin homology <IMM>
Query Match 33.8%; Score 514; DB 2; Length 365;
Best Local Similarity 39.4%; Pred. No. 4e-35;
Matches 109; Conservative 47; Mismatches 113; Indels 8; Gaps 7;
Qy 5 SLSLHYLFMGASEQDLGLSLFALGYVDOLFFVFDHE--SRVPRTPWVSSRISQMW 62
Db 26 SSMRYFTYSVRGPRGFYAVGYDDTQVRFDSDAASQRPAPWIEQE-GPEYV 84
Qy 63 LQLSQSLKGWDMFTVDFWETIMENHNHKE-SHTLQVILGCEMQEDNS--TEGYWYGYDG 120
Db 85 DQETNRVNAQSOTDRVLTGLTGRYNGQSDGSHTTQIYGVCDVGPDRFLRGYRDAYDG 144
Qy 121 QHLEFCPTDLWRAAEPRAMPPTKLEWRHKTRAKONRAYLERDCPAQLQELLEGRVYL 180
Db 145 KDYIALNEDLSRWSAADMAAQITTKRWEAAH-AEQQRAYLEGRGVWLLRRYLENGKETL 203
Qy 181 DQOVPLVKVTHH-VTSSVTTLCRALNYYPONITMKWLKQPMDAKEFEFPKVLNPGD 239
Db 204 QRTDPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQDGED-OTQDTLVELTRPAGD 262
Qy 240 GTYOGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIE 276
Db 263 GTFOKAAVVPVSGEQRYTCHVQHEGLPKPLTLRWE 299
RESULT 9
A47636
MHC class I histocompatibility antigen HLA-A11 alpha chain precursor - human
C:Species: Homo sapiens (man)
C:Date: 31-Dec-1993 #sequence_revision 28-Apr-1995 #text_change 23-Jul-1999
C:Accession: S03536; S03694; A47636; I60129
R:Mayer, W.E.; Jonker, M.; Klein, D.; Ivanyi, P.; van Seventer, G.; Klein, J.
EMBO J. 7, 2765-2774, 1988
A:Title: Nucleotide sequences of chimpanzee MHC class I alleles: evidence for trans-species inheritance of HLA-A11.
A:Reference number: S01171; MUID:89030641; PMID:2460344
A:Accession: S03536
A:Molecule type: mRNA
A:Residues: 1-365 <MA>
A:Cross-references: EMBL:X13112; NID:g32142; PIDN:CAA31504.1; PID:g32143
A:Note: This allele is designated A*1102 (formerly Allk, All.2)
R:Cowan, E.P.; Jelachich, M.L.; Biddison, W.E.; Colligan, J.E.
Immunogenetics 25, 241-250, 1987
A:Title: DNA sequence of HLA-A11: remarkable homology with HLA-A3 allows identification of HLA-A11.
A:Reference number: A47636; MUID:87192928; PMID:2437024
A:Accession: A47636
A:Molecule type: DNA
A:Residues: 26-365 <COW>
A:Cross-references: GB:M16007; GB:M16008; GB:M16009; GB:M16010; NID:g184130; PIDN:AAA654
A:Note: the authors translated the codon GAC for residue 89 as Ala, CCG for residue 104

A:Note: this allele is designated A*1101 (formerly AllE, All.1)
R:Lin, L.; Tokunaga, K.; Ishikawa, Y.; Bannai, M.; Kashiwase, K.; Kuwata, S.; Akaza, T.;
Tissue Antigens 43, 78-82, 1994
A:Title: Sequence analysis of serological HLA-A11 split antigens, All.1 and All.2.
A:Reference number: I60129; MUID:94287401; PMID:8016845
A:Accession: I60129
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-365 <RES>
A:Cross-references: GB:D16841; NID:g540516; PIDN:BAA04117.1; PID:g487909
A:Note: this allele is designated A*1101 (formerly AllE, All.1)
C:Genetics:
A:Gene: GDB:HLA-A
A:Cross-references: GDB:119310; OMIM:142800
A:Map position: 6p21.3-6p21.3
C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
C:Keywords: transmembrane protein
F:1-24/Domain: signal sequence #status predicted <SIG>
F:25-365/Product: class I histocompatibility antigen alpha chain #status predicted <EXT>
F:220-285/Domain: extracellular #status predicted <EXT>
F:220-285/Domain: immunoglobulin homology <IMM>
F:299-337/Domain: transmembrane #status predicted <TMM>
F:338-365/Domain: intracellular #status predicted <INT>
Query Match 33.7%; Score 513; DB 2; Length 365;
Best Local Similarity 39.4%; Pred. No. 4.8e-35;
Matches 109; Conservative 47; Mismatches 113; Indels 8; Gaps 7;
Qy 5 SLSLHYLFMGASEQDLGLSLFALGYVDOLFFVFDHE--SRVPRTPWVSSRISQMW 62
Db 26 SSMRYFTYSVRGPRGFYAVGYDDTQVRFDSDAASQRPAPWIEQE-GPEYV 84
Qy 63 LQLSQSLKGWDMFTVDFWETIMENHNHKE-SHTLQVILGCEMQEDNS--TEGYWYGYDG 120
Db 85 DQETNRVNAQSOTDRVLTGLTGRYNGQSDGSHTTQIYGVCDVGPDRFLRGYRDAYDG 144
Qy 121 QHLEFCPTDLWRAAEPRAMPPTKLEWRHKTRAKONRAYLERDCPAQLQELLEGRVYL 180
Db 145 KDYIALNEDLSRWSAADMAAQITTKRWEAAH-AEQQRAYLEGRGVWLLRRYLENGKETL 203
Qy 181 DQOVPLVKVTHH-VTSSVTTLCRALNYYPONITMKWLKQPMDAKEFEFPKVLNPGD 239
Db 204 QRTDPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQDGED-OTQDTLVELTRPAGD 262
Qy 240 GTYOGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIE 276
Db 263 GTFOKAAVVPVSGEQRYTCHVQHEGLPKPLTLRWE 299
RESULT 10
I56039
HLA-A30.3 precursor - human
C:Species: Homo sapiens (man)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 21-Jan-2000
C:Accession: I56039
R:Kato, K.; Trapani, J.A.; Alloppenna, J.; Dupont, B.; Yang, S.Y.
J. Immunol. 143, 3371-3378, 1989
A:Title: Molecular analysis of the serologically defined HLA-Aw19 antigens. A genetic marker for the HLA-A30.3 precursor.
A:Reference number: I56039; MUID:90038496; PMID:2478623
A:Accession: I56039
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-365 <RES>
A:Cross-references: GB:M30576; NID:g187646; PIDN:AAA59612.1; PID:g386878
C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
F:220-285/Domain: immunoglobulin homology <IMM>
Query Match 33.7%; Score 513; DB 2; Length 365;
Best Local Similarity 39.4%; Pred. No. 4.8e-35;
Matches 109; Conservative 48; Mismatches 112; Indels 8; Gaps 7;
Qy 5 SLSLHYLFMGASEQDLGLSLFALGYVDOLFFVFDHE--SRVPRTPWVSSRISQMW 62
Db 26 SSMRYFTYSVRGPRGFYAVGYDDTQVRFDSDAASQRPAPWIEQE-GPEYV 84

RESULT 12

MHC class I histocompatibility antigen HLA-A*8001 precursor - human
138439

C:Species: Homo sapiens (man)
C>Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 21-Jan-2000
C:Accession: I59638; 138439

R:Domena, J.D.; Hildebrand, W.H.; Bias, W.B.; Parham, P.
Tissue Antigens 42, 156-159, 1993

A:Title: A sixth family of HLA-A alleles defined by HLA-A*8001.
A:Reference number: I59638; MUID:94112691; PMID:8284791

A:Accession: I59638

A>Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: mRNA

A:Residues: 1-365 <DOM>

A:Cross-references: GDB:118998; NID:g306853; PIDN:AAAL17012.1; PID:g306854
R:Balas, A.; Garcia-Sanchez, F.; Gomez-Reino, F.; Vicario, J.L.
Immunogenetics 39, 452, 1994

A:Title: Characterization of a new and highly distinguishable HLA-A allele
A:Reference number: 138439; MUID:94245293; PMID:8186325

A:Accession: 138439

A>Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: mRNA

A:Residues: 1-365 <BAL>

A:Cross-references: EMBL:U03754; NID:g432407; PID:AAC04322.1; PID:g432408

C:Genetics:

A:Gene: GDB:HLA-A

A:Cross-references: GDB:119310; OMIM:142800

A:Map position: gp21.3-6p21.3

C:Superfamily: class I histocompatibility antigen; immunoglobulin homology
F:220-285/Domain: immunoglobulin homology <IMM>

Query Match 33.4%; Score 509; DB 2; Length 365;
Best Local Similarity 38.3%; Pred No. 1e-34;
Matches 106; Conservative 53; Mismatches 110; Indels 8; Gaps

Qy 5 SLSLHYLFMGASEODGLSLFEALGYVDQLFFVFDHE--SRREPTRPWYSSRISSOMW 62
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Db 26 SHSMRYEFTSVSRPGRGEPFIAGVYDSDSQVFQSDAAASORMEPRAPEQE-EPEYW 84
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Qy 63 LOLSLSKLGWDHMTDFVTIMENHNHSKE-SHTLQVLTCGCEMQEDNS-TSGYWKYGYDG 120
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 85 DEETRNKVAISQNNRANLGLTRGYVWQSDEGSGHTIQIMVGCDDVGSGFLRGYKQDAYDG 144
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Qy 121 QDLHEFCPDTLDWRAPPAWPPTKLEWRHKIRARONRAYLERDCPAOLQQLLELGRGV 180
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 145 KDYLALNEDLRSTAADMAAQITRKWEAR-RAQLRAYLEGECVGLRRYLENGKETL 203
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Qy 181 DQQVPPLVKVTHI-VTFSSVTLLRCALNYYPONITMKWLKDQPMDAKEFEFPKDVLPNGD 239
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Db 204 QRTDPDKTHTHHPISDHAEATLCWALSFPFAEITLTWORGED-QTQDTLVETVRPADG 262
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Qy 240 GTYGWTITLAVPPGEORXYTCVEHPGLDPLIVIVE 276
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
Db 263 GTFQRWAAYVPSGKKRYTCHVQHGLPEPLTLRWNE 299
||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

RESULT 13

MHC class I histocompatibility antigen HLA-A2 alpha chain (allele A*0216) p.137542

C:Species: Homo sapiens (man)
C>Date: 04-Oct-1996 #sequence_revision 04-Oct-1996 #text_change 21-Jan-2000
C:Accession: I37542; S49582

R:Barouch, D.; Krausa, P.; Bodmer, J.; Browning, M.J.; McMichael, A.J.
Immunogenetics 41, 388, 1995

A:Title: Identification of a novel HLA-A2 subtype, HLA-A*0216.
A:Reference number: I37542; MUID:95278976; PMID:7759139

A:Accession: I37542

A>Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: mRNA

A:Residues: 1-365 <RES>

A:Cross-references: EMBL:Z46633; NID:p575248; PID:CAAB66602.1; PID:p575249 ;

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 31, 2003, 14:07:04 ; Search time 33 Seconds
(without alignments)
1723.303 Million cell updates/sec

Title: US-10-092-404-1

Perfect score: 1522

Sequence: 1 RLLKSHSLHYLFMGASEQDL.....RYTCQVEHPGLDQLIVWE 276

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_21.*

- 1: sp_archaea.*
- 2: sp_bacteria.*
- 3: sp_fungi.*
- 4: sp_human.*
- 5: sp_invertebrate.*
- 6: sp_mammal.*
- 7: sp_mhc.*
- 8: sp_organelle.*
- 9: sp_phase.*
- 10: sp_plant.*
- 11: sp_rodent.*
- 12: sp_virus.*
- 13: sp_vertebrate.*
- 14: sp_unclassified.*
- 15: sp_rvirus.*
- 16: sp_bacteriap.*
- 17: sp_archaeap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1387	91.1	325	4 Q96KU8	Q96ku8 homo sapien
2	1247	81.9	348	6 Q9GL42	Q9gl42 dicerorhinu
3	1245	81.8	348	6 Q9GKZ0	Q9gkz0 ceratotheri
4	1241	81.5	348	6 Q9GL41	Q9gl41 rhinoceros
5	1238	81.3	348	6 Q9GL43	Q9gl43 diceros bic
6	1233	81.0	322	6 Q9GK81	Q9gk81 diceros bic
7	1149	75.5	359	11 Q9D754	Q9d754 mus musculus
8	952	62.5	256	4 Q96KU7	Q96ku7 homo sapien
9	948	62.3	256	4 Q9HC68	Q9hc68 homo sapien
10	899	59.1	165	4 Q9HC70	Q9hc70 homo sapien
11	859	56.4	242	4 Q9HC64	Q9hc64 homo sapien
12	802	52.7	272	11 Q9R105	Q9r105 rattus norv
13	662	43.5	161	4 Q9HC83	Q9hc83 homo sapien
14	592	38.9	116	4 Q9HC69	Q9hc69 homo sapien
15	542.5	35.6	340	7 Q9BD50	Q9bd50 pongo pygma
16	541.5	35.6	334	7 Q9TQK3	Q9tqk3 homo sapien

17	541.5	35.6	341	4 Q9NPL2	Q9npl2 homo sapien
18	541.5	35.6	341	7 Q9BCU3	Q9bcu3 pan troglod
19	541.5	35.6	341	7 Q95460	Q95460 homo sapien
20	539.5	35.4	354	7 Q95HB3	Q95hb3 anas platyr
21	538.5	35.4	341	7 Q9BCU4	Q9bcu4 pan troglod
22	530	34.8	105	4 Q9HC71	Q9hc71 homo sapien
23	519	34.1	332	7 Q9TPU7	Q9tpu7 pan troglod
24	519	34.1	365	7 Q9TPU7	Q9tpu7 pan troglod
25	517	34.0	365	7 Q9TPU6	Q9tpu6 homo sapien
26	517	34.0	371	7 Q9TPU7	Q9tpu7 homo sapien
27	516	33.9	364	7 Q92433	Q92433 sus scrofa
28	516	33.9	365	7 Q9MYG4	Q9myg4 homo sapien
29	515	33.8	168	4 Q9GKU5	Q9gku5 homo sapien
30	514	33.8	365	7 Q92747	Q92747 homo sapien
31	513	33.7	273	7 Q95IG6	Q95ig6 homo sapien
32	513	33.7	352	7 Q9SPA9	Q9spa9 sus scrofa
33	513	33.7	365	7 Q9MY15	Q9my15 homo sapien
34	512	33.6	129	4 Q9UK37	Q9uk37 homo sapien
35	512	33.6	330	7 Q91356	Q91356 macaca mula
36	512	33.6	331	7 Q92944	Q92944 macaca mula
37	512	33.6	333	7 Q98030	Q98030 papio anubi
38	512	33.6	333	7 Q98031	Q98031 papio anubi
39	511	33.6	330	7 Q92946	Q92946 macaca mula
40	511	33.6	330	7 Q92947	Q92947 macaca mula
41	511	33.6	365	7 Q91756	Q91756 homo sapien
42	510	33.5	331	7 Q92945	Q92945 macaca mula
43	510	33.5	357	7 Q90886	Q90886 pan paniscu
44	510	33.5	363	7 Q9MWA4	Q9mwk4 gorilla gor
45	510	33.5	363	7 Q9MX15	Q9mx15 pan troglod

ALIGNMENTS

RESULT 1

Q96KU8 ID Q96KU8 PRELIMINARY; PRT; 325 AA.

AC Q96KU8; DT 01-DEC-2001 (TRENBLrel. 19, Created)
DT 01-DEC-2001 (TRENBLrel. 19, Last sequence update)
DT 01-JUN-2002 (TRENBLrel. 21, Last annotation update)
DE Hemochromatosis protein.
GN HFE.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_taxid=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA Oliva R.;

RL Submitted (SEP-1999) to the EMBL/GenBank/DBSJ databases.

RN [2]

RP SEQUENCE FROM N.A.

RA Oliva R., Sanchez M.;

RT "Identification of different alternative splicing forms of the HFE

gene.";

RL Submitted (SEP-2001) to the EMBL/GenBank/DBSJ databases.

CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO THE

CC IMMUNE SYSTEM (BY SIMILARITY).

CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-

CC MICROGLOBULIN) (BY SIMILARITY).

DR EMBL; AJ249335; CAC67792.1; -

DR InterPro; IPR003006; IG_MHC.

DR InterPro; IPR001039; MHC_I.

DR Pfam; PF00047; Ig; 1.

DR Pfam; PF00129; MHC_I; 1.

DR PRINTS; PR01638; MHCCLASSI.

DR ProDom; PD000050; MHC_I; 1.

DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.

KW Glycoprotein; Transmembrane.

SO SEQUENCE 325 AA; 37514 MW; 626343ACFAA862EF CRC64;

Query Match 91.1%; Score 1387; DB 4; Length 325;


```
Best Local Similarity 100.0%; Pred. No. 2e-126;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 LGYVDDOLFVYDHESRRVPRTPWSSRSSQMWLQSLQSLGWDHMFVDFKTMENH 87
DB 27 LGYVDDOLFVYDHESRRVPRTPWSSRSSQMWLQSLQSLGWDHMFVDFKTMENH 86
QY 88 NHKESHTLQVILGCEMDENSTEGYWKYGDGDHLEFCPDTLDWRAAPRAWPTKLEW 147
DB 87 NHKESHTLQVILGCEMDENSTEGYWKYGDGDHLEFCPDTLDWRAAPRAWPTKLEW 146
QY 148 ERUKIRARONRAYLERDCPAQLOQLLELGRGVLDQVPPPLVKVTHHTVSSVTLRCRALN 207
DB 147 ERUKIRARONRAYLERDCPAQLOQLLELGRGVLDQVPPPLVKVTHHTVSSVTLRCRALN 206
QY 208 YYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQGWITLAVPPGEEQRYTCQVEHPGL 267
DB 207 YYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQGWITLAVPPGEEQRYTCQVEHPGL 266
QY 268 DQPLIVWE 276
DB 267 DQPLIVWE 275

RESULT 2
Q9GL42 PRELIMINARY; PRT; 348 AA.
AC Q9GL42;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE HFE protein.
OS Dicerorhinus sumatrensis (Sumatran rhinoceros).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Perissodactyla; Rhinocerotidae; Dicerorhinus.
OX NCBI_TaxID=89632;
RN [1]
RP SEQUENCE FROM N.A.
RA West C.J., Worley M., Beutler E.;
RT "Rhinoceros HFE Polymorphisms.";
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO THE
CC -!- IMMUNE SYSTEM (BY SIMILARITY).
CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC MICROGLOBULIN) (BY SIMILARITY).
DR EMBL: AY007543; AAG23703.1; -.
DR HSSP: Q30201; 1A6Z.
DR InterPro: IPR003597; Ig_cl.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR01039; MHC_I.
DR Pfam: PF00047; Ig; 1.
DR Pfam: PF00129; MHC_I; 1.
DR PRINTS: PR01638; MHCCLASSI.
DR ProDom: PD000050; MHC_I; 1.
DR SMART: SM00407; IgcI; 1.
DR PROSITE: PS00290; IG_MHC; UNKNOWN_1.
DR Glycoprotein; Transmembrane.
KW Glycoprotein; Transmembrane.
SQ SEQUENCE 348 AA; 39740 MW; 518BFD357AB83B90 CRC64;

Query Match 81.9%; Score 1247; DB 6; Length 348;
Best Local Similarity 81.7%; Pred. No. 8.5e-113;
Matches 223; Conservative 20; Mismatches 30; Indels 0; Gaps 0;

QY 4 RSHSLHYLFMGASERDGLSLFEALGYVDDOLFVYDHESRRVPRTPWSSRSSQMWL 63
DB 26 RSHSLRYLFMGASERDGLPLFEALGYVDDOLFVYDHESRRVPRTPWSSRSSQMWL 85
QY 64 QLSQSLGWDHMFVDFWITMENNHNHSHKESHTLQVILGCEMDENSTEGYWKYGDGDH 123
DB 86 QLSQSLGWDHMFVDFWITMENNHNHSHKESHTLQVILGCEVQEDNSTRGFWKYGDGDH 145
QY 124 LFCPDTLDWRAAPRAWPTKLEWRHKIRARONRAYLERDCPAQLOQLLELGRGVLDQ 183
DB 146 LFCPDTLDWRAAPRAWPTKLEWRHKIRARONRAYLERDCPAQLOQLLELGRGVLDQ 205
QY 184 VPPLVKVTHHTVSSVTLRCRALNYYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQ 243
DB 206 VPPLVKVTHHTVSSVTLRCRALNYYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQ 265
QY 244 GWITLAVPPGEEQRYTCQVEHPGLDQPLIVWE 276
DB 266 SWEALAVPPGEEQRYTCQVEHPGLDQPLIVWE 298

RESULT 4
Q9GL41
```

```
DB 146 LFCPDTLDWRAAPRAWPTKLEWRHKIRARONRAYLERDCPAQLOQLLELGRGVLDQ 205
QY 184 VPPLVKVTHHTVSSVTLRCRALNYYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQ 243
DB 206 VPPLVKVTHHTVSSVTLRCRALNYYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQ 265
QY 244 GWITLAVPPGEEQRYTCQVEHPGLDQPLIVWE 276
DB 266 SWEALAVPPGEEQRYTCQVEHPGLDQPLIVWE 298

RESULT 3
Q9GKZ0 PRELIMINARY; PRT; 348 AA.
AC Q9GKZ0;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE HFE protein.
OS Ceratotherium simum (White rhinoceros) (Square-lipped rhinoceros).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Perissodactyla; Rhinocerotidae; Ceratotherium.
OX NCBI_TaxID=9807;
RN [1]
RP SEQUENCE FROM N.A.
RA West C.J., Worley M., Beutler E.;
RT "Rhinoceros HFE Polymorphisms.";
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO THE
CC -!- IMMUNE SYSTEM (BY SIMILARITY).
CC -!- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC MICROGLOBULIN) (BY SIMILARITY).
DR EMBL: AY007541; AAG23701.1; -.
DR HSSP: Q30201; 1A6Z.
DR InterPro: IPR003597; Ig_cl.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR01039; MHC_I.
DR Pfam: PF00047; Ig; 1.
DR Pfam: PF00129; MHC_I; 1.
DR PRINTS: PR01638; MHCCLASSI.
DR ProDom: PD000050; MHC_I; 1.
DR SMART: SM00407; IgcI; 1.
DR PROSITE: PS00290; IG_MHC; UNKNOWN_1.
DR Glycoprotein; Transmembrane.
KW Glycoprotein; Transmembrane.
SQ SEQUENCE 348 AA; 39822 MW; 2523016ECE9FBE91 CRC64;

Query Match 81.8%; Score 1245; DB 6; Length 348;
Best Local Similarity 82.1%; Pred. No. 1.3e-112;
Matches 224; Conservative 18; Mismatches 31; Indels 0; Gaps 0;

QY 4 RSHSLHYLFMGASERDGLSLFEALGYVDDOLFVYDHESRRVPRTPWSSRSSQMWL 63
DB 26 RSHSLRYLFMGASERDGLPLFEALGYVDDOLFVYDHESRRVPRTPWSSRSSQMWL 85
QY 64 QLSQSLGWDHMFVDFWITMENNHNHSHKESHTLQVILGCEMDENSTEGYWKYGDGDH 123
DB 86 QLSQSLGWDHMFVDFWITMENNHNHSHKESHTLQVILGCEVQEDNSTRGFWKYGDGDH 145
QY 124 LFCPDTLDWRAAPRAWPTKLEWRHKIRARONRAYLERDCPAQLOQLLELGRGVLDQ 183
DB 146 LFCPDTLDWRAAPRAWPTKLEWRHKIRARONRAYLERDCPAQLOQLLELGRGVLDQ 205
QY 184 VPPLVKVTHHTVSSVTLRCRALNYYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQ 243
DB 206 VPPLVKVTHHTVSSVTLRCRALNYYPONITMKWLKQKPMDAKEFEKPKDVLPGNGDGYQ 265
QY 244 GWITLAVPPGEEQRYTCQVEHPGLDQPLIVWE 276
DB 266 SWEALAVPPGEEQRYTCQVEHPGLDQPLIVWE 298

RESULT 4
Q9GL41
```


Db 121 PONTMRLKDKQMDTKTEFEKDPKVLNPGDGTGYQWITLAVPP 163

RESULT 11

Q9HC64 PRELIMINARY; PRT; 242 AA.
AC Q9HC64;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Hemochromatosis protein splice variant 562-878del.
GN HFE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RP MEDLINE=20448010; PubMed=11001625;
RA Thénie A., Orhant M., Gicquel I., Fergelot P., Le Gall J.Y., David V.,
RA Mosser J.;
RT "The HFE gene undergoes alternate splicing processes.";
RL Blood Cells Mol. Dis. 26:155-162(2000).
CC -1- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO THE
CC IMMUNE SYSTEM (BY SIMILARITY).
CC -1- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC MICROGLOBULIN) (BY SIMILARITY).
EMBL: AF149804; AAC29342.1; -;
DR HSP; Q30201; IAGZ.
DR InterPro: IPR003597; Ig_cl.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR001039; MHC_I.
DR Pfam: PF00129; MHC_I; 1.
DR ProDom: PD000050; MHC_I; 1.
DR SMART: SM00407; IGcl; 1.
DR PROSITE: PS00290; IG_MHC; UNKNOWN_1.
KW Glycoprotein; Transmembrane.
SQ SEQUENCE 242 AA; 27826 MW; A021771A22A1F6D8 CRC64;

Query Match 56.4%; Score 859; DB 4; Length 242;
Best Local Similarity 60.9%; Pred. No. 2.5e-75;
Matches 168; Conservative 1; Mismatches 1; Indels 106; Gaps 1;
Qy 1 RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 60
Dd 23 RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFDHESRRVPRTPWSSRISSQ 82
Qy 61 MWLQSLKQWDMFTVDFTIMENHNHKSHTLQVLGCEMQEDNSTEGYKYGVDG 120
Dd 83 MWLQSLKQWDMFTVDFTIMENHNHKSHTLQVLGCEMQEDNSTEGYKYGVDG 113
Qy 121 QDHLEFCPOTLDWRAAEPRAPWPTKLEWHRKIRARONRAYLERDCPAQLQLLELGRGVL 180
Dd 114 -----VTTLCRALNHYPNITMTKWKDKQPMDAKEFEKDPKVLNPGDG 113
Qy 181 DQOVPLPVKVVHTVSSVTLRCRALNYPONITMTKWKDKQPMDAKEFEKDPKVLNPGDG 240
Dd 114 -----VTTLCRALNHYPNITMTKWKDKQPMDAKEFEKDPKVLNPGDG 156
Qy 241 TYQGWITLAVPPGEQRYTCQVEHPGLDQPLVIWE 276
Dd 157 TYQGWITLAVPPGEQRYTCQVEHPGLDQPLVIWE 192

RESULT 12

Q9R105 PRELIMINARY; PRT; 272 AA.
AC Q9R105;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Hemochromatosis gene product HFE splice variant del22.
OS Rattus norvegicus (Rat).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
SEQUENCE FROM N.A.
RP STRAIN-WISTAR; TISSUE=TESTIS;
RA Liew Y.-F., Shaw N.-S.;
RT "Alternative splice variant of the hemochromatosis gene HFE in iron
RT overloaded rats";
RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: INVOLVED IN THE PRESENTATION OF FOREIGN ANTIGENS TO THE
CC IMMUNE SYSTEM (BY SIMILARITY).
CC -1- SUBUNIT: DIMER OF ALPHA CHAIN AND A BETA CHAIN (BETA-2-
CC MICROGLOBULIN) (BY SIMILARITY).
EMBL: AF176534; AAD49965.1; -;
DR HSP; Q30201; IAGZ.
DR InterPro: IPR003597; Ig_cl.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR001039; MHC_I.
DR Pfam: PF00047; Ig; 1.
DR Pfam: PF00129; MHC_I; 1.
DR PRINTS: PR01638; MHCCLASSI.
DR ProDom: PD000050; MHC_I; 1.
DR SMART: SM00407; IGcl; 1.
DR PROSITE: PS00290; IG_MHC; UNKNOWN_1.
KW Glycoprotein; Transmembrane.
SQ SEQUENCE 272 AA; 30757 MW; ID91063CCBEF5502 CRC64;

Query Match 52.7%; Score 802; DB 11; Length 272;
Best Local Similarity 75.1%; Pred. No. 1e-69;
Matches 139; Conservative 22; Mismatches 24; Indels 0; Gaps 0;
Qy 92 ESHTLQVLGCEMQEDNSTEGYKYGVDQDHLFCPDTLDWRAAEPRAPWPTKLEWHRK 151
Dd 39 ESHLQVLGCEVEDNSTSGFWKYGVDGQDHLFCPDTLDWRAAEPRAPWPTKLEWHRK 98
Qy 152 IRARONRAYLERDCPAQLQLLELGRGVLDDQVPLVKVTHVHTSSVTLRCRALNYPQ 211
Dd 99 IRARQSDYLQDRCPQLKQVLELQGVLPVTRHASTGTSLRCQALNFPFP 158
Qy 212 NITMKWKDKQPMDAKEFEKDPKVLNPGDGTGYQWITLAVPPGEQRYTCQVEHPGLDQPL 271
Dd 159 NITRWLKDQSLDKADKNPNVLPNGDGTGYQWITLAVPPGEQRYTCQVEHPGLDQPL 218
Qy 272 IVIWE 276
Dd 219 TATWE 223

RESULT 13

Q9HC83 PRELIMINARY; PRT; 161 AA.
AC Q9HC83;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Hemochromatosis splice variant dele3-7.
GN HFE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RP MEDLINE=20448010; PubMed=11001625;
RA Thénie A., Orhant M., Gicquel I., Fergelot P., Le Gall J.Y., David V.,
RA Mosser J.;
RT "The HFE gene undergoes alternate splicing processes.";
RL Blood Cells Mol. Dis. 26:155-162(2000).
DR EMBL: AF115264; AAC29571.1; -;
DR HSP; Q30201; IAGZ.
DR InterPro: IPR001039; MHC_I.
DR Pfam: PF00129; MHC_I; 1.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal644axd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	42	Feb 13	CANCERLIT is no longer being updated
NEWS	43	Feb 24	METADEX enhancements
NEWS	44	Feb 24	PCTGEN now available on STN
NEWS	45	Feb 24	TEMA now available on STN

NEWS 46 Feb 26 NTIS now allows simultaneous left and right truncation
 NEWS 47 Feb 26 PCTFULL now contains images
 NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003
 NEWS 50 Mar 20 EVENTLINE will be removed from STN
 NEWS 51 Mar 24 PATDPAFULL now available on STN
 NEWS 52 Mar 24 Additional information for trade-named substances without
 structures available in REGISTRY
 NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

 NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:37:17 ON 31 MAR 2003

=> file medline caplus embase biosis
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:37:30 ON 31 MAR 2003

FILE 'CAPLUS' ENTERED AT 13:37:30 ON 31 MAR 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:37:30 ON 31 MAR 2003
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:37:30 ON 31 MAR 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

=> s feder J?/au or bjorkman P?/au or Schatzman R?/au
 L1 1449 FEDER J?/AU OR BJORKMAN P?/AU OR SCHATZMAN R?/AU

=> s l1 and HFE
 L2 91 L1 AND HFE

=> s l1 and PD<19980612
 '19980612' NOT A VALID FIELD CODE
 3 FILES SEARCHED...
 L3 923 L1 AND PD<19980612

=> s l2 and soluble
L4 28 L2 AND SOLUBLE

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 9 DUP REM L4 (19 DUPLICATES REMOVED)

=> dis l5 1-9 ibib abs kwic

L5 ANSWER 1 OF 9 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2001520424 MEDLINE
DOCUMENT NUMBER: 21433894 PubMed ID: 11425849
TITLE: Hydrophobic ligand binding by Zn-alpha 2-glycoprotein, a
soluble fat-depleting factor related to major
histocompatibility complex proteins.
AUTHOR: Kennedy M W; Heikema A P; Cooper A; **Bjorkman P J**;
Sanchez L M
CORPORATE SOURCE: Division of Environmental and Evolutionary Biology,
Institute of Biomedical and Life Sciences and the
Department of Chemistry, University of Glasgow, Glasgow G12
8QQ, United Kingdom.. malcolm.kennedy@bio.gla.ac.uk
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2001 Sep 14) 276 (37)
35008-13.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200110
ENTRY DATE: Entered STN: 20010925
Last Updated on STN: 20030105
Entered Medline: 20011011

AB Zn-alpha(2)-glycoprotein (ZAG) is a member of the major histocompatibility complex (MHC) class I family of proteins and is identical in amino acid sequence to a tumor-derived lipid-mobilizing factor associated with cachexia in cancer patients. ZAG is present in plasma and other body fluids, and its natural function, like leptin's, probably lies in lipid store homeostasis. X-ray crystallography has revealed an open groove between the helices of ZAG's alpha(1) and alpha(2) domains, containing an unidentified small ligand in a position similar to that of peptides in MHC proteins (Sanchez, L. M., Chirino, A. J., and Bjorkman, P. J. (1999) Science 283, 1914-1919). Here we show, using serum-derived and bacterial recombinant protein, that ZAG binds the fluorophore-tagged fatty acid 11-(dansylamino)undecanoic acid (DAUDA) and, by competition, natural fatty acids such as arachidonic, linolenic, eicosapentaenoic, and docosahexaenoic acids. Other MHC class I-related proteins (FcRn, **HFE**, HLA-Cw*0702) showed no such evidence of binding. Fluorescence and isothermal calorimetry analysis showed that ZAG binds DAUDA with K(d) in the micromolar range, and differential scanning calorimetry showed that ligand binding increases the thermal stability of the protein. Addition of fatty acids to ZAG alters its intrinsic (tryptophan) fluorescence emission spectrum, providing a strong indication that ligand binds in the expected position close to a cluster of exposed tryptophan side chains in the groove. This study therefore shows that ZAG binds small hydrophobic ligands, that the natural ligand may be a polyunsaturated fatty acid, and provides a fluorescence-based method for investigating ZAG-ligand interactions.

TI Hydrophobic ligand binding by Zn-alpha 2-glycoprotein, a **soluble**
fat-depleting factor related to major histocompatibility complex proteins.

AU Kennedy M W; Heikema A P; Cooper A; **Bjorkman P J**; Sanchez L M

AB . . . and, by competition, natural fatty acids such as arachidonic,
linolenic, eicosapentaenoic, and docosahexaenoic acids. Other MHC class
I-related proteins (FcRn, **HFE**, HLA-Cw*0702) showed no such
evidence of binding. Fluorescence and isothermal calorimetry analysis

showed that ZAG binds DAUDA with K(d) in. . .

L5 ANSWER 2 OF 9 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 2002073391 MEDLINE
DOCUMENT NUMBER: 21659940 PubMed ID: 11800564
TITLE: Mutational analysis of the transferrin receptor reveals overlapping **HFE** and transferrin binding sites.
AUTHOR: West A P Jr; Giannetti A M; Herr A B; Bennett M J; Nangiana J S; Pierce J R; Weiner L P; Snow P M; **Bjorkman P J**
CORPORATE SOURCE: Division of Biology 156-29 , California Institute of Technology, Pasadena, CA 91125, USA.
CONTRACT NUMBER: 5T32 GM07616 (NIGMS)
SOURCE: JOURNAL OF MOLECULAR BIOLOGY, (2001 Oct 19) 313 (2) 385-97. Journal code: 2985088R. ISSN: 0022-2836.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200202
ENTRY DATE: Entered STN: 20020125
Last Updated on STN: 20020205
Entered Medline: 20020204

AB The transferrin receptor (TfR) binds two proteins critical for iron metabolism: transferrin (Tf) and **HFE**, the protein mutated in hereditary hemochromatosis. Previous results demonstrated that Tf and **HFE** compete for binding to TfR, suggesting that Tf and **HFE** bind to the same or an overlapping site on TfR. TfR is a homodimer that binds one Tf per polypeptide chain (2:2, TfR/Tf stoichiometry), whereas both 2:1 and 2:2 TfR/**HFE** stoichiometries have been observed. In order to more fully characterize the interaction between **HFE** and TfR, we determined the binding stoichiometry using equilibrium gel-filtration and analytical ultracentrifugation. Both techniques indicate that a 2:2 TfR/**HFE** complex can form at submicromolar concentrations in solution, consistent with the hypothesis that **HFE** competes for Tf binding to TfR by blocking the Tf binding site rather than by exerting an allosteric effect. To determine whether the Tf and **HFE** binding sites on TfR overlap, residues at the **HFE** binding site on TfR were identified from the 2.8 A resolution **HFE**-TfR co-crystal structure, then mutated and tested for their effects on **HFE** and Tf binding. The binding affinities of soluble TfR mutants for **HFE** and Tf were determined using a surface plasmon resonance assay. Substitutions of five TfR residues at the **HFE** binding site (L619A, R629A, Y643A, G647A and F650Q) resulted in significant reductions in Tf binding affinity. The findings that both **HFE** and Tf form 2:2 complexes with TfR and that mutations at the **HFE** binding site affect Tf binding support a model in which **HFE** and Tf compete for overlapping binding sites on TfR.

Copyright 2001 Academic Press.

TI Mutational analysis of the transferrin receptor reveals overlapping **HFE** and transferrin binding sites.

AU. . . A M; Herr A B; Bennett M J; Nangiana J S; Pierce J R; Weiner L P; Snow P M; **Bjorkman P J**

AB The transferrin receptor (TfR) binds two proteins critical for iron metabolism: transferrin (Tf) and **HFE**, the protein mutated in hereditary hemochromatosis. Previous results demonstrated that Tf and **HFE** compete for binding to TfR, suggesting that Tf and **HFE** bind to the same or an overlapping site on TfR. TfR is a homodimer that binds one Tf per polypeptide chain (2:2, TfR/Tf stoichiometry), whereas both 2:1 and 2:2 TfR/**HFE** stoichiometries have been observed. In order to more fully characterize the interaction between **HFE** and TfR, we determined the binding stoichiometry using equilibrium gel-filtration and analytical ultracentrifugation. Both techniques indicate that a 2:2 TfR/**HFE** complex can form at submicromolar

concentrations in solution, consistent with the hypothesis that **HFE** competes for Tf binding to TfR by blocking the Tf binding site rather than by exerting an allosteric effect. To determine whether the Tf and **HFE** binding sites on TfR overlap, residues at the **HFE** binding site on TfR were identified from the 2.8 Å resolution **HFE**-TfR co-crystal structure, then mutated and tested for their effects on **HFE** and Tf binding. The binding affinities of **soluble** TfR mutants for **HFE** and Tf were determined using a surface plasmon resonance assay. Substitutions of five TfR residues at the **HFE** binding site (L619A, R629A, Y643A, G647A and F650Q) resulted in significant reductions in Tf binding affinity. The findings that both **HFE** and Tf form 2:2 complexes with TfR and that mutations at the **HFE** binding site affect Tf binding support a model in which **HFE** and Tf compete for overlapping binding sites on TfR.

Copyright 2001 Academic Press.

L5 ANSWER 3 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 ACCESSION NUMBER: 2001:250785 BIOSIS
 DOCUMENT NUMBER: PREV200100250785
 TITLE: Interactions of the ectodomain of **HFE** with the transferrin receptor are critical for iron homeostasis in cells.
 AUTHOR(S): Enns, Caroline A. (1); Roy, Cindy N. (1); **Feder, John N.**
 CORPORATE SOURCE: (1) Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97201 USA
 SOURCE: FASEB Journal, (March 7, 2001) Vol. 15, No. 4, pp. A60. print.
 Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
 ISSN: 0892-6638.
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB Expression of wild type **HFE** reduces the ferritin levels of cells in culture. In this report we demonstrate that the predominant hereditary hemochromatosis mutation, C282Y **HFE**, does not reduce ferritin expression. However, the second mutation, H63D **HFE**, reduces ferritin expression to a level indistinguishable from cells expressing wild type **HFE**. Further, two mutations in the cytoplasmic domain of **HFE** engineered to disrupt potential phosphorylation-mediated signal transduction events, S335M and Y342C, were functionally indistinguishable from wild type **HFE** in this assay, as was **soluble HFE**. These results implicate a role for the interaction of **HFE** with the transferrin receptor in lowering cellular ferritin levels.
 TI Interactions of the ectodomain of **HFE** with the transferrin receptor are critical for iron homeostasis in cells.
 AU Enns, Caroline A. (1); Roy, Cindy N. (1); **Feder, John N.**
 AB Expression of wild type **HFE** reduces the ferritin levels of cells in culture. In this report we demonstrate that the predominant hereditary hemochromatosis mutation, C282Y **HFE**, does not reduce ferritin expression. However, the second mutation, H63D **HFE**, reduces ferritin expression to a level indistinguishable from cells expressing wild type **HFE**. Further, two mutations in the cytoplasmic domain of **HFE** engineered to disrupt potential phosphorylation-mediated signal transduction events, S335M and Y342C, were functionally indistinguishable from wild type **HFE** in this assay, as was **soluble HFE**. These results implicate a role for the interaction of **HFE** with the transferrin receptor in lowering cellular ferritin levels.
 IT Major Concepts

Molecular Genetics (Biochemistry and Molecular Biophysics); Metabolism
IT Chemicals & Biochemicals

HFE: ectodomain; iron: homeostasis; transferrin receptor
GEN **HFE** gene: mutation

L5 ANSWER 4 OF 9 MEDLINE DUPLICATE 3
ACCESSION NUMBER: 2001088821 MEDLINE
DOCUMENT NUMBER: 20556244 PubMed ID: 11027676
TITLE: Comparison of the interactions of transferrin receptor and
transferrin receptor 2 with transferrin and the hereditary
hemochromatosis protein **HFE**.
AUTHOR: West A P Jr; Bennett M J; Sellers V M; Andrews N C; Enns C
A; Bjorkman P J
CORPORATE SOURCE: Division of Biology and Howard Hughes Medical Institute,
California Institute of Technology, Pasadena, California
91125, USA.
CONTRACT NUMBER: DK54488 (NIDDK)
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2000 Dec 8) 275 (49)
38135-8.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010118

AB The transferrin receptor (TfR) interacts with two proteins important for
iron metabolism, transferrin (Tf) and **HFE**, the protein mutated
in hereditary hemochromatosis. A second receptor for Tf, TfR2, was
recently identified and found to be functional for iron uptake in
transfected cells (Kawabata, H., Germain, R. S., Vuong, P. T., Nakamaki,
T., Said, J. W., and Koeffler, H. P. (2000) J. Biol. Chem. 275,
16618-16625). TfR2 has a pattern of expression and regulation that is
distinct from TfR, and mutations in TfR2 have been recognized as the cause
of a non-**HFE** linked form of hemochromatosis (Camaschella, C.,
Roetto, A., Cali, A., De Gobbi, M., Garozzo, G., Carella, M., Majorano,
N., Totaro, A., and Gasparini, P. (2000) Nat. Genet. 25, 14-15). To
investigate the relationship between TfR, TfR2, Tf, and **HFE**, we
performed a series of binding experiments using **soluble** forms of
these proteins. We find no detectable binding between TfR2 and **HFE**
by co-immunoprecipitation or using a surface plasmon resonance-based
assay. The affinity of TfR2 for iron-loaded Tf was determined to be 27 nm,
25-fold lower than the affinity of TfR for Tf. These results imply that
HFE regulates Tf-mediated iron uptake only from the classical TfR
and that TfR2 does not compete for **HFE** binding in cells
expressing both forms of TfR.

TI Comparison of the interactions of transferrin receptor and transferrin
receptor 2 with transferrin and the hereditary hemochromatosis protein
HFE.

AU West A P Jr; Bennett M J; Sellers V M; Andrews N C; Enns C A;
Bjorkman P J

AB The transferrin receptor (TfR) interacts with two proteins important for
iron metabolism, transferrin (Tf) and **HFE**, the protein mutated
in hereditary hemochromatosis. A second receptor for Tf, TfR2, was
recently identified and found to be functional. . . expression and
regulation that is distinct from TfR, and mutations in TfR2 have been
recognized as the cause of a non-**HFE** linked form of
hemochromatosis (Camaschella, C., Roetto, A., Cali, A., De Gobbi, M.,
Garozzo, G., Carella, M., Majorano, N., Totaro, A., and Gasparini, P.
(2000) Nat. Genet. 25, 14-15). To investigate the relationship between
TfR, TfR2, Tf, and **HFE**, we performed a series of binding
experiments using **soluble** forms of these proteins. We find no

detectable binding between TfR2 and **HFE** by co-immunoprecipitation or using a surface plasmon resonance-based assay. The affinity of TfR2 for iron-loaded Tf was determined to be 27 nM, 25-fold lower than the affinity of TfR for Tf. These results imply that **HFE** regulates Tf-mediated iron uptake only from the classical TfR and that TfR2 does not compete for **HFE** binding in cells expressing both forms of TfR.

L5 ANSWER 5 OF 9 MEDLINE DUPLICATE 4
 ACCESSION NUMBER: 2001061091 MEDLINE
 DOCUMENT NUMBER: 20532540 PubMed ID: 11078891
 TITLE: Interactions of the ectodomain of **HFE** with the transferrin receptor are critical for iron homeostasis in cells.
 AUTHOR: Roy C N; Carlson E J; Anderson E L; Basava A; Starnes S M; **Feder J N**; Enns C A
 CORPORATE SOURCE: Department of Cell and Developmental Biology, Oregon Health Sciences University, Portland 97201-3098, USA.
 CONTRACT NUMBER: DK 54488 (NIDDK)
 T32-HL00781 (NHLBI)
 SOURCE: FEBS LETTERS, (2000 Nov 10) 484 (3) 271-4.
 Journal code: 0155157. ISSN: 0014-5793.
 PUB. COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200012
 ENTRY DATE: Entered STN: 20010322
 Last Updated on STN: 20010322
 Entered Medline: 20001222

AB Expression of wild type **HFE** reduces the ferritin levels of cells in culture. In this report we demonstrate that the predominant hereditary hemochromatosis mutation, C282Y(2) **HFE**, does not reduce ferritin expression. However, the second mutation, H63D **HFE**, reduces ferritin expression to a level indistinguishable from cells expressing wild type **HFE**. Further, two **HFE** cytoplasmic domain mutations engineered to disrupt potential signal transduction, S335M and Y342C, were functionally indistinguishable from wild type **HFE** in this assay, as was soluble **HFE**. These results implicate a role for the interaction of **HFE** with the transferrin receptor in lowering cellular ferritin levels.

TI Interactions of the ectodomain of **HFE** with the transferrin receptor are critical for iron homeostasis in cells.

AU Roy C N; Carlson E J; Anderson E L; Basava A; Starnes S M; **Feder J N**; Enns C A

AB Expression of wild type **HFE** reduces the ferritin levels of cells in culture. In this report we demonstrate that the predominant hereditary hemochromatosis mutation, C282Y(2) **HFE**, does not reduce ferritin expression. However, the second mutation, H63D **HFE**, reduces ferritin expression to a level indistinguishable from cells expressing wild type **HFE**. Further, two **HFE** cytoplasmic domain mutations engineered to disrupt potential signal transduction, S335M and Y342C, were functionally indistinguishable from wild type **HFE** in this assay, as was soluble **HFE**. These results implicate a role for the interaction of **HFE** with the transferrin receptor in lowering cellular ferritin levels.

L5 ANSWER 6 OF 9 MEDLINE DUPLICATE 5
 ACCESSION NUMBER: 2000027103 MEDLINE
 DOCUMENT NUMBER: 20027103 PubMed ID: 10556042
 TITLE: The hemochromatosis protein **HFE** competes with transferrin for binding to the transferrin receptor.
 AUTHOR: Lebron J A; West A P Jr; **Bjorkman P J**
 CORPORATE SOURCE: Division of Biology, California Institute of Technology,

1200 East California Boulevard, Pasadena, CA 91125, USA.
CONTRACT NUMBER: GM07616 (NIGMS)
SOURCE: JOURNAL OF MOLECULAR BIOLOGY, (1999 Nov 19) 294 (1) 239-45.
Journal code: 2985088R. ISSN: 0022-2836.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200001
ENTRY DATE: Entered STN: 20000124
Last Updated on STN: 20000124
Entered Medline: 20000110

AB **HFE** is a class I major histocompatibility complex (MHC)-related protein that is mutated in patients with the iron overload disease hereditary hemochromatosis. **HFE** binds to transferrin receptor (TfR), the receptor used by cells to obtain iron in the form of diferric transferrin (Fe-Tf). Previous studies demonstrated that **HFE** and Fe-Tf can bind simultaneously to TfR to form a ternary complex, and that membrane-bound or **soluble HFE** binding to cell surface TfR results in a reduction in the affinity of TfR for Fe-Tf. We studied the inhibition by **soluble HFE** of the interaction between **soluble** TfR and Fe-Tf using radioactivity-based and biosensor-based assays. The results demonstrate that **HFE** inhibits the TfR:Fe-Tf interaction by binding at or near the Fe-Tf binding site on TfR, and that the Fe-Tf:TfR:**HFE** ternary complex consists of one Fe-Tf and one **HFE** bound to a TfR homodimer. Copyright 1999 Academic Press.

TI The hemochromatosis protein **HFE** competes with transferrin for binding to the transferrin receptor.

AU Lebron J A; West A P Jr; Bjorkman P J

AB **HFE** is a class I major histocompatibility complex (MHC)-related protein that is mutated in patients with the iron overload disease hereditary hemochromatosis. **HFE** binds to transferrin receptor (TfR), the receptor used by cells to obtain iron in the form of diferric transferrin (Fe-Tf). Previous studies demonstrated that **HFE** and Fe-Tf can bind simultaneously to TfR to form a ternary complex, and that membrane-bound or **soluble HFE** binding to cell surface TfR results in a reduction in the affinity of TfR for Fe-Tf. We studied the inhibition by **soluble HFE** of the interaction between **soluble** TfR and Fe-Tf using radioactivity-based and biosensor-based assays. The results demonstrate that **HFE** inhibits the TfR:Fe-Tf interaction by binding at or near the Fe-Tf binding site on TfR, and that the Fe-Tf:TfR:**HFE** ternary complex consists of one Fe-Tf and one **HFE** bound to a TfR homodimer. Copyright 1999 Academic Press.

L5 ANSWER 7 OF 9 MEDLINE DUPLICATE 6
ACCESSION NUMBER: 1998132614 MEDLINE
DOCUMENT NUMBER: 98132614 PubMed ID: 9465039
TITLE: The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding.
AUTHOR: Feder J N; Penny D M; Irrinki A; Lee V K; Lebron J A; Watson N; Tsuchihashi Z; Sigal E; Bjorkman P J ; Schatzman R C
CORPORATE SOURCE: Progenitor, Inc. (formerly Mercator Genetics, Inc.), 4040 Campbell Avenue, Menlo Park, CA 94025, USA.. feder@progenitor.com
SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 Feb 17) 95 (4) 1472-7. Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 199803
ENTRY DATE: Entered STN: 19980326
Last Updated on STN: 19980326
Entered Medline: 19980319

AB We recently reported the positional cloning of a candidate gene for hereditary hemochromatosis called **HFE**. The gene product, a member of the major histocompatibility complex class I-like family, was found to have a mutation, Cys-282 --> Tyr (C282Y), in 85% of patient chromosomes. This mutation eliminates the ability of **HFE** to associate with beta2-microglobulin (beta2m) and prevents cell-surface expression. A second mutation that has no effect on beta2m association, H63D, was found in eight out of nine patients heterozygous for the C282Y mutant. In this report, we demonstrate in cultured 293 cells overexpressing wild-type or mutant **HFE** proteins that both the wild-type and H63D **HFE** proteins form stable complexes with the transferrin receptor (TfR). The C282Y mutation nearly completely prevents the association of the mutant **HFE** protein with the TfR. Studies on cell-associated transferrin at 37 degrees C suggest that the overexpressed wild-type **HFE** protein decreases the affinity of the TfR for transferrin. The overexpressed H63D protein does not have this effect, providing the first direct evidence for a functional consequence of the H63D mutation. Addition of **soluble** wild-type **HFE** /beta2m heterodimers to cultured cells also decreased the apparent affinity of the TfR for its ligand under steady-state conditions, both in 293 cells and in HeLa cells. Furthermore, at 4 degrees C, the added **soluble** complex of **HFE**/beta2m inhibited binding of transferrin to HeLa cell TfR in a concentration-dependent manner. Scatchard plots of these data indicate that the added heterodimer substantially reduced the affinity of TfR for transferrin. These results establish a molecular link between **HFE** and a key protein involved in iron transport, the TfR, and raise the possibility that alterations in this regulatory mechanism may play a role in the pathogenesis of hereditary hemochromatosis.

AU **Feder J N**; Penny D M; Irrinki A; Lee V K; Lebron J A; Watson N; Tsuchihashi Z; Sigal E; Bjorkman P J; Schatzman R C

AB We recently reported the positional cloning of a candidate gene for hereditary hemochromatosis called **HFE**. The gene product, a member of the major histocompatibility complex class I-like family, was found to have a mutation, Cys-282 --> Tyr (C282Y), in 85% of patient chromosomes. This mutation eliminates the ability of **HFE** to associate with beta2-microglobulin (beta2m) and prevents cell-surface expression. A second mutation that has no effect on beta2m association, H63D, . . . nine patients heterozygous for the C282Y mutant. In this report, we demonstrate in cultured 293 cells overexpressing wild-type or mutant **HFE** proteins that both the wild-type and H63D **HFE** proteins form stable complexes with the transferrin receptor (TfR). The C282Y mutation nearly completely prevents the association of the mutant **HFE** protein with the TfR. Studies on cell-associated transferrin at 37 degrees C suggest that the overexpressed wild-type **HFE** protein decreases the affinity of the TfR for transferrin. The overexpressed H63D protein does not have this effect, providing the first direct evidence for a functional consequence of the H63D mutation. Addition of **soluble** wild-type **HFE**/beta2m heterodimers to cultured cells also decreased the apparent affinity of the TfR for its ligand under steady-state conditions, both in 293 cells and in HeLa cells. Furthermore, at 4 degrees C, the added **soluble** complex of **HFE**/beta2m inhibited binding of transferrin to HeLa cell TfR in a concentration-dependent manner. Scatchard plots of these data indicate that the added heterodimer substantially reduced the affinity of TfR for transferrin. These results establish a molecular link between **HFE** and a key protein involved in iron transport, the TfR, and raise the possibility that alterations in this regulatory mechanism. . .

L5 ANSWER 8 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 ACCESSION NUMBER: 1998:526310 BIOSIS
 DOCUMENT NUMBER: PREV199800526310
 TITLE: The hemochromatosis gene product (**HFE**) is present in **soluble** form in serum and is related to body iron content.
 AUTHOR(S): Li, Q. (1); Hammett, R. J. H. (1); Battaglia, E. (1); **Feder, J. N.**; Gollan, J. L. (1)
 CORPORATE SOURCE: (1) Brigham and Women's Hosp., Harvard Med. Sch., Boston, MA USA
 SOURCE: Hepatology, (Oct., 1998) Vol. 28, No. 4 PART 2, pp. 501A. Meeting Info.: Biennial Scientific Meeting of the International Association for the Study of the Liver and the 49th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases Chicago, Illinois, USA November 4-10, 1998 International Association for the Study of the Liver . ISSN: 0270-9139.
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 TI The hemochromatosis gene product (**HFE**) is present in **soluble** form in serum and is related to body iron content.
 AU Li, Q. (1); Hammett, R. J. H. (1); Battaglia, E. (1); **Feder, J. N.**; Gollan, J. L. (1)

L5 ANSWER 9 OF 9 MEDLINE DUPLICATE 7
 ACCESSION NUMBER: 1998206473 MEDLINE
 DOCUMENT NUMBER: 98206473 PubMed ID: 9546397
 TITLE: Crystal structure of the hemochromatosis protein **HFE** and characterization of its interaction with transferrin receptor.
 AUTHOR: Lebron J A; Bennett M J; Vaughn D E; Chirino A J; Snow P M; Mintier G A; **Feder J N**; **Bjorkman P J**
 CORPORATE SOURCE: Division of Biology, California Institute of Technology, Pasadena 91125, USA.
 SOURCE: CELL, (1998 Apr 3) 93 (1) 111-23. Journal code: 0413066. ISSN: 0092-8674.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199805
 ENTRY DATE: Entered STN: 19980514
 Last Updated on STN: 19980514
 Entered Medline: 19980501
 AB **HFE** is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. **HFE** binds to transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating **HFE** in iron metabolism. The 2.6 A crystal structure of **HFE** reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that **soluble** TfR and **HFE** bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:**HFE** stoichiometry (2:1) differs from TfR:transferrin stoichiometry (2:2), implying a different mode of binding for **HFE** and transferrin to TfR, consistent with our demonstration that **HFE**, transferrin, and TfR form a ternary complex.
 TI Crystal structure of the hemochromatosis protein **HFE** and characterization of its interaction with transferrin receptor.
 AU Lebron J A; Bennett M J; Vaughn D E; Chirino A J; Snow P M; Mintier G A; **Feder J N**; **Bjorkman P J**
 AB **HFE** is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. **HFE** binds to

transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating **HFE** in iron metabolism. The 2.6 Å crystal structure of **HFE** reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that **soluble** TfR and **HFE** bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:**HFE** stoichiometry (2:1) differs from TfR:transferrin stoichiometry (2:2), implying a different mode of binding for **HFE** and transferrin to TfR, consistent with our demonstration that **HFE**, transferrin, and TfR form a ternary complex.



Creation date: 02-27-2004
Indexing Officer: BWYCHE - BRANDON WYCHE
Team: OIPEBackFileIndexing
Dossier: 10092404

Legal Date: 08-05-2003

No.	Doccode	Number of pages
1	SRNT	108

Total number of pages: 108

Remarks:

Order of re-scan issued on

